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Hepatitis E virus (HEV) infection 
Hepatitis E virus (HEV), first identified in 1983 1, is the causative agent of hepatitis E. It 
infects about 20 million people and causes 70,000 deaths every year, and HEV infection has 
emerged as an important public health issue 2. Although only one serotype of HEV exists, 
there are four genotypes (HEV1-4) 3 infecting humans on the basis of classification of the 
nucleotide sequences of genome (Figure 1) 4. HEV Genotypes 1 and 2, obligate human 
pathogens, are found mainly in developing countries, and commonly transmit through 
contaminated water in areas with poor sanitary infrastructure. Although they predominately 
affects young adults, infection with HEV genotype 1 are particularly severe among pregnant 
women, with resulting high maternal, fetal and neonatal morbidity and mortality rates as 
high as 25% 5.  
HEV genotype 3 and 4, that lead to a porcine zoonosis and mostly cause 
asymptomatic infections ( > 90%), are prevalent in industrialized countries, where they are 
spread mainly through eating undercooked pork or game products 7. Since various animal 
species can serve as reservoirs, including swine, wild boar, deer, mongooses, chickens, 
rabbits, trout, cattle, camel, and ferrets, its zoonotic potential has raised considerable public 
health concerns 8. Patients of middle-aged or elderly men are particularly prone to develop 
symptomatic and self-limiting hepatitis 9. Although it was initially thought to cause acute 
infection only, chronic infection by HEV3 has been well documented in 
immunocompromised individuals, including those with HIV infection, or undergoing 
chemotherapy for cancer, but most commonly in organ transplant recipients 4. A total of 
65% of HEV-associated organ transplant recipients fail to clear the viral infection and rapidly 
develop chronic infection 4. In addition, HEV has been found with high frequency in the 
human blood supply in numerous developed countries, and several cases of transfusion-
transmitted infection have been reported 9. Thus, HEV infection is a prominent health 
concern worldwide. 
 
Molecular biology and life-cycle 
As the commonest cause of acute viral hepatitis worldwide, HEV is classified in the genus 
Orthohepevirus within the family Hepeviridae 10, containing a positive-sense single-stranded  
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Figure 1. Phylogenetic relationship of hepeviruses identified in various hosts. Genotypes 1 and 2 (gt 
1 and 2; yellow and orange, respectively) are restricted to humans and to endemic regions such as 
Asia, Africa and Mexico, genotypes 3 and 4 (gt 3 and 4; blue and green, respectively) are also found in 
a wide range of animal species. (Adapted from Yannick Debing, et al. Journal of Hepatology, Review 
2016.6) 
 
RNA genome of approximate 7,200 nucleotides in length 11, and with a cap and poly-(A) tail 
at its 5´ and 3´ ends, respectively 5. It was observed to be a naked 28-34 nm virus-like 
particle with spikes and inundations 12. The HEV genome contains three open reading frames 
(ORFs) designated ORF1, ORF2, and ORF3 13 that encode nonstructural proteins including 
RNA-dependent RNA polymerase, a capsid protein, and a small protein, respectively (Figure 
2) 14. These structures and the junction region between them containing regulatory elements 
are important for replication of the HEV genome 11. The ORF1 nonstructural polyprotein 
contains domains (starting from the N-terminal end) with methyltransferase (MeT), putative 
papain-like cysteine protease (PCP), RNA helicase (Hel), and RNA-dependent RNA 
polymerase (RdRp) activities, which are important for viral replication 11. The ORF2 protein 
consists of three linear domains and forms homodimers, which act as capsomeres and form 
the viral capsid (Figure 2) 15. The ORF3 protein is required for HEV replication in the host, but 
not in vitro; in addition, it has pleiotropic effects on host cell pathways and plays a role in 
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viral egress from infected cells 16. As many other viruses, the life cycle of HEV consists of 
binding and entry host cells, viral genome uncoating and release, translation of the viral 
replicase by the host translation machinery, polyprotein processing, viral replication, particle 
assembly and release 6. All these steps might consititute potential avenues for the 
development of antiviral therapy. 
Entry of the virus into the host is believed to be primarily by the oral route via 
contaminated water of food. Virus first replicate in the intestinal tract from where it reaches 
to the liver presumably via the portal vein. It then replicates in the cytoplasm of hepatocytes 
and released into the bile and the blood by an unknown mechanism. The pathogenesis of 
HEV infection and particularly the severe forms of it remains obscure 14. Prompting for this 
research, at first contact with the target cell, HEV, similar to many other viruses, attaches to 
heparin sulfate proteoglycans followed by entry through as yet unidentified receptor(s) 18. 
After clathrin mediated endocytosis, viral positive-strand RNA genome is released into the 
cytosol. This is followed by translation of ORF1 protein with the help of host translation 
machinery. Then full-length and a 2.2 kb subgenomic RNAs replicates through a negative-
strand RNA intermediate, and ORF2 and ORF3 proteins are translated from the subgenomic 
RNA 19. The last step of life-cycle is packaging, assembly and release of newly formed virus. 
ORF3 protein is likely associated with intracellular membranes and may trigger virion release 
via the endosomal sorting complexes required for transport (ESCRT) pathway. Recent studies 
suggest that virus secreted into the bloodstream is associated with the ORF3 protein and 
wrapped by cellular membranes while virus secreted into the bile is nonenveloped 6. 
However, it is fair to say that many aspects of HEV biology and pathogenesis are still 
required clarification. 
HEV studies have been long hindered because of its difficulty of cultivation and the 
lack of an efficient cell culture system 20, 21. In 2007, an efficient culture system with 
PLC/PRF/5 hepatic carcinoma cell lines was established, and A549 lung carcinoma cell lines 
was appeared proficient for a HEV3, isolated from faecal samples of a patient with acute 
hepatitis in Japan, and sustained a very high titre of HEV RNA 22. These cell lines also 
permitted the propagation of HEV4 from a faecal extract 21 as well as HEV1, HEV3, and HEV4 
from serum samples 23. Subsequently, the Kernow C1 strain of genotype 3 virus, isolated 
from a chronically infected patients, was adapted to grow in cultured HepG2/C3A cells 21. As 
a state-of-the-art culture model, efficient replication has also been performed in human 
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hepatoma 7 (HuH7) cell lines 20. There are two kinds of models for HEV infection in HuH7 
cells: a full-length infectious model and subgenomic replication model. These culture 
systems are essential for a better understanding of the biology and pathogenesis of HEV and 
potential targets for the development of antiviral drugs, and have been used for many 
research studies. Besides, several animal models have been developed for subsequent 
molecular and pathogenetic studies for HEV infection. The specific pathogen-free pigs have 
been identified as an alternative animal model for swine HEV3 and 4 infection 24. The recent 
discovery of HEV infection has been observed in numerous animal models including mouse 
25, rabbit 26, three shrew 27, mongolian gerbils 28, as well as nonhuman primates, such as 
chimpanzees 29 and various macaque species 30, 31. The advent of these models would now 
allow further investigation into the biology and pathogenesis of HEV infection, with revealing 
of its mechanistic details.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HEV and its genome. HEV particles contain a positive-sense genomic RNA of 7.2 kb 
(kilobases) that is capped and polyadenylated and carries short 50 and 30 untranslated regions 
(UTRs). During genome replication, a subgenomic RNA of 2 kb is also produced. The genomic RNA 
carries three open reading frames (orfs) that encode the nonstructural ORF1 (orange), capsid ORF2 
(blue), and regulatory ORF3 (brown) proteins. The ORF1 polyprotein carries various biochemical 
domains: methyltransferase (MT), protease (Pro), helicase (Hel), and RNA-dependent RNA 
polymerase (Pol). The ORF2 protein monomer contains three domains (shown in pink, green, and 
blue) that make up different structural elements on the HEV particles. The icosahedral 2-, 3-, and 5-
fold symmetry axes are indicated. (The HEV particle structure is adapted from Tetsuo Yamashita, et 
al.15. This figure is adapted from Rakesh Aggarwal and Shahid Jameel. Hepatology, Review 2011. 17) 
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Extra-hepatic manifestations 
HEV is a primarily hepatotropic virus, which was thought to exclusively infect hepatocytes 
resulting in hepatocellular necrosis and hepatitis. However, HEV can replicate to some 
extent in other tissues and HEV infection is associated with a broad range of idiopathic 
extrahepatic manifestations, including renal injury 32, acute pancreatitis 33, hematological 
diseases 34 and a variety of neurological disorders (Figure 3) 35.  
Kidney injury. Impaired renal function has been noted in both acute and chronic HEV 
infections 32, 34. Glomerular disease can be caused by HEV1 and 3 infection, as with other 
hepatotropic viruses 32. Membrano-proliferative and membranous glomerulonephritis of 
two different histological patterns of glomerular disease have been observed 32. The 
pathophysiological mechanisms of HEV associated renal injury are uncertain, but 
cryoglobulinemia may be an important cause for this and cryoglobulinemia has been 
documented for patients with chronic infection 32, 36. 
Neurological disorders. Among these, neurological disorders have been described as 
a relatively common, but under-recognized, extrahepatic manifestation related to HEV 
infection 9. An increasing number of central or peripheral nervous system diseases have 
been documented in patients associated with acute or chronic HEV infection 9, 37, including 
Guillain-Barré syndrome (GBS) and neuralgic amyotrophy (NA) 37, 38. To data, 91 cases of 
HEV-associated neurological injury have been documented, from both developed and 
developing countries (HEV 1 and 3, respectively). Interestingly, HEV RNA could be detected 
in the cerebrospinal fluid (CSF) of some patients with neurological disorders 35, but the exact 
incidence and underlying pathogenic mechanisms are not clear yet. Hitherto, the most 
widely held neuropathogenic hypothesis posits that HEV causes neurological injury by 
immune mechanisms related to molecular mimicry, as has been well described for GBS 
associated with a variety of infectious triggers 37, 39. In addition, clonal sequences were 
detected in the CSF and serum of a kidney transplant recipient with HEV associated 
neurological symptoms, and the quasispecies compartmentalization has been demonstrated, 
suggesting the possible link between the emergence of neurotropic variants and HEV-
associated neurological injury 40.The pathogenesis of these neurological disorders remains 
obscure and constitutes an important question in HEV infection. 
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Other complications associated with HEV. Acute pancreatitis in the setting of non-
fulminant HEV infection, as well as several musculoskeletal manifestations associated with 
the acute phase of HEV infection have been reported 34. Furthermore, hematological 
disorders including thrombocytopenia and aplastic anemia have been reported for acute 
HEV infection 40.  
In conjuction, the broad scope of extra-hepatic manifestations raises doubts as to the 
exact level of hepatotropism of HEV. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Reported sites of HEV replication. HEV infects and replicates primarily in the liver. 
However, studies performed in animal models reported HEV replication also in the small intestine, 
colon and lymph nodes as well as kidney, spleen and stomach. Furthermore, replication in the kidney 
has been recently suggested by the presence of HEV in the urine of patients with acute and chronic 
HEV as well as experimentally infected monkeys. Among extrahepatic manifestations, neurological 
complications are the most frequent. HEV RNA has been found in the cerebrospinal fluid of some 
patients with such complications and evidence for intrathecal antibody production has been 
provided in one case, suggesting possible infection of the central nervous system. The most severe 
symptoms are observed in pregnant women, possibly related to the reported infection of placental 
tissue. (Adapted from Yannick Debing, et al. Journal of Hepatology, Review 2016.6) 
 
Therapy and potential targets 
Although most cases of acute HEV infection are self-limiting and require no treatment , some 
patients with acute HEV1 or HEV3 infection have been treated with antiviral therapy. 
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Particularly in patients with either pre-existing chronic liver disease or severe or fulminant 
hepatitis, treatment of ribavirin monotherapy has been used to produce rapid clearance of 
HEV and avoid liver transplantation in some patients 41, 42. Effective treatment of pregnant 
women with acute HEV1 infection is not established and in demand. Ribavirin therapy is 
contraindicated in pregnancy due to teratogenicity 43, which hampers its usefulness. 
Chronic HEV infection is common in immunocompromised patients, in particular 
organ transplant recipients. These kind of patients represent the majority of chronic HEV 
patients. Reduction of immunosuppressive therapy in solid organ transplant (SOT) patients, 
especially of agents that target T cells 44, is often the first line of therapeutic intervention 45, 
and results in viral clearance in nearly one-third of patients 44, 46. Antiviral therapy is 
considered for patients for whom immunosuppressive therapy cannot be reduced and for 
those who fail to achieve viral clearance after reducing immunosuppressants. Although no 
approved HEV medication is available, ribavirin, interferon-α (IFN-α), or a combination have 
been successfully used as off-label treatment for some cases, in particular chronically 
infected patients 5. 
IFN signaling plays an important role in host defense system of innate immunity 47 
and several host factors 48-50 can be potential targets for the development of antiviral drugs. 
Furthermore, both viral functional structures and elements which serve for various steps in 
the HEV life cycle, including replication and translation, can also be good drug targets 51. In 
addition, interference with HEV RNA replication has been reported by using ribozymes and 
small interfering RNAs 52, 53. Never the less, it is evident that novel pharmaceutical agents to 
combat HEV infection are urgently needed. 
 
Scope of the thesis 
As outlined above, many immunocompromised patients in particular recipients of organ 
transplants, who receive various kinds of immunosuppressants to prevent rejection, have a 
high risk of developing chronic hepatitis, due to HEV infection 6. Although chronic HEV 
infection is generally associated with immunosuppressive therapies, little is known about 
how different immunosuppressants affect HEV infection. In part one of the thesis, we focus 
on evaluating the clinical impact of HEV in SOT patients and investigating the specific effects 
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and mechanisms of different immunosuppressive medication on the outcomes of HEV 
infection in hepatocytes. Apart from hepatitis, an increasing number of extra-hepatic 
manifestations such as renal injury and neurological disorders, have been reported 
associated with HEV infection. However, the etiology of HEV-associated renal and 
neurological injury is unknown. In part two, we investigate the infection biology and 
pathogenesis of HEV into the urine and nervous system. For anti-HEV therapy, although 
pegylated IFN-α, ribavirin or the combination have already been used to treat individual 
cases or small case series of HEV infection as off-label drugs, their mechanism-of-action in 
the setting of HEV remain poorly investigated. In addition, the specific new HEV antivirals 
either targeting the virus or host are with emergence to develop. In part three, we explore 
the anti-HEV potential of IFN-α, as well as several important host cell machinery and factors, 
to help with the management of HEV patients and future therapeutic development. It is 
hoped that these lines of investigation would contribute to the quest for better 
understanding and treatment for HEV infection. 
 
Outline of the thesis 
Part I: In Chapter 2 we comprehensively reviewed the prevalence, infection course, and 
management of HEV infection after solid organ transplantation, based on a series of 
published cohort studies, to evaluate the clinical impact of HEV in these patients. In Chapter 
3 we investigate the different impacts of commonly used immunosuppressants, including 
steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporin A [CsA]), and phenolic 
acid (MPA), on HEV infection in cell culture. In Chapter 4 we focus our attention on the 
effects and mechanism-of-actions of rapalogs (rapamycin and everolimus ), another group of 
important immunosuppressants, and its related PI3K-PKB-mTOR pathway, on the HEV 
replication by using two stat-of-the-art cell culture models. In conjunction, these studies 
provided an important insight in the interaction of immunosuppressive regimens and the 
antiviral immunity of host cell.  
Part II: In Chapter 5 we establish a monkey model for persistent HEV infection and 
investigate whether HEV can be disseminated into urine and lead to pathological changes 
within two monkeys at 272 and 650 days post infection. In Chapter 6 neurotropism of HEV is 
explored in various human neural cell lines, embryonic stem cell-derived neural lineage cells, 
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induced pluripotent stem (iPS) cell-derived human neurons and primary mouse neurons, as 
well as mouse and monkey animal models. We retrospectively analyze three cohorts of 18 
HEV-associated neurological patients to investigate whether HEV RNA is present in 
cerebrospinal fluid (CSF). These studies provide a rational explanation as to the HEV-
associated extra-hepatic manifestations. 
Part III: In Chapter 7 we characterize the role of cytokines in regulating HEV infection 
and investigate virus-host interactions in HEV infection with focusing on the IFN signaling, in 
comparison with HCV infection. In Chapter 8 we further investigate how interferon 
stimulated genes (ISGs), important downstream elements of IFN signaling, counteract with 
HEV infection, focusing on the action of IRF1 on HEV replication. This bears significant 
implications in management of HEV patients and future therapeutic development. In 
Chapter 9 we reasoned that since HEV exploits elements from host cell biochemistry, the 
role of three subunits of the eukaryotic translation initiation factor 4F (eIF4F) complex in 
HEV replication has been investigated. This provides important clues for the development of 
novel antiviral therapy against HEV. In Chapter 10 we explore whether the inhibition of HEV 
by well-known proteasome inhibitor, MG132, is specific. 
The novel insights obtained in this thesis will be summarized and discussed in 
Chapter 11, providing some clues to determine rational immunosuppressive therapy for 
HEV-associated immunocompromised patients, to understand the pathogenesis of 
extrahepatic manifestations, and to develop future strategies for HEV therapy. 
 
 
 
 
 
 
 
Figure 4. Different patterns of hepatitis E virus infection and outline of the thesis.  
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Abstract 
Hepatitis E virus (HEV) infection has emerged as a global public health issue. Although it 
often causes an acute and self-limiting infection with low mortality rates in the western 
world, it bears a high risk of developing chronic hepatitis in immunocompromised patients 
with substantial mortality rates. Organ transplant recipients who receive 
immunosuppressive medication to prevent rejection are thought to be the main population 
at risk for chronic hepatitis E. Therefore, there is an urgent need to properly evaluate the 
clinical impact of HEV in these patients. This article aims to review the prevalence, infection 
course, and management of HEV infection after solid organ transplantation by performing a 
comprehensive literature review. In addition, an in-depth emphasis of this clinical issue and 
a discussion of future development are also presented. 
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Introduction 
HEV infection is an emerging public health problem worldwide 1. It infects about 20 million 
people and causes 70,000 deaths every year 2. In fact, about a third of the world population 
lives in areas endemic for HEV and is at risk for infection 3. HEV is mainly an enterically 
transmitted pathogen that causes waterborne outbreaks in developing countries and 
sporadic cases of acute hepatitis in industrialized countries. There are four documented 
routes of transmission, including waterborne, zoonotic food borne, blood borne and 
perinatal mother-to-child transmission 4. Although only one serotype of HEV exists, there are 
four genotypes infecting humans based on classification of the nucleotide sequences of the 
genome 5. Genotypes 1 and 2 are found mainly in underdeveloped countries, where they are 
spread via contaminated water. In contrast, genotypes 3 and 4 are prevalent in industrialized 
countries, where they are spread mainly through eating undercooked pork or game 
products. These two genotypes are zoonotic, and animals serve as a reservoir 1, 6. In addition 
to pigs, several other animal species including deer, rats, mongoose, chickens, rabbits, trout 
and ferrets also harbor HEV strains, and thus its zoonotic potential has raised considerable 
public health concerns 7.  
Hepatitis E typically causes an acute and self-limiting infection in immune-competent 
individuals with low mortality rates in general. However, fulminant hepatitis and high 
mortality are described, reaching 25% in cases of pregnant women infected with genotype 1 
in developing countries and 70% in cases involving underlying liver disease infected with 
genotype 3 8. In contrast with immune-competent persons, HEV infection in 
immunocompromised patients, in particular organ transplant recipients who receive 
immunosuppressants to prevent rejection 9, have an increased risk of developing chronic 
hepatitis with substantial graft loss and mortality rates. No specific licensed treatment is 
available at the moment, and only its symptoms are treatable. The overall management of 
HEV during pregnancy is not different from managing jaundice due to other causes of viral 
hepatitis. However, having learned from managing HCV infection after liver transplantation 
10, 11, much effort is currently ongoing to optimize immunosuppressive medication and to 
apply potential anti-HEV regimens, in order to better manage HEV infection post-organ 
transplantation. This article aims to provide an overall view of the prevalence, disease 
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course and management of HEV infection after solid organ transplantation by performing a 
comprehensive literature review. 
 
Epidemiology and clinical manifestations 
Epidemics of hepatitis E occur periodically throughout the developing world, which are 
mainly caused by HEV genotype 1 (HEV1) in Asia and Africa, and HEV2 in Africa and Mexico. 
Outbreaks affecting thousands of people have occurred in India, China, Somalia and Uganda 
6. In 2007, an outbreak in Uganda infected more than 10,000 people and killed 160. By the 
end of September 2012, more than 200 cases of jaundice caused by hepatitis E had been 
reported in refugee camps in Kenya since August, and three refugee camps in South Sudan 
had seen 16 deaths and 400 cases of hepatitis E infection since July 2. This epidemic of 
hepatitis E is escalating across refugee camps in Maban County, South Sudan. So far, MSF 
has treated 3,991 patients (for symptoms only) in its health facilities in the camps and has 
recorded 88 deaths, including 15 pregnant women (www.msf.org, reported on 6 Feb 2013). 
The disease often affects young adults and is particularly severe among pregnant 
women and persons with preexisting liver diseases. It occurs as occasional sporadic cases, 
most often among elderly men with pre-existing illnesses 12. HEV-infected mothers can 
transmit the infection to the fetus, leading to premature birth, increased fetal loss and 
hypoglycaemia, hypothermia, and anicteric or icteric acute hepatitis in the newborn 13. The 
overall death rate among young adults and pregnant women is 0.5%-3% and 15%-25%, 
respectively 4, 8. In the Kashmir outbreak (1978-1979), 8.8%, 19.4% and 18.6% of pregnant 
women in the first, second and third trimesters, respectively, had clinical disease. In 
contrast, only 2.1% of non-pregnant women and 2.8% of men were affected 14. Occasional 
cases with atypical non-hepatic manifestations, such as acute pancreatitis, hematological 
abnormalities, autoimmune phenomena, and neurological syndromes have been reported 
13, although the pathogenesis of these manifestations remains unclear.  
Although the clinical issue of HEV infection initially was only recognized in developing 
countries, recent reports have raised awareness of this virus in western countries as well. In 
recent years, HEV3 infections have been reported in Europe, New Zealand, and North 
America. Both HEV3 and HEV4 are found in Japan 6, 15. In the developing world, HEV infection 
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is recently recognized as a potential cause of decompensation in patients with chronic liver 
disease and can result in a very high mortality 1, 16. In addition, HEV infection can easily be 
misdiagnosed as drug-induced hepatitis 1. However, the most serious clinical issue of HEV 
infection in the western countries exists in HEV-infected organ transplant recipients 17. 
Although this virus was initially thought to resemble hepatitis A with acute infection only, 
chronic infection was discovered later and exclusively among immunocompromised patients, 
including organ transplant recipients 9, HIV patients 18 and cancer patients receiving 
chemotherapy 19. This unique infection course in organ transplant patients urges further 
investigation.  
 
Prevalence of HEV infection in solid organ transplant patients 
Prevalence of anti-HEV antibodies 
Antibodies to HEV are indicative of exposure to HEV infections. Anti-HEV antibodies have 
been detected in 5%-30% of the general population in developing countries where the 
disease is endemic 20. In industrialized countries, prevalence of anti-HEV antibodies was 
reported to be 2.5% in the USA 21 and 0.4%-3% in Western Europe 22, 23, although the rates 
vary between different reports 24. IgG and IgM antibodies appear at the time of clinical 
onset, whereas IgG titers are increased and IgM decreased during recovery phase. In 
general, IgM antibody is detectable for only 3-12 months, whereas IgG antibody persists for 
many years 15. Thus, detection of IgG is commonly used for assessing seroprevalence of HEV. 
Of note, the earlier serological assays were developed for genotype 1; while these tests 
recently have been adapted to genotype 3 showing a much higher incidence. Thus, the 
interpretation of seroprevalence data needs to be cautious. 
To specifically investigate the seroprevalence of HEV in solid organ transplantation 
patients, we have searched the literature and identified 10 cohort studies (table 1) 9, 25-33, 
which performed EIA to detect anti-HEV IgG antibodies. Four studies are from France, three 
from Germany, one from the Netherlands, one from Canada and one from Iran. Out of the 
total 2202 solid organ transplant recipients, 256 (11.6%) patients were positive for anti-HEV 
IgG. Except for one study 27, all reported the IgG prevalence according to the types of organ 
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transplantation. Thus, we further sub-analyzed the prevalence in kidney (71/510; 13.9%), 
liver (53/718; 7.4%) and heart (31/274; 11.3%) transplantation (Figure 1A). 
 
Table 1. Prevalence of anti-HEV IgG antibody in solid organ transplantation patients 
Reference Patients Type of TX HEV test Seropositive Region 
9 327 KTX 241 
LTX 86 
ELISA: IgG 35 (14.5%) 
9 (10.5%) 
France 
25 49 KTX ELISA: IgG 3 (6.1%) France 
26 46 KTX ELISA: IgG 3 (6.5%) France 
27 700 KTX 529 
LTX 171 
ELISA: IgG 101 (14.4%) France 
28 226 LTX ELISA: IgG 10 (4.4%) Germany 
29 274 HTX ELISA: IgG 31 (11.3%) Germany 
30 124 KTX 83 
LTX 41 
ELISA: IgG 2 (2.4%) 
2 (4.9%) 
Germany 
31 285 LTX ELISA: IgG 10 (3.5%) Netherlands 
32 80 LTX ELISA: IgG 22 (27.5%) Canada 
33 91 KTX ELISA: IgG 28 (30.8%) Iran 
Total 2202   256 (11.6%)  
HTX, heart transplant; LTX, liver transplant; KTX, kidney transplant. 
 
Prevalence of HEV genomic RNA 
HEV is a non-enveloped virus classified as a Hepevirus in the family Hepeviridae. It has a 
positive-sense and single-stranded RNA genome, ranging from about 6.6-7.2 kb in length. 
The genome encodes three ORFs flanked by a capped 5’ end and a poly A tail at the 3’ end 7. 
ORF1 encodes a non-structural protein. ORF2 encodes the viral capsid protein involved in 
virion assembly, interaction with host cells and immunogenicity. ORF3, which overlaps ORF2, 
encodes a small protein involved in virion morphogenesis and release 6. Human HEV are 
classified into four genotypes with five, two, ten and seven subtypes for genotype 1, 2, 3 and 
4, respectively. However, with the increasing number of newly discovered strains, in 
particular from animals, the classification of HEV variants is currently still in transition 
without agreed definitions for genotypes and subtypes 34. 
Nevertheless, detection of HEV genomic RNA by RT-PCR remains a rigorous approach 
for diagnosis, confirmation and monitoring HEV infection. A World Health Organization 
standard is available, which makes reliable quantification possible 35. To assess the 
prevalence of HEV RNA in solid organ transplantation patients, we performed a literature 
search and identified 12 cohort studies 9, 26-32, 36-39 that have performed RT-PCR to detect 
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HEV genomic RNA (Table 2). Among those, eight studies also performed EIA to detect IgG 
that have already been included in Table 1.  
In total, 99 HEV RNA positive patients were identified out of 5050 (2%) organ 
transplant recipients (Table 2). Sub-analysis showed HEV RNA positivity in 43 out of 2676 
(1.6%) kidney, 20 out of 1089 (1.8%), 9 out of 533 (1.7%) heart, 11 out of 521 (2.1%) lung 
and two out of 14 (14.3%) multiple organ transplant patients (Figure 1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sub-analysis of anti-HEV IgG prevalence (A), HEV RNA prevalence (B), and risk of chronic 
development (C), according to the types of solid organ transplantation. KTX, kidney transplant; LTX, 
liver transplant; HTX, heart transplant; SOT, solid organ transplant. 
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Risk of developing chronic hepatitis 
To assess the overall risk of developing chronic hepatitis in solid organ transplant recipients 
who are positive for HEV RNA, data from the studies listed in Table 2 were analyzed 9, 26-32, 36-
39. Chronic infections developed in 64 out of 99 (64.6%) infected transplant recipients. Sub-
analysis showed that the risks of developing chronic hepatitis are higher than 60% in all 
types of transplant groups, although the included patient numbers are rather small (Figure 
1C). This is consistent with a large retrospective multicenter study (some centers overlap 
with the studies listed in Table 2) reporting 56 of 85 (65.9%) HEV infected organ transplant 
recipients developed chronic infection 40.  
 
Table 2. Prevalence of HEV genomic RNA in solid organ transplantation patients 
SOT: solid organ transplant; HTX: heart transplant; lung TX: lung transplant; LTX: liver transplant;  
KTX: kidney transplant. 
 
In fact, chronic infection with HEV could result in rapid progression to liver fibrosis 
and cirrhosis in organ transplant recipients. This has been observed in kidney 41, 42, liver 43 as 
well as heart 44 transplantation, although the exact risk rate is still unclear. It was observed 
Reference Patients Type of TX HEV test HEV RNA 
positive 
Chronic Region 
9 217 KTX 
LTX 
Multiple SOT 
RT-PCR 9 
3 
2 
3 
3 
2 
France 
26 44 KTX RT-PCR 0 0 France 
27 700 LTX 171; 
KTX 529 
RT-PCR 12 
22 
16 France 
36 1,350 KTX RT-PCR 16 12 France 
28 226 LTX RT-PCR 3 2 Germany 
29 274 HTX RT-PCR 4 4 Germany 
30 124 KTX 83 
LTX 41 
RT-PCR 1 
0 
1 Germany 
31 285 LTX RT-PCR 1 1 Netherlands 
37 1,200 HTX 259 
Lung TX 53 
LTX 300 
KTX 574 
Multiple SOT 14 
RT-PCR 5(1.9%) 
1 (1.9%) 
3 (1.0%) 
1 (0.2%) 
2 (14.3%) 
5 
1 
3 
1 
1 
Netherlands 
38 468 Lung TX RT-PCR 10 8 Netherlands 
32 66 LTX RT-PCR 1 1 Canada 
39 96 KTX RT-PCR 3 unknown Brazil 
Total 5050   99 (1.96%) 64  
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that four out of six heart transplant recipients developed advanced fibrosis within only 2 
years after HEV infection 44. In the large retrospective multicenter study 40, eight out of the 
56 infected patients developed cirrhosis, whereas two liver transplant patients required a 
second liver transplant, and two died because of decompensated cirrhosis. Similarly, HCV re-
infection after liver transplantation often results in accelerated recurrence of liver fibrosis 
and the early development of cirrhosis 45. Thus, an intriguing question regarding the main 
cause of rapid progression of advanced fibrosis and cirrhosis by HEV in organ transplant 
recipients is whether this is because of the virus itself, the suppressed immune system, 
particular immunosuppressants or a combination of factors. 
 
Management of HEV infection post-transplantation 
Manipulation of immunosuppression 
Immunosuppressants are used life-long in organ transplant patients in order to prevent 
rejection. Various types of immunosuppressive drugs with distinct mechanism of action to 
suppress the immune system are currently used in the clinic, including corticosteroids, 
calcineurin inhibitors, mTOR inhibitors, selective antiproliferative agents, and anti-
lymphocyte antibodies. Withdrawal or even dose reduction bears a high risk of acute 
rejection. The strong link between immunocompromising conditions and development of 
chronic HEV infection probably inspired the early exploration of manipulating 
immunosuppressive regimens in HEV-infected organ transplant patients. 
A potential beneficial effect of withdrawal immunosuppression was initially observed 
in a patient who developed acute hepatitis 1 month after kidney transplantation. When 
immunosuppressants were stopped because of septic shock, serum HEV RNA surprisingly 
became undetectable a few days later. When immunosuppression was re-introduced, viral 
RNA was again detected in serum. At its discontinuation, a few days later, HEV RNA became 
definitively undetectable 46. Reducing dosage of the calcineurin inhibitor tacrolimus was 
assumed to be associated with clearance of HEV in other cases of renal transplantation with 
acute infection 47. 
More evidence to support the potential benefits of reduction or withdrawal of 
immunosuppression comes from chronic patients 36, 40, 44, 46, 48, although the rates of viral 
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clearance after reduction of immunosuppression differ a lot among different studies. Eight 
of 15 kidney transplant 36, whereas only one of six heart transplant recipients 44 and three of 
15 different organ transplants 49 who could clear the virus after reduction of 
immunosuppression have been reported. In a large retrospective study, 18 of 56 transplant 
patients were reported to clear the virus after immunosuppression reduction 40. The use of 
tacrolimus has been associated with higher risk of developing chronic hepatitis, compared 
with another calcineurin inhibitor, cyclosporin A (CsA) 40, although the number of CsA users 
was small. In contrast, clearance of HEV after heart transplantation was found to be more 
frequent in patients with immunosuppressive medication containing mycophenolate mofetil 
(MMF) 29. However, this may be biased by a reduced dose of CsA or tacrolimus in these 
cases. 
Experience, learned from these case series and small cohort studies, suggests that 
dose reduction of immunosuppression should be the first intervention strategy to achieve 
viral clearance in HEV-infected immunocompromised patients 44. Nevertheless, long-term 
follow-up is required to assess the eventual outcome and this strategy should be used with 
caution in patients at higher risk of rejection or in those who are more difficult to monitor 
for rejection (e.g. in heart and lung transplantation). 
 
Antiviral therapy 
Although no proven antiviral therapy for HEV infection exists so far, interferon, ribavirin or a 
combination as off-label drugs have been used to treat individual cases or small case series. 
Apparently, this is based on the current standard therapy of chronic hepatitis C, which is a 
combination of peg-interferon-alpha with ribavirin. The therapeutic success depends on the 
genotype of HCV and the viral load at the start of therapy and during treatment. Overall, 
about half of the patients can develop a sustained virologic response (SVR, completely 
eradicate the virus) 50. However, in HCV recurrence after liver transplantation SVR rates of 
only 20% are observed 51. The combination of interferon and ribavirin has been reported to 
completely clear the virus in a chronic hepatitis E patient with HIV infection 52. Combination 
therapy was also occasionally used in incidental organ transplant recipients with chronic 
hepatitis E 40. Substantial success of peg-interferon monotherapy has been reported in 
treating chronic hepatitis E in liver transplant recipients 53, 54. However, interferon therapy is 
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contraindicated in kidney transplant patients 55, which has been associated with a high risk 
of acute rejection and subsequent kidney failure 56, 57. 
The use of ribavirin monotherapy is gaining acceptance for treating hepatitis E 
although this is not based on evidence. This is very different from the setting of chronic 
hepatitis C. Ribavirin, although showing anti-HCV activity in vitro 58, is generally considered 
to have little or no detectable anti-viral activity as monotherapy in HCV patients 59. By 
analyzing the early viral kinetics during ribavirin monotherapy, only minor and transient 
effects with 0.5-1 log reduction of HCV viral load were observed 60, 61. Only when combined 
with interferon-alpha, ribavirin doubles the response rate, compared with interferon alone 
62. However, ribavirin monotherapy seems sufficient to completely clear HEV in many 
reported uncontrolled cases. In a patient with severe acute hepatitis E patient infected with 
genotype 3 HEV, treatment with ribavirin for 21 days resulted in undetectable viral RNA in 
serum with normalization of alanine aminotransferase level 63. In four patients with 
genotype 1 HEV-induced acute on chronic liver failure, treatment with ribavirin resulted in 
clearance of the virus without serious adverse effects 64. More evidence to support ribavirin 
monotherapy comes from the organ transplantation setting. Success of HEV clearance by 
ribavirin has been claimed in various types of organ transplantation, including kidney 55, 65, 
heart 29, 44, 66, lung 38 , and multi-organ 67 recipients. In a recent prospective case series, 10 of 
11 acute HEV patients spontaneously recovered and the one with severe acute infection was 
cured after ribavirin therapy. Of 11 organ transplant recipients with prolonged HEV viraemia, 
nine patients achieved viral clearance after ribavirin treatment 49.  
The overall response rate to interferon, ribavirin or combination therapy is far from 
conclusive, because only limited number of patients have been treated so far with 
considerable variations of viral clearance rates and no randomized controls. In the large 
retrospective study, among 20 patients who received antiviral therapy (interferon = 5; 
ribavirin = 14 and combination = 1), 14 patients achieved sustained viral clearance and six 
were still viremic and still receiving therapy 40. Clearly, a proper randomized controlled trial 
of the efficacy of anti-HEV therapies is urgently called for and such an endeavor should also 
result in the definition of standard guidelines for treating hepatitis E. 
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Discussion 
The current diagnosis of HEV is based on detection of anti-HEV antibodies, PCR amplification 
of the viral RNA genome, or combination of both techniques, but none have formal Food 
and Drug Administration approval 15. Diagnosis of acute infection relies on the detection of 
specific IgM antibodies; whereas the determination of previous exposure to HEV is based on 
detection of IgG antibodies. In organ transplant patients, it is more common to evaluate the 
prevalence of IgG antibodies. Currently, a few enzyme immunoassays are available either 
developed by individual laboratories or from commercial sources. However, these assays use 
different HEV antigens and their sensitivity and specificity vary widely 68, 69. Thus, the 
detection of HEV genomic RNA from blood or fecal samples by RT-PCR serves as an 
important line for the diagnosis, confirmation and monitoring of the infection. Despite only 
one serotype, there are four genotypes as well as other less defined strains discovered from 
various infected animals 34, the genome of HEV thus can vary dramatically. Therefore, the 
design of specific primers and particular protocols for PCR amplification by different 
laboratories can result in huge bias and variation. A proper positive control, for instance 
produced by the World Health Organization, is recommended to be included in every PCR 
assay. In the organ transplant setting, the current assumption is that these patients are only 
affected by genotype 3 HEV. The published studies almost exclusively focused on the 
diagnosis of genotype 3. An intriguing question is whether other genotypes can also infect 
these patients. It will be of great interest, for instance, to evaluate the prevalence of 
genotype 1 in transplant patients in Asia. Although a combination of serologic and molecular 
7assays were used for many of the studies in the transplant setting, there is still a possibility 
of positivity for only antibody or only viral RNA 37, 39. Thus, there is an urgent need for 
developing robust and standardized diagnostic assays, possibly combining both serology and 
molecular techniques and including properly produced control materials.  
Other than immunosuppressive medication, whether genotype is also responsible for 
chronic progression could be an interesting question because only genotype 3 is reported in 
organ transplant patients. Regarding immunosuppression in general, clinical evidence 
showed that lymphocyte subset counts, mainly cluster of differentiated 4 T-cells, were found 
to be significantly lower in HEV patients who then evolved to chronicity compared with 
those who cleared the virus within 6 months 9. It is not surprising that a healthy immune 
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system can control and even eliminate the infection. Thus, dose reduction or even 
withdrawal (if possible) of immunosuppression is the first intervention strategy to achieve 
viral clearance in HEV-infected transplant patients 44, although bearing the risk of graft 
rejection. Another aspect learned from HCV recurrence in liver transplantation is that 
different types of immunosuppressants could interact positively or negatively with the host 
immune system as well as with the virus directly 11. In fact, there is evidence in HEV-
transplant patients that tacrolimus but not CsA has been found to be more frequently 
associated with persistent infection 40, whereas MMF may help to clear the virus 29. 
However, the current clinical studies are not able to conclusively address the impact of 
different immunosuppressants, because of limited patient numbers. Thus, there is 
substantial room for fundamental and translational research to further investigate these 
interesting questions by using state-of-art HEV cell culture 70 and possibly animal models 71, 
72. 
Despite a clear benefit of manipulating immunosuppressive regimens, a substantial 
proportion of patients is still not able to clear the virus and rapidly progresses towards 
chronic hepatitis 40. Antiviral therapy appears to be the only option for managing those 
patients. Although no proven medication is available for HEV, transplant hepatologists have 
apparently learned from the standard treatment of chronic hepatitis C. Strikingly, ribavirin 
monotherapy appears sufficient to achieve HEV clearance in some reported patients, 
whereas ribavirin is only effective when combined with interferon for treating chronic 
hepatitis C. Its anti-HCV mechanism has been proposed as direct inhibition of viral 
replication by depletion of intracellular nucleotide pool, “error catastrophe” or 
immunomodulation 73, although much is still not proven and controversial 74. A joint effort 
from the bed and the bench is thus required to solidly evaluate the anti-HEV efficacy and the 
working mechanism of ribavirin. A potential limitation of ribavirin is side effects, in particular 
for transplant patients already under immunosuppression. One death has been reported 
after experiencing a virological breakthrough associated with ribavirin dose reduction 
because of severe anaemia 49. Another cautionary note is that drug-drug interactions may 
occur between ribavirin and particular immunosuppressants. Development of new antiviral 
therapy would be another scenario, although there is apparent lack of interest from 
pharmaceutical companies because of low rate of financial return for this disease. Thus, the 
hope and responsibility of developing new anti-HEV remedies now rest on academia. 
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Conclusion 
On the basis of a series of published cohort studies, the prevalence of anti-HEV IgG is 
approximately 11.6% and genomic viral RNA is 2% in solid organ transplant patients. A total 
of 65% of patients who were positive for HEV RNA developed chronic infection. Reduction of 
immunosuppression is the first intervention strategy to achieve viral clearance, otherwise 
treatment with off-label antivirals, in particular ribavirin, should be considered. Because of 
limited patient numbers and no randomized trials, the exact efficacy and safety of either 
immunosuppression reduction or antiviral therapy are inconclusive. However, the clinical 
evidence is encouraging for these two approaches.  
Nevertheless, HEV remains largely under diagnosed in the general population as well 
as in transplant patients. Because only a few transplant centers are performing the screening 
primarily for research purposes, with technical limitations and possible patient selection 
bias, the data represented by this study may not be able to fully reflect the real clinical 
status. However, this is a moment to call attention to this emerging clinical issue in the 
transplant setting, hopefully leading to proper positioning of its clinical impact soon and 
finally solving the problems.  
 
Chapter 2 
42 
References 
1. Dalton HR. Hepatitis: hepatitis E and decompensated chronic liver disease. Nat Rev 
Gastroenterol Hepatol 9, 430-432 (2012). 
2. Park SB. Hepatitis E vaccine debuts. Nature 491, 21-22 (2012). 
3. Ahmad I, Holla RP & Jameel S. Molecular virology of hepatitis E virus. Virus Res 161, 47-58 
(2011). 
4. Mushahwar IK. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, 
epidemiology, and prevention. J Med Virol 80, 646-658 (2008). 
5. Purdy MA & Khudyakov YE. The molecular epidemiology of hepatitis E virus infection. Virus 
Res 161, 31-39 (2011). 
6. Kamar N, et al. Hepatitis E. Lancet 379, 2477-2488 (2012). 
7. Raj VS, et al. Novel hepatitis E virus in ferrets, the Netherlands. Emerg Infect Dis 18, 1369-
1370 (2012). 
8. Moal V, Zandotti C & Colson P. Emerging viral diseases in kidney transplant recipients. Rev 
Med Virol 23, 50-69 (2013). 
9. Kamar N, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J 
Med 358, 811-817 (2008). 
10. Ciesek S & Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV 
recurrence. J Viral Hepat 19, 1-8 (2012). 
11. Pan Q, Tilanus HW, Metselaar HJ, Janssen HL & van der Laan LJ. Virus-drug interactions--
molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol 9, 355-
362 (2012). 
12. Borgen K, et al. Non-travel related Hepatitis E virus genotype 3 infections in the Netherlands; 
a case series 2004 - 2006. BMC Infect Dis 8, 61 (2008). 
13. Aggarwal R & Jameel S. Hepatitis E. Hepatology 54, 2218-2226 (2011). 
14. Khuroo MS, Teli MR, Skidmore S, Sofi MA & Khuroo MI. Incidence and severity of viral 
hepatitis in pregnancy. Am J Med 70, 252-255 (1981). 
15. Hoofnagle JH, Nelson KE & Purcell RH. Hepatitis E. N Engl J Med 367, 1237-1244 (2012). 
16. De Silva S, Hassan-Ibrahim MO, Austin M, Newport M & Verma S. Hepatitis E infection is an 
under recognized cause of acute decompensation in patients with chronic liver disease. Dig 
Liver Dis 44, 930-934 (2012). 
17. Kamar N, Legrand-Abravanel F, Izopet J & Rostaing L. Hepatitis E virus: what transplant 
physicians should know. Am J Transplant 12, 2281-2287 (2012). 
18. Dalton HR, Bendall RP, Keane FE, Tedder RS & Ijaz S. Persistent carriage of hepatitis E virus in 
patients with HIV infection. N Engl J Med 361, 1025-1027 (2009). 
19. Ollier L, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin 
lymphoma taking rituximab. Ann Intern Med 150, 430-431 (2009). 
20. Aggarwal R & Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 24, 
1484-1493 (2009). 
21. Tsang TH, et al. Acute hepatitis E infection acquired in California. Clin Infect Dis 30, 618-619 
(2000). 
HEV in organ transplantation 
43 
22. Ijaz S, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, 
and molecular epidemiological characteristics. J Infect Dis 192, 1166-1172 (2005). 
23. Mansuy JM, et al. Hepatitis E in the south west of France in individuals who have never 
visited an endemic area. J Med Virol 74, 419-424 (2004). 
24. Scotto G, Martinelli D, Giammario A, Prato R & Fazio V. Prevalence of antibodies to hepatitis 
e virus in immigrants: a seroepidemiological survey in the district of foggia (Apulia-southern 
Italy). J Med Virol 85, 261-265 (2013). 
25. Buffet C, et al. A high hepatitis E virus seroprevalence among renal transplantation and 
haemophilia patient populations. J Hepatol 24, 122-125 (1996). 
26. Maylin S, et al. Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of 
French immunocompromised. J Clin Virol 53, 346-349 (2012). 
27. Legrand-Abravanel F, et al. Hepatitis E virus infection without reactivation in solid-organ 
transplant recipients, France. Emerg Infect Dis 17, 30-37 (2011). 
28. Pischke S, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant 
recipients. Liver Transpl 16, 74-82 (2010). 
29. Pischke S, et al. Chronic hepatitis e in heart transplant recipients. Am J Transplant 12, 3128-
3133 (2012). 
30. Hoerning A, et al. Prevalence of hepatitis E virus infection in pediatric solid organ transplant 
recipients--a single-center experience. Pediatr Transplant 16, 742-747 (2012). 
31. Haagsma EB, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver 
Transpl 15, 1225-1228 (2009). 
32. Halac U, et al. Chronic hepatitis E infection in children with liver transplantation. Gut 61, 597-
603 (2012). 
33. Rostamzadeh Khameneh Z, Sepehrvand N & Masudi S. Seroprevalence of hepatitis E among 
Iranian renal transplant recipients. Hepat Mon 11, 646-651 (2011). 
34. Smith DB, Purdy MA & Simmonds P. Genetic variability and the classification of hepatitis E 
virus. J Virol 87, 4161-4169 (2013). 
35. Baylis SA, Hanschmann KM, Blumel J, Nubling CM & Group HEVCS. Standardization of 
hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to 
evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol 49, 
1234-1239 (2011). 
36. Moal V, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern 
France. J Med Virol 85, 462-471 (2013). 
37. Pas SD, et al. Hepatitis E virus infection among solid organ transplant recipients, the 
Netherlands. Emerg Infect Dis 18, 869-872 (2012). 
38. Riezebos-Brilman A, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart 
Lung Transplant 32, 341-346 (2013). 
39. Passos AM, Heringer TP, Medina-Pestana JO, Ferraz ML & Granato CF. First report and 
molecular characterization of hepatitis E virus infection in renal transplant recipients in Brazil. 
J Med Virol 85, 615-619 (2013). 
40. Kamar N, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus 
infection who have received solid organ transplants. Gastroenterology 140, 1481-1489 
(2011). 
Chapter 2 
44 
41. Kamar N, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant 
recipients. Am J Transplant 8, 1744-1748 (2008). 
42. Gerolami R, Moal V & Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant 
recipient. N Engl J Med 358, 859-860 (2008). 
43. Haagsma EB, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver 
Transpl 14, 547-553 (2008). 
44. Koning L, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant 
recipients. J Heart Lung Transplant 32, 78-85 (2013). 
45. van der Laan LJ, et al. Results of a two-center study comparing hepatic fibrosis progression in 
HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. Transplant Proc 
42, 4573-4577 (2010). 
46. Kamar N, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 
hepatitis-E virus infection after organ transplantation. Transplantation 89, 353-360 (2010). 
47. Kamar N, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. 
Transplantation 93, 617-623 (2012). 
48. Halleux D, Kanaan N, Kabamba B, Thomas I & Hassoun Z. Hepatitis E virus: an 
underdiagnosed cause of chronic hepatitis in renal transplant recipients. Transpl Infect Dis 14, 
99-102 (2012). 
49. Pischke S, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre 
experience. Liver Int, 33, 722-726 (2013). 
50. Pan Q, Peppelenbosch MP, Janssen HL & de Knegt RJ. Telaprevir/boceprevir era: from bench 
to bed and back. World J Gastroenterol 18, 6183-6188 (2012). 
51. Samuel D, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after 
liver transplantation: a randomized study. Gastroenterology 124, 642-650 (2003). 
52. Dalton HR, Keane FE, Bendall R, Mathew J & Ijaz S. Treatment of chronic hepatitis E in a 
patient with HIV infection. Ann Intern Med 155, 479-480 (2011). 
53. Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ & Niesters HG. Treatment of 
chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver 
Transpl 16, 474-477 (2010). 
54. Kamar N, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after 
liver transplantation. Clin Infect Dis 50, e30-33 (2010). 
55. Kamar N, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e 
virus infection. Gastroenterology 139, 1612-1618 (2010). 
56. Weimar W, et al. The incidence of cytomegalo- and herpes simplex virus infections in renal 
allograft recipients treated with high dose recombinant leucocyte interferon: a controlled 
study. Scand J Urol Nephrol Suppl 92, 37-39 (1985). 
57. Rostaing L, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in 
kidney transplant recipients. Transplantation 59, 1426-1431 (1995). 
58. Pan Q, Tilanus HW, Janssen HL & van der Laan LJ. Ribavirin enhances interferon-stimulated 
gene transcription by activation of the interferon-stimulated response element. Hepatology 
53, 1400-1401; author reply 1402 (2011). 
59. Lee JH, et al. Effect of ribavirin on virus load and quasispecies distribution in patients infected 
with hepatitis C virus. J Hepatol 29, 29-35 (1998). 
HEV in organ transplantation 
45 
60. Pawlotsky JM, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 
703-714 (2004). 
61. Rotman Y, et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic 
hepatitis C. Gut, 63, 161-169 (2014). 
62. Poynard T, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 
weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection 
with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352, 
1426-1432 (1998). 
63. Gerolami R, et al. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol 52, 60-62 
(2011). 
64. Goyal R, Kumar A, Panda SK, Paul SB & Acharya SK. Ribavirin therapy for hepatitis E virus-
induced acute on chronic liver failure: a preliminary report. Antivir Ther 17, 1091-1096 (2012). 
65. de Niet A, et al. Chronic hepatitis E after solid organ transplantation. Neth J Med 70, 261-266 
(2012). 
66. Chaillon A, et al. Sustained virologic response with ribavirin in chronic hepatitis E virus 
infection in heart transplantation. J Heart Lung Transplant 30, 841-843 (2011). 
67. Mallet V, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis 
E. Ann Intern Med 153, 85-89 (2010). 
68. Bendall R, Ellis V, Ijaz S, Ali R & Dalton H. A comparison of two commercially available anti-
HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. 
J Med Virol 82, 799-805. 
69. Ghabrah TM, et al. Comparison of tests for antibody to hepatitis E virus. J Med Virol 55, 134-
137 (1998). 
70. Shukla P, et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture 
depends on an inserted human gene segment acquired by recombination. J Virol 86, 5697-
5707 (2012). 
71. Purcell RH & Emerson SU. Animal models of hepatitis A and E. ILAR J 42, 161-177 (2001). 
72. Boonstra A, van der Laan LJ, Vanwolleghem T & Janssen HL. Experimental models for 
hepatitis C viral infection. Hepatology 50, 1646-1655 (2009). 
73. Feld JJ & Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of 
hepatitis C. Nature 436, 967-972 (2005). 
74. Paeshuyse J, Dallmeier K & Neyts J. Ribavirin for the treatment of chronic hepatitis C virus 
infection: a review of the proposed mechanisms of action. Curr Opin Virol 1, 590-598 (2011). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 3 
 
Calcineurin inhibitors stimulate and mycophenolic acid 
inhibits replication of hepatitis E virus 
 
YijinWang1, Xinying Zhou1, Yannick Debing2, Kan Chen1,3, Luc J.W. van der Laan4,  
Johan Neyts2, Harry L. A. Janssen1,5, Herold J. Metselaar1,  
Maikel P. Peppelenbosch1, and Qiuwei Pan1 
 
1Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center 
and Postgraduate School Molecular Medicine, Rotterdam, Netherlands; 2Department of 
Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, 
Belgium; 3Bio-X Center, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, 
China; 4Department of Surgery, Erasmus MC-University Medical Center and Postgraduate 
School Molecular Medicine, Rotterdam, Netherlands; and 5Division of Gastroenterology, 
University Health Network, Toronto, Canada 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gastroenterology. 2014 Jun; 146:1775-1783.  
  
 
Immunosuppressants differentially affect HEV 
49 
Abstract 
Background and aims: Many recipients of organ transplants develop chronic hepatitis, due 
to infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally 
associated with immunosuppressive therapies, little is known about how different 
immunosuppressants affect HEV infection. Methods: A subgenomic HEV replication model, 
in which expression of a luciferase reporter gene is measured, and a full-length infection 
model were used. We studied the effects of different immunosuppressants, including 
steroids, calcineurin inhibitors (tacrolimus [FK506] and cyclosporine A), and mycophenolic 
acid (MPA, an inhibitor of inosine monophosphate dehydrogenase) on HEV replication in 
human hepatoma cell line Huh7. Expression of cyclophilins A and B (the targets of 
cyclosporine A) were knocked down using small hairpin RNAs. Results: Steroids had no 
significant effect on HEV replication. Cyclosporine A promoted replication of HEV in the 
subgenomic and infectious models. Knockdown of cyclophilin A and B increased levels of 
HEV genomic RNA by 4.0 ± 0.6-fold and 7.2 ± 1.9-fold, respectively (n = 6, P < 0.05). A high 
dose of FK506 promoted infection of liver cells with HEV. In contrast, MPA inhibited HEV 
replication. Incubation of cells with guanosine blocked the antiviral activity of MPA, 
indicating that the antiviral effects of this drug involve nucleotide depletion. The 
combination of MPA and ribavirin had a greater ability to inhibit HEV replication than MPA 
or ribavirin alone. Conclusions: Cyclophilins A and B inhibit replication of HEV; this might 
explain the ability of cyclosporine A to promote HEV infection. On the other hand, the 
immunosuppressant MPA inhibits HEV replication. These findings should be considered 
when physicians select immunosuppressive therapies for recipients of organ transplants who 
are infected with HEV. 
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Introduction 
Hepatitis E virus (HEV) is one of the most common causes of acute hepatitis worldwide. It is 
a single-stranded positive-sense RNA virus, which mainly infects the liver hepatocytes. 
Although only a single HEV serotype is recognized, at least four different genotypes of 
human HEV exist 1. Genotypes 1 and 2 are found mainly in developing countries and are 
transmitted via contaminated water sources. In contrast, genotypes 3 and 4 are prevalent in 
industrialized countries, and are zoonotic nature and spread mainly through eating 
undercooked pork or game products 2. In general, HEV infection is a self-limiting disease and 
associated with low mortality, but fulminant hepatitis and high mortality have been 
described, reaching 25% in cases of pregnant women infected with genotype 1 in developing 
countries 3. In the Western world, the main clinical challenge is posed by HEV genotype 3 
infection in patients receiving orthotopic organ transplantation 4. More than 60% of organ 
recipients infected with HEV will develop chronic hepatitis with rapid progression to cirrhosis 
5, 6. Which factors determine outcome in these patients remains obscure at best, hampering 
efforts to develop rational therapy and to address the increasing challenge of HEV infection 
in organ transplantation recipients. 
Organ transplant patients take immunosuppressants for life-long, in order to prevent 
graft rejection. The resulting immunosuppression, however, also affects host immunity 
against viral challenges, and the use of immunosuppressive drugs has been proposed to be a 
key factor for developing chronic hepatitis after HEV infection 4. Consequently, dose 
reduction of immunosuppression is often used as the first intervention strategy to achieve 
viral clearance in HEV-infected organ recipients 7. Interestingly, however, clinical evidence 
suggests that different immunosuppressive regimens can differentially affect the infection 
course of HEV. The calcineurin inhibitor tacrolimus, but not cyclosporin A (CsA), has been 
found to be more frequently associated with persistent infection 6, and mycophenolate 
mofetil (MMF), the pre-drug form of mycophenolic acid (MPA) can help to clear the virus 8. 
However, the current clinical studies are not able to conclusively address the impact of 
different immunosuppressants because of limited patient numbers and lack of mechanistic 
insight as to how differences in immunosuppressive medication might be linked with an 
altered clinical course of HEV infection. 
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The observation that different immunosuppressive medication seems to have specific effects 
on the outcome of HEV infection suggests that such medication can have direct effects on 
viral replication, apart from influencing antiviral immunity. This consideration prompted us 
to test whether different immunosuppressive medication affects HEV replication in 
hepatocytes directly. The recent development of a genotype 3-based cell culture system 9, 10 
makes it possible to study such questions in a highly detailed fashion. We show that 
different commonly used immunosuppressants have very specific effects on viral replication 
and that especially calcineurin inhibitors strongly facilitate HEV replication, and MPA 
suppresses viral replication. Thus, these results will serve as an important reference about 
the choice of particular immunosuppressive medication for HEV-infected orthotopic organ 
transplant recipients. 
 
Materials and methods  
Immunosuppressants 
CsA and tacrolimus (FK506) were purchased from Abcam (Cambridge, MA). Dexamethasone 
(Dex), prednisolone (Pred) and MPA were purchased from sigma (St Louis, MO). All the 
reagents were dissolved in dimethylsulfoxide (DMSO), except MPA, which was dissolved in 
methanol. The effects of these immunosuppressants on host cell viability were determined 
by MTT assay (Supplementary Figure 1). 
 
Cell culture  
Human hepatoma cell line Huh7 and human embryonic kidney epithelial cell line 293T cells 
were cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum, 100 IU/mL penicillin and 100 IU/mL 
streptomycin. 
 
HEV cell culture models 
A plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank 
Accession Number JQ679013) and a construct containing subgenomic HEV sequence coupled 
with a gaussia luciferase reporter gene (p6-Luc) were used to generate HEV genomic RNA by 
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using the Ambion mMESSAGE mMACHINE® in vitro RNA transcription Kit (Life Technologies 
Corporation) 9, 10. Huh7 cells were electroporated with p6 full-length HEV RNA or p6-Luc 
subgenomic RNA to generate infectious or replication models, respectively 10. 
 
Quantification of HEV infection 
For the HEV replication model (p6-Luc), the activity of secreted gaussia luciferase in the cell 
culture medium was measured using BioLux® Gaussia Luciferase Flex Assay Kit (New England 
Biolabs, Ipswich, MA), as quantification of viral replication. To further determine the specific 
effects on viral replication-related luciferase activity, Huh7 cells constitutively expressing the 
firefly luciferase reporter gene driven by the human PGK promoter were used as household 
luciferase activity for normalization 11. For firefly luciferase, luciferin potassium salt (100 mM; 
Sigma) was added to cells and incubated for 30 minutes at 37°C. Both gaussia and firefly 
Luciferase activity were quantified with a LumiStar Optima luminescence counter (BMG 
LabTech, Offenburg, Germany). 
For the p6 infectious HEV model, SYBR Green-based quantitative real-time 
polymerase chain reaction (qRT-PCR) was used to quantify genomic RNA. The HEV primer 
sequences were 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-
CCGTGGCTATAATTGTGGTCT-3’ (antisense), and the primers of housekeeping gene GAPDH 
were 5’-TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
(antisense). 
 
Gene knockdown by lentiviral vector delivered short hairpin RNA 
Lentiviral vectors, targeting  Cyclophilin A (CypA), Cyclophilin B (CypB) or GFP, were 
produced in 293T cells as previously described 12. After pilot study, the shRNA vectors 
exerting optimal gene knockdown were selected. The shRNA sequences were: CypA, 5’-
CCGGTGGTGACTTCACACGCCATAACTCGAGTTATGGCGTGTGAAGTCACCATTTTTG-3’, and CypB, 
5’-CCGGGCCTTAGCTACAGGAGAGAAACTCGAGTTTCTCTCCTGTAGCTAAGGCTTTTTG-3’. 
To generate stable gene knockdown cells, Huh7 cells were transduced with lentiviral 
vectors. Since the vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 2.5 µg/ml puromycin (Sigma) in the cell culture medium. 
For the infectious model, HEV particles were incubated with knockdown and control Huh7 
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cells. For the subgenomic model, p6-Luc cells were directly transduced with lentiviral shRNA 
vectors and selected by adding 2.5 µg/ml puromycin. 
 
Western blot 
For Western blot, commercial antibodies against CypA and CypB (Rabbit polyclonal; Abcam, 
Cambridge, UK) were used. Proteins in cell lysates were heated 5 min at 95°C followed by 
loading onto a 15% sodium dodecyl sulfate-polyacrylamide SDS gel and separating by 
electrophoresis (SDS-PAGE). After 90 minutes running in 115 V voltage, proteins were 
electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane 
(Invitrogen) for 1.5 hour with an electric current of 250 mA. Subsequently, the membrane 
was blocked with 2.5 mL blocking buffer and 2.5 mL PBS containing 0.05% Tween 20 (PBS-T). 
It was followed by incubation with rabbit anti-CypA (1:5000) or anti-CypB (1:7500) antibody 
overnight at -4°C. Membrane was washed 3 times followed by incubation for 1.5h with an 
anti-rabbit peroxidase conjugated secondary antibody (1:5,000). After 3 times washing, 
protein bands were detected with Odyssey 3.0 Infrared Imaging System. 
 
Statistical analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann–Whitney 
test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values less than 0.05 
were considered statistically significant. 
 
Results 
Glucocorticosteroids did not affect HEV replication 
Prednisolone (Pred) and its close analogue dexamethasone (Dex) remain important drugs in 
the clinical management of patients receiving orthotopic organ transplantation 13. To study 
the possible effects of these drugs on HEV replication, we used a model in which cells were 
transfected with a subgenomic construct of HEV coding sequence in which the 5’ portion of 
ORF2 was replaced with the in-frame secreted form of luciferase derived from the marine 
copepod Gaussia princeps. Accumulation of luciferase thus serves as reporter for HEV RNA 
synthesis (p6-Luc), and the loss of the capsid protein precludes the formation of novel viral 
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particles. In parallel, Huh7 cells constitutively expressing a non-secreted firefly luciferase 
were used for normalization of non-specific effects on luciferase signals. However, as shown 
in Figure 1, neither Pred nor Dex significantly affected HEV replication. We conclude that 
steroids have no direct effects on HEV replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The effects of steroids on HEV replication in subgenomic cell culture model. Huh7 cells-
based subgenomic HEV replicon containing the luciferase reporter gene was treated for 24h, 48h and 
72h with a dose-range of Dex and Pred. (A) Dex and Pred (B) didn’t significantly affect luciferase 
activity. Date represent as Mean ± SD of three independent experiments. 
 
CsA dose-dependently enhanced HEV replication 
CsA, a calcineurin inhibitor, is an important drug for prevention of graft rejection. To 
examine the effects of CsA on HEV replication, We tested the effects of 0.1, 0.5 and 5 μg/mL 
CsA on viral replication using the subgenomic p6-Luc model as a read-out. It appeared that 
CsA dose-dependently increased HEV replication-related luciferase activity (Figure 2A). 
Consistently, CsA also dose-dependently increased HEV infection in the full-length (p6) 
infectious model (Figure 2B). 48 hours treatment with CsA (5 μg/mL) resulted in 2.67 ± 0.7-
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fold (Mean ± SD, n = 5, P < 0.01) increase of HEV genomic RNA level (determined by qRT-
PCR), compared with the control (Figure 2B). CsA directly promotes viral replication in a 
hepatocyte-like cells and experimentation was initiated to establish the molecular basis of 
this effect. 
 
 
Figure 2. CsA promoted HEV infection. (A) The subgenomic HEV replicon containing the luciferase 
reporter gene was treated for 24 (n = 5), 48 (n = 7) and 72 hours (n = 7) with different doses of CsA. 
Treatment with CsA (0.5 or 5 μg/mL) significantly increased HEV luciferase activity. (B) The Huh7 
cells-based infectious HEV model was treated with CsA for 48 hours. CsA significantly increased HEV 
RNA at 0.5 and 5 μg/mL concentrations (n = 5). Date represent as Mean ± SD of multiple 
experiments. * P < 0.05; ** P < 0.01. 
 
Silencing the cellular targets of CsA, cyclophilin A and B, enhanced HEV 
replication 
CsA acts through binding and inhibition of the cyclophilin A/B complex. The effects of CsA on 
HEV replication could be potentially mediated through cyclophilins. Cyclophilin A (CypA) 14 
and B (CypB) 15 have been implicated in the anti-hepatitis C virus (HCV) mechanism of CsA. 
Therefore, lentiviral-mediated RNA interference was used for knockdown of these two genes, 
as to allow investigation of their potential function in the effects of CsA on HEV replication. 
To this end, Huh7 cells were transduced with integrating lentiviral vectors expressing both 
shRNA and puromycin. Cells stably transduced with the vector were selected and expanded 
by adding puromycin to the relevant cell cultures. The shRNA clones with most potent 
efficacy of CypA and CypB knockdown were selected for follow-up experimentation (Figure 
3A). Cells stably integrated with shRNA targeting GFP (as control), CypA or CypB were 
inoculated with infectious HEV viruses (p6). The level of infection was quantified by qRT-PCR 
of genomic viral RNA in the cells 3 days post-inoculation. As shown in Figure 3B, knockdown 
of CypA has resulted in 4.0 ± 0.6-fold (Mean ± SEM, n = 6, P < 0.01) increase of HEV RNA; 
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whereas knockdown of CypB has resulted in 7.4 ± 1.9-fold (Mean ± SEM, n = 6, P < 0.05) 
increase of viral gemonic RNA. Consistently, silencing of CypA and CypB in HEV subgenomic 
model significantly increased viral replication-related luciferase activity by 350.4 ± 11.7% 
(Mean ± SEM, n = 12, P < 0.0001) and 406 ± 14.5% (Mean ± SEM, n = 12, P < 0.0001), 
respectively (Figure 3C). The most straightforward explanation of these results is that CsA 
through cyclophilin binding and inhibition facilitates HEV infection (Figure 2). 
 
 
 
 
 
 
 
 
Figure 3. Gene silencing of CypA or CypB 
facilitated HEV infection. (A) Western 
blotting showed dramatic down-regulation 
of CypA and CypB protein by lentiviral RNAi 
mediated gene knockdown. (B) Silencing of 
CypA or CypB resulted in a significant 
increase of cellular HEV RNA. Date 
represent as Mean±SEM of six independent 
experiments. * P < 0.05. (C) Silencing of 
CypA or CypB significantly increased viral 
replication-related luciferase activity in the 
HEV subgenomic model (Mean ± SEM, n = 
12 replicates of three experiments in total). 
*** P < 0.001. 
 
 
High dose of FK506 promoted HEV replication  
FK506 is another type of calcineurin inhibitor that binds to FK binding proteins. To determine 
the effects of FK506 on HEV replication, p6-Luc cells were treated with FK506 at 
concentrations of 0.1, 0.5 and 5 μg/mL. As shown in Figure 4A, only high does (5 μg/mL) of 
FK506 significantly increased HEV replication, seen at 24, 48 and 72 hours post-treatment. 
This was also further confirmed in the p6 infectious model that HEV genomic RNA was 
increased by 35 ± 9.6% (Mean ± SD, n = 4, P < 0.01) by treatment with 5 μg/mL FK506 for 48 
hours (Figure 4B).  
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Because the immunosuppressive mechanisms of calcineurin inhibitors are mediated 
via the Ca2+-NFAT signal transduction, we tested the effects of N,N-Dimethyl-D-erythro-
sphingosine (DMS), a compound that can efficiently increase cellular Ca2+ levels,16 on HEV 
infection. As shown in Supplementary Figure 2A, DMS (1-4 µg/ml) triggered clear induction 
of Ca2+ levels in Huh7 cells visualized with a fluorescent dye, Fluo-4/AM. However, no clear 
effects were observed on HEV infection in either the subgenomic (Supplementary Figure 2B) 
or the infectious (Supplementary Figure 2C) model. Thus, the proviral effects of calcineurin 
inhibitors on HEV infection appear to be independent of Ca2+ levels. 
 
 
Figure 4. High dose of FK506 enhanced HEV infection. (A) Treatment with 5 μg/mL (but not 0.5 and 1 
μg/mL) resulted in significant increase of luciferase activity in the HEV subgenomic model (Mean ± 
SD, n = 5-8) and (B) significant increase of HEV RNA in the infectious model (Mean ± SD, n = 4). * P < 
0.05; ** P < 0.01; *** P < 0.001.  
 
MPA inhibited HEV replication by depletion of cellular nucleotide pool  
MPA, an inhibitor of inosine monophosphate dehydrogenase (IMPDH) (the biosynthesis of 
guanine), is an immunosuppressive drug often used in organ transplantation, but also has a 
broad antiviral activity against a spectrum of viruses 17. We investigated whether MPA could 
also be able to inhibit HEV infection. Treatment with MPA (0.1-10 μg/mL) has resulted in a 
significant reduction of HEV replication-related luciferase activity in the subgenomic replicon. 
For example, with 10 μg/mL MPA treatment, the luciferase activity were 42.8 ± 2.3% (Mean 
± SEM, n = 9, P < 0.001), 32.8 ± 5.3% (Mean ± SEM, n = 10, P < 0.001) and 39.5 ± 4.6% (Mean 
± SEM, n = 12 P < 0.001) of the control group at day 1, 2 and 3, respectively (Figure 5A). 
Consistently, MPA also dose-dependently inhibited cellular viral RNA in the infectious HEV 
model. 48 hours treatment with MPA (10 μg/mL) resulted in 65 ± 9% (Mean ± SD, n = 5, P < 
0.01) inhibition of HEV genomic RNA level (determined by qRT-PCR), compared with the 
control (Figure 5B).  
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Figure 5. Potent anti-HEV activity of MPA. (A) Treatment of MPA for 24, 48 or 72 hours has resulted 
in significant reduction of HEV luciferase activity in the subgenomic model (Mean ± SEM, n = 9-12). 
(B) In the infectious model, treatment with 0.1, 1 and 10 μg/mL of MPA for 48 hours has significantly 
inhibited HEV RNA by 32%, 57% and 65%, respectively (Mean ± SD, n = 5). * P < 0.05; ** P < 0.01; *** 
P < 0.001.  
 
To further investigate whether the effects of MPA are via depletion of cellular 
nucleotides, additional guanosine was added to the MPA treatment. As shown in Figure 6, 
supplement of exogenous guanosine completely abrogated the antiviral activity of MPA in 
both subgenomic and infectious HEV models, suggesting that the action of MPA is 
exclusively via nucleotide depletion. Immunosuppressive drugs have highly diverse effects 
on HEV replication, calcineurin inhibitors stimulating viral replication but MPA exerting direct 
inhibition of HEV replication 
 
 
 
 
 
 
 
 
Figure 6. Supplement of exogenous guanosine completely abrogated the anti-HEV effects of MPA. 
(A) In the subgenomic HEV replicon, the antiviral effects by treatment of MPA at concentration of 10 
μg/mL for 24, 48 and 72 hours were abrogated by adding exogenous guanosine (100 μg/mL) (Mean ± 
SEM, n = 7-10). (B) Similarly, the antiviral effects by treatment of MPA at concentration of 10 μg/mL 
for 48h was also abrogated by adding 100 μg/mL exogenous guanosine in the infectious model 
(Mean ± SEM, n = 8). ** P < 0.01; *** P < 0.001. 
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Figure 7. Combination of MPA with ribavirin extended their antiviral activity. Treatment with 
ribavirin alone has showed significant anti-HEV effects (Mean ± SEM, n = 16 replicates in total) and a 
combination of MPA with ribavirin demonstrated an additional antiviral potency in particular 
combination groups; MPA doses: 1 µg/ml; 10 µg/ml; ribavirin doses: 25 µm; 100 µm. (A) 1 µg/ml 
MPA combined with 25 µm ribavirin. (B) 10 µg/ml MPA combined with 25 µm ribavirin. (C) 10 µg/ml 
MPA combined with 100 µm ribavirin. (D) 1 µg/ml MPA combined with 25 µm ribavirin * P < 0.05; ** 
P < 0.01; *** P < 0.001. 
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Combination of MPA with ribavirin extended their antiviral activity  
Because the use of ribavirin monotherapy as off-label drug is gaining favor for treating 
hepatitis E 18, we also investigated the antiviral effects of combining MPA with ribavirin. As 
shown in Figure 7, a serial of combination groups have demonstrated a general beneficial 
effect and no negative drug-drug interference was observed. For instance, combining 1 
µg/ml MPA with 25 µm ribavirin resulted in 76 ± 1% inhibition of HEV luciferase, whereas 
MPA alone resulted in 60 ± 2% and ribavirin alone resulted in 17 ± 3% inhibition (Mean ± 
SEM, n = 16, P < 0.001) after 72 hours treatment (Figure 7A). Therefore, a combination of 
ribavirin with MPA appears compatible against HEV infection and constitutes an attractive 
clinical option for preventing rejection in HEV-infected patients. 
 
Discussion 
Immunosuppressive medication has been proposed to be a key factor for developing chronic 
hepatitis E in organ transplantation recipients 4 and is often solely attributed to diminished 
antiviral immunity. Clinical evidence, however, suggests that different immunosuppressive 
regimens can differentially affect the infection course of HEV 6, 8. By testing different 
immunosuppressants in two HEV replication models, we have consistently demonstrated 
that steroids (Pred and Dex) did not affect viral replication, calcineurin inhibitors (CsA and 
FK506) promoted HEV infection, and MPA suppressed viral infection in vitro. The 
concentrations of these immunosuppressants used in this study are in general covering the 
achievable blood concentrations in patients 19-21. Of note, animal studies have indicated that 
certain immunosuppressant even accelerates in the liver and drug levels in hepatocytes will 
exceed those observed in serum 22. Therefore, we propose that the results of this in vitro 
study will be a valuable reference regarding the choice of particular immunosuppressant for 
orthotopic organ transplantation patients who are infected with HEV. 
Steroids have been used since the early years of organ transplantation. Pred and its 
close analogue Dex are potent suppressors of the immune system, as they modulate cellular 
and inflammatory responses via stimulation or inhibition of gene transcription 23. In the 
setting of liver transplantation for HCV patients, evidence suggested that steroid boluses 
used to treat acute rejection are associated with an increase in viral load and the severity of 
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HCV recurrence 24, 25. Using subgenomic cell culture model of HCV replicon, a study 
demonstrated that both Pred and Dex have no stimulatory effect on viral RNA levels, but 
rather have minor inhibitory effects 13. As to infectious HCV model, however, Pred was 
reported to promote HCV infection by enhancing virus entry, including up-regulation of two 
essential HCV entry factors: occludin and scavenger receptor class B type I 26. In both 
subgenomic and infectious models of HEV, we did not observe clear effect on HEV infection 
by either Pred or Dex. Although limited studies have reported the impact of steroids in HEV 
patients, one case report has documented a good clinical and biochemical response to 
steroid therapy in a patient of acute hepatitis E with autoimmune hepatitis, who maintained 
health with low dose of steroids 27. 
The first in vitro evidence that CsA but not FK506 can inhibit HCV replication 28 
sparked the clinical debate on the possible differential effects of these two drugs on HCV 
recurrence after liver transplantation 29. Several follow-up studies have demonstrated that 
the targets of CsA, CypA and CypB, are host factors supporting HCV infection 14, 15. CsA exerts 
anti-HCV effects by inhibition of these cellular factors 30. Interestingly, we observed a 
proviral effect of CsA in HEV cell culture models. Using RNA interference gene silencing 
approach, we further demonstrated that knockdown of either CypA or CypB enhanced HEV 
infection, suggesting that both factors could restrict HEV infection. This convincingly 
explained why CsA could facilitate HEV infection. Although a number of reports have 
demonstrated a supportive role of CypA in infections of HIV 31, HCV 14, or HBV 32, recent 
studies also reported that CypA possesses a repressive effect on the replication of some 
viruses including Influenza A virus 33 and rotavirus 34, similar to what we have observed for 
HEV. Because the mechanistic insight is still largely missing for the antiviral action of 
cyclophilins, it deserves further investigation. In addition, we also observed a proviral effects 
of FK506, but only at high dose. To our knowledge, there is no evidence of FK506 affecting 
HCV infection in cell culture 28, 35. In fact, compared with CsA, dose reduction of FK506 was 
assumed to be more associated with clearance of HEV in cases of renal transplantation with 
acute infection 36. In a large retrospective study (although only 85 patients included), the use 
of FK506 was the main predictive factor for chronic hepatitis E in organ recipients 6. Our in 
vitro results have indicated that both FK506 and CsA can promote HEV infection. However, 
these data do not necessarily contradict to the clinical observation, because the number of 
patients currently investigated in the clinic is rather too small to draw solid conclusion. In 
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addition, besides the direct effects we observed in cell culture, drugs can also have indirect 
influence on the infection.  
The antiviral effects of MPA/MMF have been demonstrated against a broad spectrum 
of viruses, including dengue virus, West Nile, yellow fever virus, Chikungunya virus, HBV and 
HCV 36-39. This is consistent with our finding that MPA also potently inhibited HEV replication. 
For several viruses, MPA exerts antiviral effects by targeting IMPDH to deplete cellular 
nucleotide pools 36. In case of HCV, the IMPDH-dependent pathway only partially 
contributed to its antiviral activity 11. In contrast, supplementation of exogenous guanosine 
completely abrogated the anti-HEV activity of MPA, suggesting a crucial role of IMPDH 
inhibition leading to depletion of cellular nucleotides. Interestingly, clearance of HEV after 
heart transplantation was found to be more frequent in patients with immunosuppressive 
medication containing MMF 8, although this may be biased by a reduced dose of CsA or 
FK506 in these cases. 
Despite of a clear benefit of manipulating immunosuppressive regimens, a 
substantial proportion of patients is still not able to clear the virus and rapidly progresses 
towards chronic hepatitis 6. Although no proven medication is available, the use of ribavirin 
monotherapy as off-label drug is gaining acceptance for treating hepatitis E 18. An intriguing 
question is whether immunosuppressants can interfere with or promote the anti-HEV 
efficacy of ribavirin. In this study, we have finally demonstrated a beneficial effect of 
combining ribavirin with MPA (Figure 7). This does provide a proof-of-concept that it is 
important to choose the right immunosuppressive medication while under antiviral therapy 
of HEV in organ transplant recipients. 
In conclusion, this study has profiled differential effects of different 
immunosuppressants on HEV infection in cell culture. Steroids did not affect genotype 3 HEV 
replication in vitro, but high dose of FK506 promoted HEV infection. CsA dose-dependently 
facilitated HEV infection by targeting cellular factors CypA and CypB. In contract, MPA 
potently suppressed HEV infection by depletion of cellular nucleotide pools. In addition, a 
clear beneficial effect was observed when MPA combined with another antiviral regimen 
ribavirin. Although experimental research alone will not be able to clarify these complicated 
but important clinical issues, the knowledge gained from this study is for sure a valuable 
reference for the management of immunosuppression in organ transplantation recipients 
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infected with HEV. Hopefully, it will also promote the initiation of randomized controlled 
clinical studies to address these issues in the near future. 
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Supplementary methods and Figures 
MTT assay 
Huh7 cells were plated in 96-well plates and treated with immunosuppressants. At the indicated 
times, the number of metabolically active cells was quantified by the 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (MTT, 0.5 mg/mL) assay. 
 
Measurement of [Ca2+]i concentration 
The intracellular [Ca2+]i concentration was measured using the fluorescent dye, Fluo-4/AM 
(Dojindo Laboratories, Kumamoto, Japan). The Huh7 cells were treated with serial dilutions of 
DMS for 48 hours, then resuspended in PBS containing 1% bovine serum and incubated for 30 min 
with 5 μM Fluo-4/AM in the dark. After being washed with PBS, the Fluo-4/AM-labeled cells were 
observed under an inverted fluorescence microscope. 
 
 
Supplementary Figure1. The effects of immunosuppressants on viability of Huh-7 cells. Cells were 
treated with immunosupprants at different concentrations for 24, 48 and 72 hours. Cell viability 
was assayed by the MTT test. Shown is Mean ± SD from at least 3 independent experiments. 
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Supplementary Figure 2. Induction of cellular Ca2+ concentration by N,N-Dimethyl-D-erythro-
sphingosine (DMS) did not affect HEV infection. (A) DMS (1-4 µg/ml) triggered clear induction of 
Ca2+ levels in Huh7 cells visualized with a fluorescent dye, Fluo-4/AM. (B) HEV replication in the 
subgenomic model was not affected by DMS treatment for 24, 48 and 72 hours, respectively. (C) 
HEV infection was also not affected by DMS treatment for 48 hours in the infectious model 
quantified by qRT-PCR. Shown is Mean ± SD from 3 independent experiments. 
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Abstract 
Background and aims: Humans are frequently exposed to hepatitis E virus (HEV). 
Nevertheless, the disease mainly affects pregnant women and immunocompromised 
individuals. Organ recipients receiving immunosuppressants, such as rapalogs, to prevent 
rejection have a high risk for developing chronic hepatitis following HEV infection. Rapalogs 
constitute potent inhibitors of mTOR including rapamycin and everolimus. As a master 
kinase, the mechanism-of-action of mTOR is not only associated with the 
immunosuppressive capacity of rapalogs but is also tightly regulated during pregnancy 
because of increased nutritional demands. Methods: We thus investigated the role of mTOR 
in HEV infection by using two state-of-the-art cell culture models: a subgenomic HEV 
containing luciferase reporter and a full-length HEV infectious cell culture system. Results: In 
both subgenomic and full-length HEV models, HEV infection was aggressively escalated by 
treatment of rapamycin or everolimus. Inhibition of mTOR was confirmed by Western blot 
showing the inhibition of its down-stream target, S6 phosphorylation. Consistently, stable 
silencing of mTOR by lentiviral RNAi resulted in a significant increase in intracellular HEV 
RNA, suggesting an antiviral function of mTOR in HEV infection. By targeting a series of other 
up- and down-stream elements of mTOR signaling, we further revealed an effective basal 
defense mechanism of PI3K-PKB-mTOR pathway against HEV, which is through the 
phosphorylated eIF4E-binding protein 1 (4E-BP1), however independent of autophagy 
formation. Conclusions: The discovery that PI3K-PKB-mTOR pathway limits HEV infection 
through 4E-BP1 and acts as a gate-keeper in human HEV target cells bears significant 
implications in managing immunosuppression in HEV-infected organ transplantation 
recipients. 
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Introduction 
Although hepatitis E virus (HEV) infection is underdiagnosed, it is clear that the virus 
represents one of the most abundant infectious challenges to humans 1. In Western 
countries, HEV infection of healthy individuals almost exclusively remains subclinical and 
otherwise causes an acute and self-limiting infection in immune-competent individuals with 
low mortality rates 2. In contrast, patients with HEV infection in immunocompromised 
individuals that include organ transplantation recipients 3, HIV patients 4 and cancer patients 
receiving chemotherapy 5 have substantially high risk of developing chronic hepatitis. The 
use of immunosuppressants, such as rapalogs, in organ transplant recipients to prevent 
rejection is associated with substantial pathology and in particular an increased risk of 
developing chronic hepatitis with substantial graft loss and mortality rates 6.  
However, in undernourished populations in the developing world, fulminant hepatitis 
and high mortality are described, reaching 25% in case of pregnant women 6. In the current 
(2012-2013) hepatitis E outbreak among refugees in South Sudan, a total of 5,080 acute 
jaundice syndrome cases had been reported from all four Maban County refugee camps, as 
of January 27, 2013. An acute jaundice syndrome case-fatality rate of 10.4% was observed 
among pregnant women across all camps 7. Humans appear to have powerful HEV 
combating mechanisms, but that apparently require good nutritional and host defense 
status for optimal functionality 8. The nature of these mechanisms has not been 
characterized, due to the lack of robust HEV cell culture models. The advent of new 
technology that mimics the HEV infectious process in vitro, in particular the development of 
in vitro adapted infectious clones and subgenomic HEV reporters, has led to hopes that the 
mechanisms that control HEV infection in normal physiology can now be identified 9, 10. 
Rapalogs comprise, amongst others rapamycin (RAPA, rapamune, sirolimus; originally 
isolated from Streptomyces hygroscopicus) and everolimus (the 40-O-[2-hydroxyethyl] 
derivative of rapamycin). This immunosuppressive medication is gaining increasing 
popularity in the transplantation context, mainly because of its low nephrotoxicity 11. Their 
molecular mode of action is well characterized and involves inhibition of the mammalian 
target of rapamycin (mTOR) pathway. mTOR is a central element within the 
phosphatidylinositol-3 kinase (PI3K)-protein kinase B (PKB)-mTOR signaling 12 and integrates 
nutritional information and receptor tyrosine kinase signaling to control cellular growth via a 
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variety of cellular effectors, including activation of p70 S6 kinase and subsequent protein 
synthesis as well as inhibition of autophagy. Activation of PI3K-PKB-mTOR signaling following 
viral infection of liver cells has been reported and linked to both viral supportive functions 
(e.g. prevention of apoptosis in hepatitis C-infected cells) 13, but also to the induction of the 
production of antiviral interferons 14. Thus, generally speaking the role of this signaling 
cascade in combating viral infection of the liver remains unclear, prompting further research. 
Given the important and increasing role of rapalogs implications in both clinical 
practice and the lack of insight into the mechanisms employed by the body to constrain HEV 
infection, we investigated the role of the PI3K-PKB-mTOR signaling cascade in HEV infection 
using state-of-the-art cell culture models. These results show that mTOR inhibition 
drastically promotes HEV replication in a autophagy-independent fashion but through 
phosphorylated 4E-BP1 in infected hepatocytes. 
 
Materials and methods 
Reagents  
Stocks of rapamycin (Merck, Schiphol-Rijk, Netherlands) and everolimus (Sigma-Aldrich, St 
Louis, MO) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) with 
final concentration of 2mM. Stocks of LY294022, an inhibitor of PI3K-PKB (Sigma-Aldrich), 
BEZ 235, a dual inhibitor of PI3K-PKB and mTOR (Selleck Chemicals), FG-4592, an inhibitor of 
HIF-1α (Selleck Chemicals) and PF-478671, an inhibitor of p70 S6 kinase (Selleck Chemicals) 
were dissolved in DMSO. All agents were stored in 15 µl aliquots and frozen at -20°C. 
Antibodies including LC3-I/II (Cell signalling technology, Netherland), S6, phosphor S6, p70 S6 
kinase, phosphor PKB, 4E-BP1 and β-actin (Santa Cruz Biotech, Santa Cruz, CA); anti-rabbit or 
anti-mouse IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave, Victoria, BC, 
Canada) were used for Western blot. Lentiviral particles of GFP-LC3-II (Millipore, Billerica, 
MA, USA), expressing GFP-LC3 fusion protein, were used for visualization of autophagy 
formation. Other reagents including EBSS medium (Lonza), E-64-d (Santa Cruz Biotech, Santa 
Cruz, CA), pepstatin A (Santa Cruz Biotech, Santa Cruz, CA) and chloroquine (Sigma–Aldrich) 
were also used. 
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HEV cell culture models 
HEV genomic RNA was generated from a plasmid construct containing the full-length HEV 
genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a gaussia luciferase reporter gene (p6-
Luc), using the Ambion mMESSAGE mMACHINE® in vitro RNA transcription Kit (Life 
Technologies Corporation) 9, 10. The human hepatoma Huh7 cells were collected and 
centrifuge for 5 minutes, 1500 rpm, 4℃. Supernatant was removed and washed with 4 mL 
Optimem by centrifuging for 5 minutes, 1500 rpm, 4℃. Cell pellet was re-suspended in 100 
ul Optimem and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. 
Electroporation was performed with the Bio-Rad's electroporation systems using the 
protocol of a designed program (240 volt, pulse length 0.5, number 1 and cuvette 4 mm) 9. 
The supernant of the long term cultured p6 full-length HEV RNA cells were conllected and 
used as secondary genuine infection. 
 
Cell culture 
Naïve or vector transduced Huh7 cells (human hepatoma cell line) and HEK293T cells 
(human fetal kidney epithelial cell line) were cultured in Dulbecco’s modified Eagle medium 
(DMEM) (Invitrogen-Gibco, Breda, Netherlands) complemented with 10% (v/v) fetal calf 
serum (Hyclone, Lonan, Utah), 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine (Invitrogen-Gibco). Stable firefly luciferase expressing cells were generated by 
transducing naïve Huh7 cells with a lentiviral vector expressing the firefly luciferase gene 
under control of the human phosphoglyserate kinase (PGK) promoter (LV-PGK-Luc). For 
visualization of autophagy formation, Huh7 cells were transduced with lentiviral vector 
expressing the GFP-LC3 fusion protein.  
 
Gene knockdown by lentiviral vector delivered short hairpin RNA (shRNA) 
Lentiviral vectors (Sigma–Aldrich), targeting mTOR, 4E-BP1 or GFP (shCon), were obtained 
from the Erasmus Center for Biomics and produced in HEK 293T cells as previously described 
15. After pilot study, the shRNA vectors exerting optimal gene knockdown were selected. 
These shRNA sequences were described in Supplementary Table 1. 
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To generate stable gene knockdown cells, Huh7 cells were transduced with lentiviral 
vectors. Since the vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 2.5 μg/ml puromycin (Sigma) in the cell culture medium. 
For the infectious model, HEV particles were incubated with knockdown and control Huh7 
cells. 
 
Measurement of luciferase activity  
For gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured using BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and incubated for 30 
minutes at 37℃. Both gaussia and firefly Luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to the cells seeded in 96-well plate and the cells grow at 37℃ with 5% CO2 for 3 hrs. 
The medium was removed and 100 μL of DMSO was added to each well. The absorbance of 
each well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 
nm. All measurements were performed in triplicates. 
 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit ( TAKARA BIO INC). The cDNA of HEV and GAPDH were 
amplified by 40 cycles and quantified with SYBRGreen-based real-time PCR (MJ Research 
Opticon, Hercules, CA, USA) according to manufacturer’s instructions. GAPDH was 
considered as reference gene to normalize gene expression. The HEV primer sequences were 
5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-CCGTGGCTATAATTGTGGTCT-3’ 
(antisense), and the primers of housekeeping gene GAPDH were 5’-
TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ (antisense). 
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Western blot assay 
Proteins in cell lysates were heated 5 min at 95℃ followed by loading onto a 10-15% sodium 
dodecyl sulfate-polyacrylamide SDS gel and separated by electrophoresis (SDS-PAGE). After 
90 minutes running in 120 voltage, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 hrs with an electric current 
of 250 mA. Subsequently, the membrane was blocked with 2.5 mL blocking buffer and 2.5 
mL PBS containing 0.05% Tween 20 (PBS-T). It was followed by incubation with rabbit LC3-
I/II, p-PKB, p-mTOR, mTOR 4E-BP1, p-4E-BP1 or p-S6 (1:1000) antibody overnight at 4℃. 
Membrane was washed 3 times followed by incubation for 1.5 hrs with anti-rabbit or anti-
mouse IRDye-conjugated secondary antibodies (Li-cor, Lincoln, USA) (1:5,000) at room 
temperature. Blots were assayed for actin content as standardization of sample loading, and 
scanned and quantified by Odyssey infrared imaging (LI-COR Biosciences, Lincoln, NE, USA). 
Results were visualized with Odyssey 3.0 software.  
 
Confocal laser electroscope assay 
Lipidated LC3 (LC3-II) is a robust marker of autophagic membranes. Autophagosomes were 
visualized as bright green fluorescent protein GFP-LC3-II puncta by fluorescence microscopy. 
For nutrient starvation, cells were incubated in EBSS medium with 1 mM pepstatin A and E-
64-d solution for overnight prior to fix for confocal laser electroscope analysis. The cells were 
fixed with 70% ethanol and GFP-LC3-II puncta was detected using confocal electroscope. 
 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were performed with 
Mann-Whitney test. Differences were considered significant at a P value less than 0.05. 
 
Results 
mTOR inhibition by rapalogs facilitates HEV replication 
The 7.2-kb genome of HEV is a single strand positive-sense of RNA containing three 
overlapping reading frames (ORFs). We employed a model in which human hepatoma cells  
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Figure 1. mTOR inhibition by rapalogs facilitate HEV replication. (A) Western blot showed inhibition 
of S6 phosphorylation by treatment of 500 nM rapamycin for 48 hrs. β-actin served as an internal 
reference. (B) Western blot showed inhibition of S6 phosphorylation by treatment of 500 nM 
everolimus for 48 hrs. β-actin served as an internal reference. (C) In the Huh7 cell-based subgenomic 
HEV replicon, treatment with rapamycin dose-dependently increased viral replication-related 
luciferase activity (Mean ± SD, n = 3 independent experiments with each 2-3 replicates). (D) 
Rapamycin did not increase cell proliferation determined by MTT assay (OD490 value) (Mean ± SD, n = 
5). (E) In the Huh7 cell-based subgenomic HEV replicon, treatment with everolimus dose-
dependently increased viral replication-related luciferase activity (Mean ± SD, n = 3 independent 
experiments with each 2-3 replicates). (F) Everolimus did not increase cell proliferation determined 
by MTT assay (OD490 value) (Mean ± SD, n = 5). (G) In the HEV infectious model, rapamycin 
significantly increased cellular viral RNA determined by qRT-PCR (Mean ± SD, n = 5). (H) everolimus 
also significantly increased cellular HEV RNA in the infectious model (Mean ± SD, n = 3-6). Treatment 
time was indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 0.01. 
 
(Huh7) were transfected with a 3’ subgenomic construct of HEV coding sequence in which 
the 5’ portion of ORF2 was replaced with the in-frame secreted form of luciferase derived 
from the marine copepod Gaussia princeps (p6-Luc) (Supplementary Figure 1). Accumulation 
of luciferase in Huh7 cells thus serves as reporter for HEV RNA synthesis, whereas the loss of 
the capsid protein in the model system precludes the formation of novel viral particles 9, 10. 
In parallel, Huh7 cells constitutively expressing a non-secreted firefly luciferase are used for 
normalization of non-specific effects on luciferase signals. In addition, a Huh7 based full-
length infectious HEV model (p6) was also employed (Supplementary Figure 1) 9, 10.  
Direct investigation of the phosphorylation status of phospho-Ser-240/224 S6 and 
phospho-Ser-473 PKB showed that Huh7 cells represent a PI3K-PKB-mTOR-proficient model 
system (Figure 1A and B). Importantly, inhibiting mTOR rendered this system sensitive to 
HEV infection as evident from higher levels of G. princeps luciferase and that increased over 
the time domain. Treatment with 100 and 1000 ng/ml of rapamycin for 48 hrs resulted in 1.9 
± 0.4 (Mean ± SD, n = 3, P < 0.05) and 2.7 ± 0.6 (Mean ± SD, n = 3, P < 0.01) -fold increase of 
HEV luciferase activity (Figure 1C) and corresponds to a concomitant decrease in mTOR 
activity as assessed by phospho-Ser-240/224 S6 levels (Figure 1A). At 72 hrs, HEV luciferase 
activity was further increased up to 3.8 ± 0.5 (Mean ± SD, n = 3, P < 0.01) and 4.9 ± 0.5 
(Mean ± SD, n = 3, P < 0.01) -fold, respectively (Figure 1C). A possible artifact here would 
direct growth-promoting effects of rapamycin, but MTT assay showed that rapamycin did 
not promote cell growth (Figure 1D). 
Next to rapamycin, everolimus is often used for clinical mTOR inhibition following 
orthotropic organ transplantation. Like rapamycin, everolimus also remarkably permitted 
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HEV replication. In the p6-Luc model, treatment with 1ng/ml of everolimus has already 
significantly increased HEV luciferase activity. Treatment with 100 and 1000 ng/ml of 
everolimus resulted in 7.0 ± 2.2 (Mean ± SD, n = 3, P < 0.01) and 6.7 ± 1.4 (Mean ± SD, n = 3, 
P < 0.01) -fold increase at 48 hrs, 5.3 ± 0.8 (Mean ± SD, n = 3, P < 0.01) and 5.6 ± 1.9 (Mean ± 
SD, n = 3, P< 0.05) -fold increase of HEV luciferase activity at 72 hrs (Figure 1E). Everolimus 
also did not promote cell proliferation determined by MTT assay (Figure 1F). 
Dephosphorylation of S6 was also confirmed (Figure 1B)  
To exclude that this effect is an consequence of the loss of the capsid protein and 
ORF3 protein in our luciferase model, we repeated experiments with the full-length 
infectious HEV model. Again, HEV infection was facilitated under mTOR-deficient conditions. 
For instance, treating with 100 or 1000 ng/ml rapamycin has increased viral RNA levels up to 
2.6 ± 0.6 (Mean ± SD, n = 5, P < 0.01) or 2.1 ± 0.4 (Mean ± SD, n = 5, P < 0.01)-fold, 
respectively (Figure 1G). Treatment with 1, 10, 100 and 1000 ng/ml of everolimus for 48 hrs 
resulted in increase of cellular viral RNA up to 1.6 ± 0.1 (Mean ± SD, n = 3, P < 0.01), 1.5 ± 0.3 
(Mean ± SD, n = 6, P < 0.05), 2.0 ± 0.1 (Mean ± SD, n = 3, P < 0.01) and 2.1 ± 0.2 (Mean ± SD, 
n = 3, P < 0.01) (Figure 1G). Hence, both major drugs used for clinical mTOR inhibition 
provoke an altered cellular state in hepatocyte-like cells that allows efficient HEV replication 
to proceed. 
 
Gene silencing of mTOR by RNAi enhances HEV replication 
To evaluate the direct effects of mTOR on HEV, Huh7 cells were transduced with integrating 
lentiviral vectors expressing short hairpin RNA (shRNA) specifically targeting mTOR or a 
control shRNA (shCon). As shown in Figure 2A, three of the tested four shRNA vectors 
targeting mTOR exert potent gene silencing capacity, resulting in a profound down-
regulation of mTOR protein level but an elevation of PKB expression (probably due to a 
feedback activation). Correspondingly, mTOR silencing resulted in significant increase of 
cellular HEV RNA level, which were measured by qRT-PCR after inoculation of HEV particles 
which indicating genuine infection for 72 hrs. For instance, knockdown of mTOR by the 
shmTOR clone 2 led to 2.6 ± 0.8-fold (Mean ± SD, n = 3, P < 0.05) increase of HEV RNA (Figure 
2A). These data provide direct and strong evidence that mTOR plays an important role in 
restricting HEV infection. 
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Figure 2. Gene silencing of mTOR and 4E-BP1 by lentiviral RNAi enhances HEV replication 
independent of autophagy machinery. (A) Knockdown of mTOR by lentiviral shRNA vectors. 
Compared with the control vector transduced cells, the shmTOR clone 1, 2 and 3 but not 4 expert 
potent silencing capability shown at protein levels of both total- (t-mTOR) and phospho-mTOR (p-
mTOR), which also resulted in dramatic elevation of phospho-PKB (p-PKB). S6 phosphorylation (p-S6) 
was also determined by Western blot and β-actin served as an internal reference. Correspondingly, 
knockdown of mTOR resulted in significant increase of cellular HEV RNA level (Mean ± SD, n = 3), 
which were measured by qRT-PCR after inoculation of HEV particles which indicating genuine 
infection for 72 hrs. * P < 0.05; ** P < 0.01. (B) Illustration of the effects on HEV infection by 
inhibiting different components of the PI3K-PKB-mTOR pathway. Rapamycin/everolimus, inhibitors of 
mTOR; LY294022, an inhibitor of PI3K-PKB; BEZ-235, a dual inhibitor of PI3K-PKB and mTOR; PF-
4708671, an inhibitor of p70 S6 kinase and FG-4592, an inhibitor of HIF-1α were used. (C) Naïve 
Huh7, subgenomic HEV replicon and HEV infected Huh7 cells were treated with rapamycin and 
everolimus for 48 hrs. The accumulation of LC3-II, a hallmark of autophagy formation, was not 
observed by Western blot analysis. β-actin was served as an internal reference. (D) Consistently, 
green puncta formation, an indication of autophagosome formation, was not observed in Huh7 cells 
expressing GFP-LC3-II fusion protein, by treatment of rapamycin and everolimus for 24, 48 and 72 
hrs. In contrast, autophagosome formation was observed in the positive control groups treated with 
30 µM chloroquine for 48 hrs or at the circumstance of starvation in BESS media with 1 µM pepstatin 
A and E-64-d for either 18 or 24 hrs. Oil-lenses (40×) was used (1024×1024 image). (E) Western blot 
showed inhibition of 4E-BP1 phosphorylation by treatment of 500 nM everolimus for 48 hrs. β-actin 
served as an internal reference. (F) Knockdown of 4E-BP1 by lentiviral shRNA vectors. Compared with 
the control vector transduced cells, the sh4E-BP1 clone 53, 55, 56 and 57 but not 54 expert potent 
silencing efficacy shown at protein levels of total 4E-BP1 (t-4E-BP1), β-actin served as an internal 
reference. (G) Correspondingly, knockdown of 4E-BP1 resulted in significant increase of cellular HEV 
RNA level (Mean ± SD, n = 5). * P < 0.05; ** P < 0.01. 
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mTOR limits HEV replication via 4E-BP1 
mTOR is a key kinase controlling cellular behavior. Its most important effector pathways 
include induction of protein transcription via p70 S6 kinase pathway (Figure 2B) 14. However, 
this pathway does not seem a major effector mechanism as inhibition of p70 S6 kinase by its 
inhibitor PF-478671 did not affect HEV infection (Supplementary Figure 2). Inhibition of 
another downstream target of mTOR, hypoxia-inducible factor-1alpha (HIF-1α) by FG-4592 
(Supplementary Figure 3) also did not affect HEV infection. Notably, mTOR is also the main 
inhibitor of autophagy in cellular metabolism and it is possible that HEV replication requires 
autophagosome formation. However, inhibition of mTOR did not change the levels of 
microtubule-associated protein 1 light chain 3 β (LC3-II) in our model system (Figure 2C), a 
hallmark of autophagosome formation. Furthermore, Huh7 cells stably intergraded with a 
lentiviral vector expressing GFP-LC3-II were used to visualize autophagosome formation. In  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Inhibition of PI3K-PKB promotes viral replication. (A) In the Huh7 cell-based subgenomic 
HEV replicon, treatment with LY294022, a PI3K inhibitor, dose-dependently increased viral 
replication-related luciferase activity (Mean ± SD, n = 3). (B) LY294022 did not affect cell proliferation 
determined by MTT assay (OD490 value) (Mean ± SD, n = 4). (C) In the HEV infectious model, LY294022 
significantly increased cellular viral RNA determined by qRT-PCR (Mean ± SD, n = 3). (D) Western blot 
showed inhibition of PKB, S6 and p70 S6 kinase phosphorylation by treatment of 5 µm LY294022 for 
48 hrs. β-actin served as an internal reference. Treatment time was indicated as 24, 48 or 72 hrs. * P 
< 0.05; ** P < 0.01. 
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the positive control groups, cells were either treated with 30 μM chloroquine or under 
condition of starvation in EBSS medium. As expected, green puncta of LC3-II was clearly 
emerging, indicating the formation of autophagosome (Figure 2D). In contrast, no changes of 
the autophagy machinery were observed with treatment of rapamycin or everolimus (Figure 
2D), which was consistent with the results of Western blot (Figure 2C). Thus, these findings 
exclude the possibility that the proviral effect of rapamycin/everolimus is via the autophagy 
machinery. 
4E-BP1 is another important element induced by mTOR for cellular cap-dependent 
translation 75. Treatment of mTOR inhibitor everolimus (500 nM) for 48 hrs resulted in clear 
dephosphorylation of 4E-BP1 as shown by Western blot (Figure 2E). To further confirm the 
regulation of HEV replication by 4E-BP1, Huh7 cells were transduced with integrating 
lentiviral vectors expressing shRNA specifically targeting 4E-BP1 or a control shRNA (shCon). 
Cells stably transduced with the vector were also selected and expanded by adding 
puromycin to the relevant cell cultures. Four out of five shRNA vectors targeting 4E-BP1 
exert gene silencing capacity, resulting in a various level down-regulation of total 4E-BP1 
protein (Figure 4F). Correspondingly, we selected two 4E-BP1 silencing cell-lines with 
optimal gene silencing potency that resulted in a significant increase of cellular HEV RNA 
level, which was measured by qRT-PCR of HEV RNA. For instance, knockdown of 4E-BP1 by 
the sh4E-BP1 clone 53 led to 1.7 ± 0.6-fold (Mean ± SD, n = 5, P < 0.01) increase of HEV RNA 
and clone 56 led to 2.4 ± 0.9-fold (Mean ± SD, n = 4, P < 0.05) increase (Figure 4G). 
Consistently, the clone 54 with minimal gene silencing efficacy only exert minor effect (1.3 ± 
0.3-fold, Mean ± SD, n = 4, P > 0.05) on HEV replication (Figure 4G). These data indicated 
that the antiviral effect of mTOR is via its downstream target, 4E-BP1. 
 
Inhibition of PI3K-PKB promotes viral replication 
Although distinct molecules, rapamycin and everolimus share important structural 
characteristics. To exclude the possibility that the effects of these compounds on HEV 
replication represent a mTOR-independent off-target effect, independent confirmation of 
the role of PI3K/PKB/mTOR signaling cascade in preventing HEV replication was sought 
through experiments in which more upstream elements of this signaling cascade were 
targeted (Figure 2B). When Huh7 p6-Luc cells were treated with different concentrations 
(0.1-10 μM) of the well-established PI3K inhibitor LY294002, enhancement of HEV  
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Figure 4. Simultaneous inhibition of PI3K and mTOR further increased viral replication. In the HEV 
subgenomic replicon, viral replication-related luciferase activity was presented when 1, 5 or 10 µM 
LY294022 was combined with 100/1000 nM of rapamycin (A) or everolimus (B). Treatment time was 
indicated as 24, 48 or 72 hrs. Data was presented as Mean ± SD, n = 11 replicates in total. (C) BEZ-235 
is a dual inhibitor of PI3K-PKB and mTOR. In the Huh7 cell-based subgenomic HEV replicon, 
treatment with BEZ-235 significantly increased viral replication-related luciferase activity (Mean ± SD, 
n = 5). (D) In the HEV infectious model, BEZ-235 significantly increased cellular viral RNA determined 
by qRT-PCR (Mean ± SD, n = 3). (E) Western blot showed inhibition of PKB, S6 and p70 S6 kinase 
phosphorylation by treatment of 1 nM BEZ-235. β-actin served as an internal reference. Treatment 
time was indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 0.01 
 
replication became apparently similar to that observed with mTOR inhibitors (Figure 3A), 
which was also not related to enhanced cell proliferation (Figure 3B). Consistently, LY294002 
also significantly increased cellular HEV RNA in the infectious model up to 3.2 ± 1.1-fold 
(Mean ± SD, n = 3, P < 0.05) at dose of 10 μM (Figure 3C). These effects corresponded with 
the observed inhibition of the biological target (Figure 3D). 
 
Simultaneous inhibition of PI3K and mTOR further enhanced viral replication 
Simultaneous treatment with rapamycin/everolimus and LY294002 apparently had stronger 
effects than rapamycin or LY294002 alone. The strongest effect on HEV replication was 
observed with the combination of 100 ng/ml rapamycin and 10 μM LY294002 at 48 hrs (up 
to 12.1 ± 3.1-fold, Mean ± SD, n = 11, P < 0.01 Vs untreated; P < 0.01, Vs rapamycin; P< 0.01, 
Vs LY294002) (Figure 4A), and at 72 hrs with the combination of 1000 ng/ml rapamycin and 
10 μM LY294002 (up to 31.7 ± 9.9-fold, Mean ± SD, n = 11, P < 0.01 Vs untreated; P < 0.05, Vs 
rapamycin; P < 0.01, Vs LY294002) (Figure 4A). Similar effects were observed when 
everolimus was combined with LY294002 (Figure 4B). Furthermore, these results were found 
not to be related to enhancement of cell proliferation either with rapamycin (Supplementary 
Figure 4A) or everolimus (Supplementary Figure 4B). BEZ-235 is a dual inhibitor of mTOR and 
PI3K signalling, which is at the stage of clinical development for treating cancer patients 
(NCT00620594, ClinicalTrials.gov) (Figure 2B). We further investigated the effect of 
simultaneously inhibiting PI3K-PKB and mTOR by a single compound BEZ-235. As shown in 
Figure 4C and 4D, BEZ-235 significantly promoted HEV infection in both models. 
Furthermore, results corresponded to inhibition of biological targets of this pathway (Figure 
4E). The most straightforward interpretation of these data is that HEV can efficiently 
replicate in the context of deficient signaling through the PI3K-PKB-mTOR cascade. 
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Discussion 
Large zoonotic reservoirs of hepatitis E exist in cattle and poultry and it is generally accepted 
that humans are frequently infected with the virus 6. Almost invariably, however, the disease 
remains subclinical 2. Here we present evidence that the inability of HEV to effectively 
replicate in humans is linked to constitutive mTOR activation. This novel action of mTOR in 
directly counteracting viral replication in liver cell themselves rather as acting through the 
adapted immune system, represents a highly novel non-canonical action of this kinase in a 
new adapted immune system-independent antiviral mechanism and thus our results are 
highly unexpected.  
Patients after orthotropic organ transplantation when receiving 
immunosuppressants, such as rapalogs, to prevent rejection are well known to be at 
extremely high risk of developing chronic hepatitis with persistence of infection 3, 17, 18. It is 
known that the clinical symptoms of this hepatitis reacts very well to reducing dose of 
immunosuppression 18. Hitherto, this beneficial effect of decreasing immunosuppressive 
therapy was attributed to increased immunity 19. However, different types of 
immunosuppressants can also have direct effects on HEV replication in the target cells of the 
virus 20. In transplantation patients, the blood concentrations of rapalogs can reach by 
approx. 15 ng/ml 21, 22, whereas the levels in cancer patients can be up to approx.100 ng/ml 
23. We have demonstrated that 1 ng/ml everolimus has sufficient to trigger a significant 
stimulatory effects on HEV replication in vitro, which thus clearly bears important clinical 
relevance. 
In fact, more evidence supporting the potential proviral effects of rapalogs have 
come from hepatitis B virus (HBV) infected patients. In a randomized clinical trial comparing 
two everolimus dosing schedules in patients with advanced hepatocellular carcinoma, four 
patients were hepatitis B surface antigen (HBsAg)-seropositive. During treatment of 
everolimus, all these patients experienced episodes of HBV flare with > 1-log increase in the 
serum HBV DNA level accompanied by alanine transaminase elevations 24. Similarly, a 
patient with renal cell carcinoma also experienced a HBV flare during everolimus treatment 
25. These observations could be explained by affecting the adaptive immune system but may 
also by direct effects on viral replication. The current experimental study has firmly 
demonstrated the proviral effects of both rapamycin and everolimus in two state-of-the-art 
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HEV cell culture models. Further detailed mechanistic investigation has revealed an antiviral 
function of the PI3K-PKB-mTOR pathway, which appears support the recent clinical 
observations in viral hepatitis patients 17, 24, 25. 
Another group of patients at high risk for HEV caused death constitute pregnant 
women 26. Although this effect is in literature generally linked to diminished immunity 26, 
immune suppression during pregnancy is relatively moderate 27. Interestingly, the increased 
nutritional demands of pregnancy 28 provoke a powerful activation of the ATP/ADP-sensitive 
kinase AMPK 29. In turn, this kinase is potent inhibitor of mTOR 30 and indeed pregnancy is 
associated with a significant down regulation of mTOR 31. It is tempting to speculate that 
pregnancy-specific down regulation of mTOR may help to understand why this group is 
specifically sensitive to HEV infection. In apparent agreement, malnutrition in general is also 
associated with susceptibility to HEV 7. We thus speculate that HEV may preferentially affect 
the human population when hepatic mTOR activity is below its constitutive level. 
Because of its favorable side effect-profile, rapalog therapy is quickly gaining 
popularity for treating a variety of clinical syndromes, especially in oncological disease, in 
congenital diseases like Peutz-Jeghers syndrome and Tuberous sclerosis complex, in 
transplantation medicine and autoimmunity. Therefore, recognition of the anti-HEV function 
of PI3K-PKB-mTOR pathway bears magnificent implications in clinical practice regarding the 
choice of particular immunosuppressant for HEV-infected organ transplant recipients. In 
particular, the use of mTOR inhibitors in these patients should be taken caution. In addition, 
these results may also help to understand the underline mechanism that why pregnant 
women are more susceptible to HEV infection with devastating outcome. 
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Supplementary Figures and Tables 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Genomic structure of the infectious HEV (p6) and subgenomic HEV 
replicon (p6-Luc) models. 
 
 
Supplementary Figure 2. PF-478671, a p70 S6 kinase inhibitor has no effect on HEV 
replication. (A) In the Huh7 cell-based subgenomic HEV replicon, treatment with PF-478671 
for 24, 48 and 72 hrs did not have clear effects on viral replication-related luciferase activity. 
(B) PF-478671 did not increase cell proliferation determined by MTT assay (relative OD490 
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value). (C) In the HEV infectious model, treatment with PF-478671 also did not have clear 
effects on HEV cellular RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. FG-4592, a HIF-1α inhibitor has no effect on HEV infection. (A) In 
the Huh7 cell-based subgenomic HEV replicon, treatment with FG-4592 for 24, 48 and 72 hrs 
did not have clear effects on viral replication-related luciferase activity. (B) FG-4592 did not 
increase cell proliferation determined by MTT assay (relative OD490 value). (C) In the HEV 
infectious model, treatment FG-4592 also did not have clear effects on HEV cellular RNA.  
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Supplementary Figure 4. Simultaneous inhibition of PI3K and mTOR did not affecte cell 
proliferase. In the HEV subgenomic replicon, viral replication-related luciferase activity was 
presented when 1, 5 or 10 µM LY294022 was combined with 100/1000 nM of rapamycin (A) 
or everolimus (B). Treatment time was indicated as 24, 48 or 72 hrs. Cell proliferation 
determined by MTT assay (relative OD490 value). 
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Supplementary Table 1. shRNA sequences 
shmTOR-1 CCGGGCCAGAATCTATTCATTCTTTCTCGAGAAAGAATGAATAGATTCTGGCTTTTTG 
shmTOR-2 CCGGGCCTTGTTTGTGGCTCTGAATCTCGAGATTCAGAGCCACAAACAAGGCTTTTTG 
shmTOR-3 CCGGGAACCAATTATACCCGTTCTTCTCGAGAAGAACGGGTATAATTGGTTCTTTTTG 
shmTOR-4 CCGGGCTGTGCTACACTACAAACATCTCGAGATGTTTGTAGTGTAGCACAGCTTTTTG 
sh4E-BP1-53 CCGGGCCAGGCCTTATGAAAGTGATCTCGAGATCACTTTCATAAGGCCTGGCTTTTTG 
sh4E-BP1-54 CCGGAGGATCATCTATGACCGGAAACTCGAGTTTCCGGTCATAGATGATCCTTTTTTG 
sh4E-BP1-55 CCGGACAGTTTGAGATGGACATTTACTCGAGTAAATGTCCATCTCAAACTGTTTTTTG 
sh4E-BP1-56 CCGGCGGTGAAGAGTCACAGTTTGACTCGAGTCAAACTGTGACTCTTCACCGTTTTTG 
sh4E-BP1-57 CCGGGCGCAATAGCCCAGAAGATAACTCGAGTTATCTTCTGGGCTATTGCGCTTTTTG 
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Hepatitis E virus (HEV) is the most common cause of acute hepatitis worldwide. Recently, it 
is also recognized to cause chronic hepatitis (persistent infection for longer than 6 months) 
in immunocompromised patients 1. Because HEV has a fecal-oral transmission route, patient 
fecal samples in addition to their blood have been widely used for diagnosis and monitoring 
the infection. Surprisingly, a recent study by Geng et al. has discovered dissemination of HEV 
into urine 2. This intriguing finding bears important implications in understanding the 
infection biology and pathogenesis of HEV, as well as diagnosis and management of patients 
with hepatitis E. 
The authors have described the presence of HEV RNA in the urine samples from one 
chronic case and 3 out of 8 acute hepatitis E patients. They further demonstrated the 
dissemination of HEV RNA into the urine of two experimentally infected monkeys 
(inoculated with human genotype 1 or 4 HEV) up to 4 weeks post-inoculation. However, the 
virus was subsequently cleared from these two infected monkeys. Thus, this model appears 
to represent acute and self-limiting infection. More interestingly, freshly collected urine 
from an infected monkey was infectious and resulted in acute hepatitis after inoculation into 
a naïve monkey.  
Since we are interested in chronic hepatitis E 3, we have attempted to establish a 
monkey model for persistent HEV infection. Two 2-year-old male rhesus macaques (#1 and 
#2) were intravenously injected with 2 mL of fecal supernatant from swine infected with HEV 
(genotype 4, KM01 strain, 2 x 104 copies). One macaque (#3) without inoculation served as 
control. Surprisingly, HEV RNA was constantly detected in both serum (Figure 1A) and fecal 
(Figure 1B) samples from both monkeys up to 650 (#1) and 272 (#2) days post-inoculation 
(dpi), as we have followed up to date. The successful establishment of this model can 
potentially mimic chronic HEV infection in patients.  
Althought it remains unclear what are the exact factors contributing to the persistent 
infection, this particular swine HEV strain that we have used could be one of the important 
factors. Upon inoculation, both macaques had only very weak and transient humoral 
immune response, as shown by the low serum levels of anti-HEV IgM and IgG (Figure 1C). At 
day 7, minor elevation of IgM (Figure 1C) was observed accompanied by slight increase of 
serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (Figure 
1D), but it was normalized shortly. HEV IgG was hardly detectable throughout the infection 
course (Figure 1C). Since HEV is a single-standard RNA virus, it is prone to mutagenesis  
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Figure 1. Rhesus macaques persistently infected with HEV shed virus into urine. Quantification of 
HEV genomic RNA in serum (A) and stool samples (B) from #1 and #2 monkeys was determined by 
qRT-PCR. (C) Measurement of serum HEV IgM and IgG levels by ELISA kit. (D) Measurement of serum 
ALT and AST levels. (E) Quantification of HEV genomic RNA in urine samples from #1 and #2 monkeys 
at 650 and 272 days-post-inoculation (dpi), respectively. (F) Quantification of HEV genomic RNA in 
liver and kidney tissues of #1 monkey. (G) Histology of the liver tissue of #1 monkey with 
haematoxylin and eosin (HE) staining; 100x. Histology of the kidney tissue of #1 monkey with HE (H) 
and Periodic acid-Schiff (PAS) (I) staining, 200x. Details of methodology were provided in 
Supplementary Information file. 
HEV shades virus into urine 
103 
during viral replication and thereby could possibly evolve to better adapt to the host. 
Nevertheless, further investigations are still required to determine the exact factors causing 
persistent infection. 
Consistent with the study by Geng et al. 2, we also detected HEV RNA in the urine of 
both monkeys at 272 and 650 dpi, respectively (Figure 1E), although the titers in urine are 
lower than in feces (Figure 1B) but comparable to the serum levels (Figure 1A). One 
intriguing question is how HEV can be disseminated into urine ? Geng et al. 2 have proposed 
that HEV may enter the urine from the liver through viremia or following replication in the 
kidney. The authors have assessed the impact of HEV infection on kidney in an infected 
monkey. Although renal function appears normal, viral protein was detected and 
pathological changes were observed at 4 weeks post-inoculation. Because our #1 macaque 
persistently infected with HEV died unexpectedly, we were able to perform both virological 
and pathological evaluation for both liver and kidney tissues. As expected, HEV is positive in 
the liver as shown by qRT-PCR of the viral genome (Figure 1F), but no clear histological 
change was observed (Figure 1G). Interestingly, HEV was also positive in the kidney (Figure 
1F) and clear pathological changes were observed (Figure 1H and 1I). Renal cortical tissue 
showed signs of congestion as seen in the glomeruli and in the peritubular capillaries (Figure 
1H). In addition, there is ischemia as denoted by an increased space of Bowman in the 
glomeruli and mild to moderate acute tubular necrosis (Figure 1I). This may indicate that 
HEV could replicate in kidney and subsequently cause tissue injury, which may facilitate the 
release of the virus into urine, although detailed investigation is certainly required to further 
explore the role of HEV infection in renal physiology and pathology. Since HEV infection has 
recently been reported to be associated with renal manifestations in patients 4, it would be 
interesting for Geng et al. to also look into kidney functions and potential renal 
manifestations in their patients who are positive for HEV in their urine 2. 
In summary, it is clear that HEV could be released into urine in acute and chronically 
infected HEV patients and monkeys. Because monkeys are capable of modelling both acute 
and chronic HEV infection, they are particularly useful for further mechanistic study towards 
understanding how HEV was disseminated into urine, as well as for HEV research in general.  
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Supplementary materials and methods 
Quantification of HEV RNA by Real-Time qPCR 
Total RNA was extracted from serum, feces or tissues (liver and kidney) by Trizol (Invitrogen, 
America), according to the instructions of the manufacturer. Reverse transcription was 
performed using an MLV Reverse Transcriptase for RT-nPCR (Takara, Japan) according to the 
instructions of the manufacturer. The copy number of HEV in serum, feces or tissues was 
analyzed using SYBR green-based qPCR assays with HEV specific primers as described 
previously 5. In brief, the synthesized first-strand cDNA (2 µL) was added as a template. Real-
time qPCR was performed under the following conditions: 95°C for 30 s, followed by 39 
cycles of 95°C for 5 s and 60 C for 31 s. The housekeeping gene (GAPDH) served as a loading 
control. Real-time qPCR was performed using an ABI PRISM 7300 Real-Time PCR System.  
 
Measurement of HEV IgG and IgM by ELISA  
HEV IgG and IgM antibodies were determined using a commercial ELISA kit (KHB, China) 
based on recombinant HEV fusion proteins according to the instructions of the 
manufacturer.  
 
Profile liver biochemistry in serum 
The serum levels of ALT were measured with an automated biochemistry analyzer (Olympus 
2700, Japan). 
 
Histopathology  
Tissues for histologic examination were fixed in 10% neutral buffered formalin, routinely 
processed, sectioned at a thickness of 4 μm, and then stained with hematoxylin and eosin 
(HE), or Periodic acid–Schiff (PAS).  
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Abstract 
Although hepatitis E virus (HEV), as a hepatotropic virus, is supposed to exclusively infect the 
liver and only cause hepatitis, a broad range of extrahepatic manifestations, including in 
particular idiopathic neurological disorders, have been reported in association with its 
infection. In this study, we demonstrated that various human neural cell lines and embryonic 
stem cell-derived neural lineage cells were susceptible to HEV infection. Induced pluripotent 
stem (iPS) cell-derived human neurons and primary mouse neurons were more permissive 
for HEV infection compared to human liver cells. In mice and monkeys peripherally 
inoculated with HEV particles, viral RNA and protein were detected in brain tissues. Finally, 
patients with HEV-associated neurological disorders shed virus into cerebrospinal fluid (CSF), 
indicating direct infection of their nervous system. These results challenge the dogma of HEV 
as a pure hepatotropic virus and suggest that HEV infection should be considered in the 
differential diagnosis of idiopathic neurological disorders. 
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Introduction 
Hepatitis viruses, classified as A, B, C, D and E, share the common feature of infecting human 
liver resulting in hepatocellular inflammation. Hepatitis E virus (HEV) containing a positive-
sense, single-stranded RNA genome belongs to Hepeviridae family and is the most common 
cause of acute hepatitis worldwide 1. Although it was initially thought to cause acute 
infection only, chronic infection has been well documented in immunocompromised 
individuals, including those with HIV infection, or undergoing chemotherapy for cancer, but 
most commonly in organ transplantation recipients 2. In contrast to other hepatotropic 
viruses, HEV genotypes 3 and 4 are now recognized as zoonotic in developed countries with 
a broad spectrum of animals serving as reservoirs, with the true primary host being the pig 3. 
HEV infection is surprisingly common in developed countries 4. Infections are normally 
asymptomatic or unrecognized and as a result HEV has found its way into the human blood 
supply. For example, recent data shows that 1 in 600 blood donors in the Netherlands are 
viraemic at the time of donation 5. Notably however, the health risks following viraemic 
blood transfusion remain unclear. 
Previously, HEV was thought to exclusively infect hepatocytes resulting in 
hepatocellular necrosis and hepatitis. However, a number of recent studies have shown that 
HEV infection is associated with a broad range of idiopathic extrahepatic manifestations, 
including renal injury, acute pancreatitis, hematological diseases and a variety of 
neurological disorders 6. Among these, neurological disorders have been described as a 
relatively common, but under-recognized, extrahepatic manifestation related to HEV 
infection 4, 7, 8. An increasing number of central or peripheral nervous system diseases have 
been documented in patients associated with acute or chronic HEV infection 4, 7, 9-11, 
including Guillain-Barre syndrome (GBS) and neuralgic amyotrophy (NA) 4, 9, 12. 
The etiology of HEV-associated neurological injury is unknown. In the existing 
paradigm, HEV is considered to be primarily a hepatotropic virus. Hitherto, the most widely 
held neuropathogenic hypothesis posits that HEV causes neurological injury by immune 
mechanisms related to molecular mimicry, as has been well described for GBS associated 
with a variety of infectious triggers 9, 13. The alternative hypothesis, however, that HEV 
causes direct injury via neurotropism has not been sufficiently evaluated. The aim of the 
present study was to investigate if HEV can directly infect the nervous system. Our results 
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demonstrate that HEV is capable of central nervous system infection in multiple species and 
therefore should be considered as a neurotropic virus. 
 
Materials and methods 
HEV plasmids.  
HEV genomic RNA was generated from a plasmid construct containing the full-length HEV 
genome (genotype 3 Kernow-C1 p6 clone, GenBank accession number JQ679013) or a 
construct containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter 
gene (p6-Luc), using the Ambionm MESSAGE MACHINE in vitro RNA transcription Kit (Life 
Technologies Corporation) 33, 36. 
 
Reagents and cell culture.  
Human IFN-α (Thermo Scientific, the Netherlands) was dissolved in PBS. Ribavirin (Sigma-
Aldrich, St Louis, MO) and rapamycin (Bio-Connect, TE Huissen, the Netherlands) were 
dissolved in DMSO (Sigma). Mycophenolic acid (MPA) (Sigma) was dissolved in methanol. 
Human hepatoma cell line HuH7 was cultured in Dulbecco’s modified Eagle medium (DMEM) 
(Invitrogen-Gibco, Breda, the Netherlands) supplemented with 10% (v/v) fetal calf serum 
(Hyclone, Lonan, Utah), 100 IU/ml penicillin, 100 lg/ml streptomycin and 2 mM L-glutamine 
(Invitrogen-Gibco). All the neural cell lines were kind gifts: glioblastoma U87 cell line was 
from Department of Viroscience, Erasmus Medical Centre, glioblastoma U343 cell line was 
from Dr. Elly Hol (Department of Translational Neuroscience, Brain Center Rudolf Magnus, 
University Medical Center Utrecht), neuroepithelioma SK-N-MC cell line was from Dr. 
Thomas Pietschmann (Institute for Experimental Virology, Twincore, Centre for Experimental 
and Clinical Infection Research), and neuroblastoma SH-SH5Y cell line was from Dr. Marcel E. 
Meima (Department of Internal Medicine, Erasmus Medical Center). They were cultured in 
DMEM supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin, 100 lg/ml 
streptomycin and 2 mM L-glutamine. Human embryonic stem cell (H9) derived-neural 
progenitor cells (hES-NPCs) were cultured and differentiated as previously described 37. iPS 
cell-derived iCell Neurons of highly pure population of human neurons (Cellular Dynamics 
International, Inc., CDI, WI, USA.) were cultured in the complete iCell Neurons maintenance 
Chapter 6 
112 
medium (CDI) as the guild line described 
(https://cellulardynamics.com/assets/CDI_iCellNeuronsUsersGuide.pdf). All cells were 
cultured in an incubator at 37°C with 5% CO2. 
 
Electroporation of HEV RNA.  
The glioblastoma U87 cells were collected and centrifuged for 5 min, 1500 rpm, 4°C. The 
supernatant was removed and the cells were washed with 4 ml Opti-MEM (Thermo 
Scientific, the Neterlands) by centrifuging for 5 min, 1500 rpm, 4°C. The cell pellet was re-
suspended in 100 μl Opti-MEM and mixed with p6 full-length HEV RNA or p6-Luc 
subgenomic RNA. Electroporation was performed with the Bio-Rad’s electroporation 
systems using the protocol of a designed program (400 volt, pulse length 0.5, number 1 and 
cuvette 4 mm) 36. The supernatant of cultured p6 full-length HEV RNA electroporated cells 
were collected to perform secondary infection. 
 
Isolation and culture of primary mouse neurons.  
The primary mouse cerebellum and hippocampus were isolated from E17-E19 mouse 
embryos. In brief, the cerebellum and hippocampus were dissected in ice-cold HBSS 
supplemented with 20 µg/ml Gentamicin (both from Life Technologies), then incubated with 
10 U/ml Papain (Sigma), 2.5 U/ml DNAse I (Roche) and 4 mM MgCl2 (Sigma) at 33°C for 30 
min. The cerebella were titrated in HBSS with 2.5 U/ml DNAse I and 4 mM MaCl2, and were 
filtered with 200 µM Nylon mesh. After washing in HBSS twice, the cells were plated on poly-
ornithine (500 µg/mL, Sigma) coated 1.5H glass-bottomed slide (ibidi) at a density of 1.2 × e6 
cells/cm2. For electroporation, these primary mouse neurons were transfected with p6 full-
length HEV RNA using a Nucleofector 4D (Lonza) according to manufacturer’s protocol 
before plating. The culture medium contains PNGM neural basal medium (Lonza), GS-21 
supplement (Globalstem), 5 µg/ml Gentamicin and 2 mM Glutamax (Life Technologies). Half 
of the medium was changed once a week, and 2 µM Ara-C (Sigma) was added to prevent glia 
growth. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR).  
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RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, the Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of HEV, human and mouse 
GAPDH were amplified by 40 cycles and quantified with a SYBR Green-based real-time PCR 
(MJ Research Opticon, Hercules, CA, USA) according to the manufacturer’s instructions. 
GAPDH was considered as a reference gene to normalize gene expression. The HEV primer 
sequences were 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-
CCGTGGCTATAATTGTGGTCT-3’ (antisense), the primers of human housekeeping gene 
Human GAPDH were 5’-TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’-
CTCCGATGCCTGCTTCACTACCTT-3’ (antisense), and the primers of mouse GAPDH were 5’-
CATCACTGCCACCCAGAAGACTG-3’ (sense) and 5’-ATGCCAGTGAGCTTCCCGTTCAG-3’ 
(antisense).  
 
Measurement of luciferase activity.  
For gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured by the BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs) and 
quantified with a LumiStar Optima luminescence counter (BMG LabTech, Offenburg, 
Germany). 
 
MTT assay.  
Cells seeded in 96-well plates were cultured with 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St Louis, MO) at 37 °C with 5% CO2 for 3 
h. After removing the medium, 100 μl of DMSO was added to each well for 50 min 
inoculation. The absorbance of each well was read on the microplate absorbance readers 
(BIO-RAD) at a wavelength of 490 nm. All measurements were performed in triplicate. 
 
Western blot assay.  
The supernatant of HEV RNA electroporated U87 cells with lysate buffer and DTT were 
heated 5 min at 95°C followed by loading onto a 10% sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. After 90 min running at 
120 V, proteins were electrophoretically transferred onto a polyvinylidenedifluoride (PVDF) 
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membrane for 1.5 h with an electric current of 250 mA. Subsequently, the membrane was 
blocked with 2.5 ml blocking buffer and 2.5 ml PBS containing 0.05% Tween 20 (PBS-T). It 
was followed by incubation with primary HEV ORF2 (1:1000) antibodies (aa 434-457, clone 
1E6, Millipore, Amsterdam-Zuidoost, the Netherlands) overnight at 4°C. The membrane was 
washed 3 times followed by incubation for 1.5 h with anti-mouse IRDye-conjugated 
secondary antibodies (LI-COR Biosciences, Lincoln, USA) (1:5000) at room temperature. Blots 
were scanned by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, NE, USA). Results 
were visualized and quantitated with Odyssey 3.0 software. 
 
Animal models of HEV infection.  
The Animal Care and Use Committee of the Kunming University of Science and Technology 
approved the study protocol and provided the guidelines for this study. Specific-pathogen-
free (SPF) male Balb/c nude mice were purchased from the National Rodent Laboratory 
Animal Resources, Shanghai Branch (China) and maintained in a pathogen-free animal 
facility. Prior to their inoculation with HEV, all the mice were tested negative for HEV IgG and 
IgM antibodies and HEV antigens in both their sera and feces. Swine HEV (Genotype 4, KM01 
strain) isolated from the feces was intravenously injected into mouse with a viral load of 1 x 
105 copies/ml, as calculated by the viral genomic titer determined by qRT-PCR. Mice were 
humanely euthanized, at 14 days post-inoculation following the guidelines of the Care and 
Use of Laboratory Animals.  
Rhesus macaque were from Institute of Medical Biology, Chinese Academy of 
Medical Sciences and Peking Union Medical College. Prior to their inoculation with HEV, they 
were tested negative for HEV IgG and IgM antibodies and HEV antigens in both of sera and 
feces. Two 2-year-old male rhesus macaques were intravenously injected with 2 ml of fecal 
supernatant from swine infected with HEV (genotype 4, KM01, 2 x 104 copies/ml) as 
previously established 20. One macaque without inoculation served as a control. One monkey 
that died unexpectedly after over 600 days of chronic infection was subjected for analysis. 
For the mice and monkey, serum samples, liver tissues and brain tissues were collected for 
qRT-PCR quantification of HEV RNA. The brain tissues were collected for 
immunohistochemistry staining of ORF2 viral protein. 
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Immunohistochemistry.  
For immunofluorescence, cell lines and primary mouse brain cells grown on coverslips were 
fixed with 4% (w/v) paraformaldehyde (PFA) for 10 min at RT. After three washes with PBS 
buffer, cells were permeabilized with 0.1% (v/v) Triton X-100 for 10 min and washed three 
times with PBS. Cells were then incubated with primary anti-HEV ORF2 antibody (1:200) at 
4°C overnight and washed three times with PBS, followed by incubation with Anti-mouse-
Alexa Fluor® 488-Conjugate antibody (Cell Signaling Technology) (1:1000) covalently linked 
to fluorophores and DAPI for 1 h. Confocal images were visualized with an inverted LSM 510 
confocal microscope (Zeiss LSM510, Jena, Germany) using a 40x oil immersion objective. All 
images were analyzed with a Zeiss LSM Image Browser (version 4.2). 
For immunohistochemistry assay of cell cultures and brain tissues of mouse and 
monkey, slides were wash by PBS-T after deparaffinization. Antigen retrieval were 
performed in citric acid buffer (pH = 6) and PBS with 1.5% H2O2 were added at RT for 10 min 
to remove background. Rinse with PBS-T followed by blocking with 5% nonfat milk. Slides 
were incubated with primary anti-HEV ORF2 antibody (1:200) at 4°C overnight. After being 
rinsed in PBS-T, the slides were incubated for 30 min in Dako EnVision + System-HRP 
Labelled Polymer anti-mouse antibody (Dako, Carpinteria, USA), then rinsed with PBS-T and 
incubated in DAB solution (0.05% DAB, 0.0017% H2O2, PBS). To finish, the slides were rinsed 
twice with distilled water, counterstained with hematoxylin for 20 seconds, dehydrated in 
ethanol, cleared in xylene and embedded. Staining was visualized by a Nikon light 
microscope (Nikon, Amsterdam, the Netherlands). 
 
Retrospective analysis of patient data.  
Three cohorts of 18 HEV-associated neurological patients at CHU Rangueil (Toulouse, 
France), Erasmus MC-University Medical Center (Rotterdam, Netherlands) and Royal 
Cornwall Hospital (UK) were identified for analysis. 
 
Statistical analysis.  
Data were presented as mean ± SEM. Comparisons between two groups were performed 
with Mann-Whitney U test. Differences were considered significant at a p value less than 
0.05. 
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Results 
HEV infects neurons in cell culture.  
 
Figure 1. Neural cells are 
permissive for HEV 
infection in vitro. A, Cellular 
HEV RNA levels of various 
human neural cell lines and 
human embryonic stem cell-
derived neuron progenitor 
cells (hES-NPCs), and B, 
cellular HEV RNA levels of 
induced pluripotent stem 
(iPS) cell-derived human 
neurons were analyzed with 
inoculation of cell culture-
derived HEV particles for 24, 
48 and 96 hrs, compared to 
human liver HuH7 cells, 
which are considered the 
canonical model for HEV 
infection (Mean ± SD, n = 3-
4). The level of HEV 
infection in HuH7 cells for 
24 hrs serves as 1. 
 
To investigate whether HEV can directly infect human neural cells, neuroblastoma SH-SH5Y, 
neuroepithelioma SK-N-MC, glioblastoma U87 and U343 cell lines were employed. A human 
liver cell line, human hepatoma 7 (HuH7), was used as a positive control because of its high 
permissiveness for HEV infection. After inoculation with cell culture-derived HEV particles for 
24, 48 and 96 hrs, intracellular viral RNA was quantified by qRT-PCR. All of the neural cell 
lines were permissive to HEV infection. U87 and SH-SH5Y cells exerted a similar susceptibility 
compared to HuH7 cells, whereas U343 and SK-N-MC cells were less susceptible than HuH7 
cells to HEV infection (Figure 1A). Moreover, human embryonic stem cell (H9) derived-neural 
progenitor cells (hES-NPCs) (Supplementary Figure 1A) exhibited a particularly high 
susceptibility to HEV infection, compared to HuH7 liver cells (Figure 1A). We investigated 
HEV infection of cultures in which neuronal differentiation of hES-NPC was induced. These 
cultures especially appeared remarkably permissive for HEV infection, as evidenced by the 
abundance of intracellular HEV RNA quantified four days after inoculation of HEV particles 
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(Supplementary Figure 1B). Subsequently, induced pluripotent stem (iPS) cell-derived human 
neurons with highly pure population of mixture of post-mitotic neural subtypes, as observed 
under the white-light microscopy analysis (Supplementary Figure 1c), strikingly exhibited the 
highest efficiency of HEV replication level by cellular HEV RNA levels especially at 96 hrs of 
virus infection, compared to HuH7 liver cells (Figure 1B). HEV copy numbers presented a 
time-dependent increase in the secreted medium (Supplementary Figure 1D). These results 
demonstrate that HEV is able to directly infect neural cells in vitro. 
 
Long-term replication and production of HEV in neural cells.  
Further detailed study of HEV infection was performed using the glioblastoma U87 cell line, a 
long-established and generally considered an appropriate model for investigating the 
molecular details of virus-related neuropathology 14. Upon electroporation of the full-length 
genomic HEV RNA, viral protein ORF2 was subsequently expressed in U87-HEV cells as 
detected by immunofluorescent and immunohistochemical staining (Figure 2A and 
Supplementary Figure 2). We further investigated whether these U87-HEV cells can secret 
viral particles into the supernatant. To this end, a HEV plasmid based standard curve was 
constructed as a reference to assess and quantify the production of infectious virion 
(Supplementary Figure 3A). We observed that HEV load was 1.7 x 106 copies/ml in 
supernatant of U87-HEV cells and 1.3 x 109 copies/ml in ultra-centrifuged medium 
(Supplementary Figure 3B). Viral protein was detected in the ultra-centrifuged medium by 
Western blot analysis (Figure 2B). Thus human glioblastoma cells appear capable of 
supporting the HEV life cycle. 
To ascertain whether glioblastoma cells also can support long-term production of 
HEV, the viral load of extra-cellular U87-HEV medium was monitored over 30 consecutive 
days and high viral loads were consistently secreted over this entire time frame (Figure 2C). 
For U87-HEV-Luc cells with electroporation of subgenomic HEV RNA in which ORF2 was 
replaced by a gaussia luciferase reporter gene (p6-Luc), secreted luciferase activity directly 
serves as a pseudomarker for the level of HEV replication. Glioblastoma cells apparently 
supported long-term HEV replication as luciferase activity could be readily detected for 30 
days (Figure 2D). Furthermore, comparable levels of HEV infection were detected upon 
inoculation of HuH7 liver cells and U87 cells with U87-produced HEV particles for 96 hrs,  
 
Chapter 6 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Neuroglial cells support long-term HEV replication and production. A, 
Immunofluorescence staining of viral protein ORF2 (green) in neuroglial U87 cells upon 
electroporation of the full-length genomic HEV RNA. DAPI (blue) was applied to visualize nuclei. 
Shown confocal images are representative for three independent experiments. (Scale bar, 50 µm. 
40x oil immersion objective). B, In ultra-centrifuged supernatant produced by U87-HEV cells, viral 
protein ORF2 is observed by Western blot assay. C, U87 supports long-term production of HEV as 
tested by copy numbers in the medium for 30 days. (Mean ± SD, n = 2, each with two replicate 
experiments). D, In U87 cells upon electroporation of the sub-genomic HEV RNA with luciferase 
reporter, HEV luciferase activity representing virus replication level has been detected maintaining 
for 30 days. (Mean ± SD, n = 2, each with two replicate experiments). E, RT-PCR result indicates that 
HuH7 and U87 cells are permissive for secondary infection with inoculation of U87-HEV produced 
viral particles for 96 hrs. GAPDH serves as a reference gene. One representative experiment of three 
is shown. 
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demonstrating that these cells produce infectious particles (Figure 2E), a hall mark of bona-
fide infectivity. These data show that human glioblastoma cells are capable of supporting 
long-term replication and production of infectious HEV. 
 
Drug treatments on HEV replication in neuroglial cells.  
HEV-associated neurological manifestations are documented in both immunocompetent 
patients and immunocompromised patients who are in particular organ transplant 
recipients. If managed/treated adequately, viral load can be reduced in most of the patients 
and neurological symptoms can be resolved 15. Reducing the dose of immunosuppressants is 
often the first line of therapeutic intervention for immunosuppressed patients 16. Although 
no approved HEV medication is available, ribavirin or interferon-α (IFN-α) have been used as 
off-label treatment for some cases, in particular chronically infected patients. We previously 
have demonstrated the anti-viral effects of ribavirin 17 and IFN-α 18, the anti-viral effect of 
the immunosuppressant mycophenolic acid (MPA) 17, and the pro-viral effect of the 
immunosuppressant rapamycin 19 in liver cell lines infected with HEV, suggesting that such 
drugs have promise for combating neural HEV infection as well. Proof for this notion came 
from experiments in which we studied the effects of clinically relevant concentrations of 
these medications, in neuroglial U87 cells employing the subgenomic HEV replication model 
U87-HEV-Luc cells and infectious U87-HEV cells. IFN-α significantly exhibited dose-
dependent anti-viral effects in U87-HEV-Luc cells and high dose (1000 IU/ml) potently 
reduced the level of cellular HEV RNA level in U87-HEV cells (Figure 3A). A subset of 
interferon stimulated genes (ISGs) was significantly induced following treatment with 1000 
IU/ml IFN-α, indicating that canonical interferon signaling mediates these anti-HEV effects in 
neuroglial cells (Figure 3B). Analogously, anti-HEV effects of ribavirin in these neuroglial cell 
cultures were observed, supporting the use for this compound for treating HEV infection 
complicated by neurological manifestations (Figure 3C). Interestingly, the 
immunosuppressive medication MPA (often used to suppress organ rejection) counteracted 
HEV infection, but a pro-viral effect of the immunosuppressant rapamycin (often used to 
suppress organ rejection) was observed (Figure 3D and E). MTT results showed no 
cytotoxicity treating with these drugs in U87 cells (Figure 3F). Thus our data indicates that 
the use of MPA may be indicated as an immunosuppressive regimen for counteracting 
rejection in organ transplant recipients at risk for HEV infection, whereas ribavirin appears a 
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rational choice for combating an established HEV infection complicated by neurological 
manifestations. 
 
Figure 3. Drug treatments for HEV infection in neuroglial cells. (A) 100 (low)/1000 (high) IU/ml IFN-
α, (C) 10 (low)/100 (high) μM RBV, (D) 1 (low)/10 (high) μg/ml MPA and (E) 100 (low)/1000 (high) nM 
rapamycin are treated in U87-HEV-Luc cells for 24, 48 and 72 hrs and in U87-HEV cells for 48 hrs. HEV 
luciferase activity and cellular RNA level were analyzed respectively. B, 1000 IU/ml IFN-α significantly 
induced a subset of interferon stimulated genes (ISGs). F, MTT assay shows no cytotoxicity of these 
drug treatments for three days in U87 cells. 
 
Primary mouse neurons efficiently support HEV infection.  
Further support for the results obtained with respect to the neurotropism of HEV came from 
experiments in which we conducted to infect primary isolated mouse neurons with HEV. 
Primary cerebellar and hippocampal neurons cultured from mouse embryos were incubated 
with cell culture-derived HEV particles (Figure 4A). HEV replicated efficiently in both 
neuronal cultures, as judged by cellular levels of HEV RNA. As compared to the canonical 
model for HEV replication, Huh7 cells, HEV infection in cerebellar cultures, was 7.09 ± 4.51  
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Figure 4. HEV infects 
primary mouse 
neurons. A, 
Cerebellar and 
hippocampal neurons 
were cultured and 
inoculated with HEV 
particles for 96 hrs. B, 
RT-PCR result shows 
a time-dependent 
increase of HEV 
replication in both 
neurons (Mean ± 
SEM, n = 5, P < 0.05). 
Immunofluorescence 
staining of viral 
protein ORF2 (green) 
were detected three 
days electroporation 
of HEV RNA in 
primary (C) cerebellar 
and (E) hippocampal 
neurons. DAPI (blue) 
was applied to 
visualize nuclei. 
(Scale bar, 50 µm.) 
RT-PCR result 
indicates that 
primary (E) cerebellar 
and (F) hippocampal 
neurons are 
permissive for 
secondary infection 
with inoculation of 
viral particles for 96 
hrs. GAPDH serves as 
a reference gene. 
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and 11.16 ± 18.09 -fold (mean ± SEM, n = 5, P < 0.05) more efficient at 48 and 72 hrs, 
respectively. In hippocampal cultures, when compared with the Huh7 benchmark, HEV 
infection was 6.03 ± 3.92 and 4.91 ± 10.14-fold (mean ± SEM, n = 5, P < 0.05) more efficient 
at 48 and 72 hrs, respectively (Figure 4B). We next examined whether these mouse neurons 
can produce infectious HEV particles. For full length of HEV genome RNA was electroporated 
in cerebellar cells with detection of the viral ORF2 protein employing immunofluorescent 
staining for this protein at 72 hrs (Figure 4C). HEV RNA was present both in the cells and in 
the supernatant of these cultures. Inoculation of naïve cells with the supernatant resulted in 
HEV infection (Figure 4D). Similar results were observed in hippocampal cells (Figure 4E and 
F). In conjunction, these data demonstrate that both primary cerebellar and hippocampal 
cultures are capable of the production infectious HEV particles in vitro and show that 
primary neurons are more susceptible to HEV infection as compared to the canonical model 
for HEV infectivity, in human HuH7 liver cells. 
 
HEV infects the brains of mouse and monkey.  
The definitive proof for the notion that the central nervous system is a primary target for 
infection by HEV would be demonstration of such infection in vivo. Hence, mice were 
intravenously inoculated with fecal samples contacting HEV particles via tail vein injection 
(Figure 5A). As expected, high titers of HEV genomic RNA were detected in serum samples 
and mouse liver at 14 days post-inoculation (dpi). Importantly in parallel measurement of 
HEV levels in mouse brain revealed a high level of infection in this organ (Figure 5B). 
Consistently, in the cerebellum of the mouse brain tissue, viral protein ORF2 was observed 
expressing in the granule layer by immunohistochemistry analysis (Figure 5C). Analogously, 
in a monkey (rhesus macaque) model for persistent HEV infection20 in an animal dying 
unexpectedly after over 600 days of chronic infection, viral RNA was detected in serum, liver 
and brain tissue of this monkey (Figure 5B). Again, Viral protein ORF2 was expressed in 
granule layer of cerebellum (Figure 5C). These data show that HEV infects the brains of 
mouse and monkey following experimental inoculation of HEV. 
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Figure 5. HEV infection in the brains of mouse and monkey. A, Three mice and one monkey have 
been tail intravenously injected and inoculated with HEV strains for 14 days and over 600 days with 
chronic infection separately. B, Viral RNA has been observed in serum samples, liver tissues and brain 
tissues of infected mouse and monkey. C, Viral HEV ORF2 protein are observed in brain tissues of 
infected mouse and chronically infected monkey by immunohistochemical assay. Brain tissues of un-
infected mouse serve as a control. For monkey brain tissues, staining without inoculating viral 
antibody samples serve as a control. Cerebellum of the brain were observed and HEV positivity 
presented in the granule cell layer of the cerebellum. Hematoxylin (blue) was applied to visualize 
nuclei, and DAB solution was used to visualize cytoplasm (Scale bar: 50 µm). 
 
Human patients with HEV-associated neurological disorders shed virus into 
cerebrospinal fluid.  
Our data that HEV can infect brain tissue suggest that the neurological manifestations 
associated with HEV do not necessarily relate to autoimmunity but may relate to direct HEV 
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Patient Country Gender Age Immunocompetence IgG HEV IgM HEV PCR serum PCR faeces PCR CSF Type of neurologic disorder 
1 NL M 55 + + + - NT - GBS 
2 NL F 60 + + + - NT - GBS 
3 NL M 67 + + + - NT - GBS 
4 NL M 44 + + + - NT - GBS 
5 UK M 58 + + + + NT - NA 
6 UK M 52 + + + + NT - NA 
7 UK M 49 - + + + + + Peripheral neuropathy 
8 UK M 34 + + + + NT - Peripheral neuropathy 
9 UK M 42 + + + + NT - GBS 
10 FR M 74 + + + + + + GBS 
11 FR M 33 + - + + + - GBS 
12 FR M 59 - + + + + + Ataxia 
13 FR M 32 - + + + + + Cognitive dysfunction 
14 FR M 44 - + + + + + Polyradiculoneuropathy 
15 FR M 66 - + + + + - GBS 
16 FR F 33 + - + + + - Meningitis 
17 FR M 56 + + + + + - NA 
18 FR M 57 - + + + NT + GBS 
 
infection. In order to test this hypothesis directly, cerebrospinal fluid (CSF) from patients 
with HEV-associated neurological disorders was collected and tested for the presence of HEV 
RNA by PCR, employing patients with bona fide acute or chronic HEV infection, as evident 
from testing serum for HEV antibody IgM, IgG and HEV RNA. We thus analyzed three 
different cohorts of patients (some patients have been described in our previous 
publications) with HEV-associated neurological disorders 9, 21-23. Over half of the patients 
were positive for HEV RNA in serum samples indicating active infection in these patients 
(Table 1). Among these patients, 42.9% (six out of 14) shed virus into CSF. These results 
suggest that HEV may directly infect central nervous system and/or peripheral nerve roots in 
humans.  
 
Table1. Characteristics of patients with HEV-associated neurological disorders*. 
 
 
 
 
 
 
 
*Ig, immunoglobulin; HEV, hepatitis E virus; CSF, cerebrospinal fluid; NL, the Netherlands; UK, United 
Kingdom; FR, France; +, positive; -, negative; NT, not tested; GBS, Guillain-Barré syndrome, NA, 
neuralgic amyotrophy. 
 
 
 
 
HEV infects nervous system 
125 
Discussion 
The data in the present study show that HEV can efficiently infect neural cell types and 
tissues at efficacies that exceed that of canonical liver-derived models. Thus the aspect of 
HEV appears also neurotropic, substantially challenging current dogma. The data appear 
clinically relevant in that HEV can be recovered from the CSF of patients with acute HEV 
infection complicated by neurological manifestations. As HEV infection is often undiagnosed, 
they/the data suggest that HEV may be involved in at least some cases of “idiopathic” 
neurological disease. Taken together these findings challenge the conventional wisdom that 
HEV is primarily a hepatotropic virus and helps our understanding of the potential 
pathogenic mechanism of HEV-associated neurological injury. 
Recent studies show that HEV demonstrates tropism to a range of tissues of non-
hepatological origin. Although liver cells are commonly used for modelling HEV infection in 
vitro, a human lung epithelial cell line A549 24 and some ectodermally-derived cell lines 25, 26 
have been reported to support HEV replication in cell culture. We have recently 
demonstrated that mouse embryonic fibroblasts are also susceptible for HEV infection 27. In 
nude mice experimentally infected with HEV, viral RNA was detected in liver, spleen, kidney, 
jejunum, ileum and colon 28. In the tree shrew (tupaia belangeri chinensis), HEV capsid 
protein was expressed in the liver, spleen, and kidney 29. In specific-pathogen-free rabbits 
infected with rabbit HEV strain, both positive and negative-stranded viral RNA and antigen 
expression were detected in liver, brain, stomach, duodenum and kidney, suggesting its 
active replication in these tissues 30. In Mongolian gerbils infected with a genotype 4 strain of 
swine HEV, the virus could be detected in the liver, kidney, spleen and small intestine 31. In 
rhesus macaques infected with human 32 or swine 20 HEV strains, viral infection in kidney and 
dissemination of viruses into urine were observed. Thus our data add on a gathering 
momentum that HEV is not an exclusively hepatotropic virus. Furthermore, our studies also 
demonstrate the clinical relevance of extra-hepatic infection. Finally, our studies suggest 
that use of MPA for preventing rejection in organ transplant recipients might be 
accompanied by a lower incidence of HEV-associated neurological manifestations and that 
ribavirin is suitable for managing such complications. 
The strain of human HEV used in the current study deserves comment. Kernow C1p6 
was isolated form a UK patient with HIV-1 chronically infected with HEV genotype 3 (case 7, 
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table1) 33, 34. The patient had neurological symptoms in the legs which resolved with viral 
clearance following therapy with ribavirin/Peg-interferon 35. The strain of HEV isolated from 
the patient was shown to have a novel virus-host recombination 33. Thus, this strain of HEV 
was unusual and had documented ability to produce clinically relevant neurological injury in 
humans. However, for the in vivo mouse and monkey experiments we used HEV genotype 4 
of porcine origin. This suggests that multiple HEV stains share high neurotropism. The clinical 
observation that HEV-associated neurological injury is found worldwide and caused by HEV 
of differing genotypes would support this notion4. 
In conclusion, HEV is neurotropic in vitro and in vivo in mice, monkeys and probably 
human beings. These findings challenge the notion that HEV is primarily a hepatotropic virus 
and suggest HEV infection as a possibility in idiopathic neurological disease. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. A, After differentiation, embryonic stem cell-derived neuron 
progenitor cells (hES-NPCs) (untransformed) as appearing under white-light microscopy. 
Scale bar: 100 µm. B, After inoculation of HEV particles for 96 hrs, RT-PCR result showed that 
these differentiated neurons derived from hES-NPCs support HEV replication. GAPDH serves 
as a reference gene. One representative experiment of three is shown. C, Induced 
pluripotent stem (iPS) cell-derived human neurons (untransformed) were observed under 
white-light microscopy. Scale bar: 100 µm. D, Time-dependent increase of HEV copy 
numbers secreted from the human neurons into the medium. 
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Supplementary Figure 2. HEV RNA electroporated to neuroglial U87 cells. 
Immunohistochemistry assay for HEV ORF2 in U87-HEV cells. (Scale bar, 50 µm.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. HEV copy numbers of U87-HEV produced medium. A, HEV plasmid 
based standard curve is generated by plotting the log copy number versus the cycle 
threshold (CT) value. B, HEV copy numbers in supernatant of U87-HEV cells and ultra-
centrifuged medium, compared with U87 cell culture medium (negative CTR). 
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Abstract 
Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. 
Although there is no proven medication for hepatitis E, pegylated Interferon-α (IFN-α) has 
been used as off-label drug for treating HEV. However, the efficacy and molecular 
mechanisms of how IFN signaling interacts with HEV remain undefined. As IFN-α has been 
approved for treating chronic hepatitis C for decades and the role of interferon signaling has 
been well-studied in hepatitis C virus (HCV) infection, this study aimed to comprehensively 
investigate virus-host interactions in HEV infection with focusing on the IFN signaling, in 
comparison to HCV infection. A comprehensive screen of human cytokines and chemokines 
revealed that IFN-α was the sole humoral factor inhibiting HEV replication. IFN-α treatment 
exerted a rapid and potent antiviral activity against HCV; whereas it had moderate and 
delayed anti-HEV effects in vitro and in patients. Surprisingly, blocking the basal IFN pathway 
by inhibiting JAK1 to phosphorylate STAT1 has resulted in drastic facilitation of HEV, but not 
HCV infection. Gene silencing of the key components of JAK-STAT cascade of the IFN 
signaling, including JAK1, STAT1 and interferon regulatory factor 9 (IRF9) stimulated HEV 
infection. In conclusion, compared to HCV, HEV is less sensitive to IFN treatment. In contrast, 
the basal IFN cascade could effectively restrict HEV infection. This bears significant 
implications in management of HEV patients and future therapeutic development. 
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Introduction  
As an emerging infectious pathogen, hepatitis E virus (HEV) represents the most common 
cause of acute viral hepatitis 1. Outbreaks of hepatitis E occur periodically throughout the 
developing world, which often cause fulminant hepatitis with high mortality (reaching 25%) 
in the case of pregnant women 2. In the industrialized countries, HEV usually only causes an 
acute and self-limiting infection, it however bears a high risk of developing chronic hepatitis 
in immunocompromised patients with substantial mortality rates 3. Thus, it is important to 
understand the underlying mechanisms of the distinct infection courses of different 
populations upon exposure to HEV. For severely affected patients, there is an urgent need 
for developing optimal therapies, because no proven antiviral medication is available for 
hepatitis E. 
Cytokines induced by viral infection play a key role in host defense against the 
infection 4, but their roles in anti-HEV immunity remain largely obscure. HEV provokes the 
production of a panel of inflammatory cytokines and chemokines with considerable higher 
levels in experimental models and in patients 4-7. However, the action of these HEV-induced 
cytokines on the life-cycle and pathogenesis of HEV infection remain unknown. Interferons 
(IFNs), pleiotropic cytokines, are of vital importance for the innate defense against viral 
infection 8. They are grouped into three classes including type I, II and III, which bind to 
distinct receptors to stimulate their antiviral responses in host cells 9. Pegylated IFN-α in 
combination with ribavirin was considered the standard antiviral therapy for chronic 
hepatitis C virus (HCV) infection 10. In addition, type III IFN-lambdas (IFN-λs), which appear to 
have less side effects than IFN-α, are currently clinically evaluated for the treatment of 
chronic hepatitis C 11, 12. Although Pegylated IFN-α, ribavirin or the combination have already 
been used to treat individual cases or small case series of HEV infection as off-label drugs 13-
15, their mechanism-of-actions in the setting of HEV remain poorly investigated. 
Intriguingly, basal JAK-STAT signaling in the absence of exogenous IFN stimulation 
could already serve as a first line of intracellular antiviral defense 16. In fact, the 
seroprevalence of HEV is substantially high in both developing and developed countries; 
whereas majority healthy people have only asymptomatic or self-limiting acute infection. 
Thus, humans clearly have powerful defense mechanisms against HEV. It is of an intriguing 
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question whether basal IFN signaling plays a crucial role in the process of HEV resistance or 
self-limiting.  
The absence of robust cell culture models has hampered fundamental and 
translational research of HEV. Fortunately, subgenomic and infectious models for HEV 
infection have come available 17 and such models were recently used in studying the 
infection biology and assessing potential antivirals 18-20. In this study, we comprehensively 
characterized the role of cytokines in regulating HEV infection. IFN-α was found the sole 
humoral factor provoking inhibition of HEV replication. Further investigation identified the 
essential role of basal IFN signaling and the key components of JAK-STAT cascades in 
protecting against HEV replication. These results revealed distinct mode-of-actions of basal 
and treatment activated IFN signaling in controlling HEV infection. 
 
Materials and methods 
Patients  
Chronic HEV patients treated with pegylated IFN-α monotherapy at CHU Rangueil, Toulouse, 
France were selected and 4 cases were identified. Patient 1, 2 and 3 were 
immunocompromised patients with liver transplantation and patient 4 had hematologic 
disease. HEV viral kinetics was analyzed in these four patients by retrieving HEV RNA titters 
(log copies/mL) at day 0, 1, 3, 7, 15, 21 and 30 post-treatment. The study was approved by 
the institutional review boards of Toulouse Hospital, and all of the patients presented their 
written informed consent to participate in this study. 
 
Reagents  
Cytokines and chemokines (PeproTech or R&D Systems) were used for screening. Human 
IFNs (Thermo Scientific, Netherlands) were dissolved in culture medium. Stocks of Jak 
inhibitor I (Santa Cruz Biotech, Santa Cruz, CA) was dissolved in DMSO (Sigma-Aldrich, St 
Louis, MO) with a final concentration of 5 mg /mL. Stocks of AG-490 and CP 690550were 
dissolved in DMSO with a final concentration of 10 mg /mL. Antibodies including phospho-
STAT1, total STAT1, phosphor-JAK1, interferon stimulated factor 9 (IRF9) (Cell Signalling 
Technology, Netherlands) and β-actin (Santa Cruz Biotech, Santa Cruz, CA); anti-rabbit or 
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anti-mouse IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave, Victoria, BC, 
Canada) were also used. 
 
Cell culture models 
HEV genomic RNA was generated from a plasmid construct containing the full-length HEV 
genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene (p6-
Luc), using the Ambion MESSAGE MACHINE in vitro RNA transcription Kit (Life Technologies 
Corporation) 17, 21. The human hepatoma 7 (Huh7) cells were collected and centrifuged for 5 
min, 1500 rpm, 4°C. Supernatant was removed and washed with 4 mL Opti-MEM by 
centrifuging for 5 min, 1500 rpm, 4°C. The cell pellet was re-suspended in 100 μl Opti-MEM 
and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. Electroporation was 
performed with the Bio-Rad’s electroporation systems using the protocol of a designed 
program (240 volt, pulse length 0.5, number 1 and cuvette 4 mm) 17. Huh7-ET replicon was 
based on Huh7 cells containing a subgenomic HCV bicistronic replicon (1389/NS3-
3V/LucUbiNeo-ET) and maintained with 250 µg/ml G418. Huh7 cells harboring the full-length 
JFH1-derived genome was used as an infectious HCV model 22.  
 
Gene knockdown and overexpression by lentiviral vector 
Lentiviral vectors (Sigma-Aldrich) targeting JAK1, STAT1, IRF9 or GFP control were obtained 
from the Erasmus Center for Biomics and produced in HEK 293T cells as previously described 
23. After a pilot study, the shRNA vectors exerting optimal gene knockdown were selected. 
These shRNA sequences were described in Supplementary Table 1. To generate gene 
knockdown or overexpression cells, Huh7 cells were transduced with lentiviral vectors. Since 
the knockdown vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 2.5 μg/ml puromycin (Sigma) to the cell culture medium.  
 
Measurement of luciferase activity 
For Gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and incubated for 30 
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min at 37 °C. Both gaussia and firefly Luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to cells seeded in 96-well plates and the cells grew at 37 °C with 5% CO2 for 3 hrs. The 
medium was removed and 100 μl of DMSO was added to each well. The absorbance of each 
well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 nm. All 
measurements were performed in triplicates. 
 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA was quantified with a SYBR 
Green-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) according to the 
manufacturer’s instructions. GAPDH was considered as reference gene to normalize gene 
expression. Human primer sequences were included in Supplementary Table 2. 
 
Western blot assay 
Proteins in cell lysates were heated 5 min at 95 °C followed by loading onto sodium dodecyl 
sulphate-polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. Proteins were 
electrophoretically transferred onto PVDF membrane (Invitrogen) for 1.5 hrs with an electric 
current of 250 mA. Subsequently, the membrane was blocked with blocking buffer. It was 
followed by incubation with rabbit p-JAK1, p-STAT1, t-STAT1, IRF9 (1:1000) antibodies 
overnight at 4 °C. The membrane was washed 3 times and incubated for 1 hrs with anti-
rabbit or anti-mouse IRDye-conjugated secondary antibodies (1:5000) at room temperature. 
Blots were scanned and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, 
NE, USA). Results were visualized and quantitated with Odyssey 3.0 software. 
 
Statistical analysis 
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All results were presented as mean ± SEM. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a p value less than 0.05 
*or 0.01 **. 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. HEV replication was insensitive to the regulation of cytokines and chemokines. Huh7-p6-
Luc cells were treated with cytokines at 100 ng/ml (except for IFN-α and IFN-β at 100 IU /mL) for 24 
(A), 48 (B) and 72 hrs (C), and then luciferase activity was measured. (Mean ± SEM, n = 4). ** P < 
0.01. 
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HEV replication is insensitive to the regulation of cytokines and chemokines 
Viral infections often induce various cytokines and chemokines that in turn modulate the 
infection course 24. We thus investigated the effects of a panel of cytokines and chemokines 
on host susceptibility to HEV infection. To this end, we employed cell culture model of 
human hepatoma cells (Huh7 cell line) transfected with subgenomic construct of HEV coding 
sequence in which the 5’ portion of ORF-2 was replaced with the in-frame gaussia luciferase 
reporter (p6-Luc) 17. In parallel, Huh7 cells constitutively expressing a non-secreted firefly 
luciferase are used for normalization of non-specific effects on luciferase signals 18, 20. 
Exploiting this experimental system, 36 cytokines and chemokines, including type I, II and III 
IFNs, interleukins and others, were examined in the HEV replicon, culture medium served as 
control. MTT assay has shown that these cytokines/chemokines in general did not exert 
cytotoxicity to host cells (Supplementary Figure 1). However, except for some forms of IFNs, 
other cytokines and chemokines had no significant effects on HEV replication (Figure 1). 
Hence, HEV replication is in general insensitive to the regulation of cytokines and 
chemokines, except for type I interferons, suggesting that antiviral immunity to HEV is 
mediated through a very specific branch of our immune system. 
 
HEV, compared to HCV, is less sensitive to IFN-α treatment  
Based on the results of our profiling of humoral factors involved in anti-HEV immunity, we 
further investigated the action of IFN-α, the archetypical type I IFN that has been 
successfully used to treat chronic HCV in the clinic for decades 25. As expected, treatment of 
IFN-α resulted in robust inhibition of HCV replication in the Huh7-based subgenomic replicon 
containing a luciferase reporter (Figure 2A), suggesting that our model system can reflect 
clinically relevant processes. High dose of IFN-α (10-1000 IU/mL) almost completely 
suppressed HCV replication as early as after 24 hrs treatment. In contrast, the action of IFN-
α, although evidently present, was much less effective in suppressing HEV replication in a 
similar subgenomic replicon that also contains a luciferase reporter. Moderate inhibitory 
effects were observed only after 72 hrs treatment with relatively high concentrations (100 
IU/mL: 31% ± 8, mean ± SEM, n = 3 independent experiments with each 2-3 replicates, P < 
0.01; 1000 IU/mL: 41% ± 3, mean ± SEM, n = 3 independent experiments with each 2-3 
replicates, P < 0.01) (Figure 2B). Consistently, in the full-length HCV and HEV infectious  
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Figure 2. IFN-α exerted moderate but delayed antiviral activity against HEV. (A) In the Huh7 cell-
based subgenomic HCV replicon, treatment with IFN-α dose-dependently decreased viral replication-
related luciferase activity.(Mean ± SEM, n = 3 independent experiments with each 2-3 replicates). (B) 
In the Huh7 cell-based subgenomic HEV replicon, treatment with IFN-α moderately inhibited viral 
replication-related luciferase activity (Mean ± SEM, n = 3 independent experiments with each 2-3 
replicates). (C) In the full-length HEV and HCV infectious model, IFN-α significantly decreased cellular 
viral RNA at 48 hrs determined by qRT-PCR (Mean ± SEM, n = 5). Significant differences between level 
of INF-α antiviral effects were observed. (D) Four chronic HEV patients were treated with 
monotherapy of INF-α and the viral load were analyzed within 30 days. Treatment time was indicated 
as 24, 48 or 72 hrs * or + P < 0.05; ** or ++ P < 0.01. 
 
models, IFN-α had significantly more potent antiviral effects against HCV than HEV (Figure 
2C). In apparent agreement, whereas it is well-known that chronic HCV patients who 
respond to IFN-α therapy often experience a rapid and sharp reduction of viral load within 
the first few days upon treatment 26, 27, we observed that three out of four chronic HEV 
patients had only minor fluctuation of viral load within first two weeks of pegylated IFN-α 
treatment, although all the patients eventually cleared the virus (Figure 2D). These results 
indicate that IFN-α exerts a moderate and delayed antiviral activity against HEV, in contrast 
to the rapid and potent effect of this cytokine against HCV, which suggests that their 
underlying antiviral mechanisms differ. 
The notion that anti-viral activity of IFN-α towards HEV is mechanistically different 
from that against HCV was further supported by experiments in which the anti-viral effect of 
alternative member of the family of type I, II and III IFNs were investigated. IFN-β and IFN-γ 
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effectively inhibits HCV replication in the replicon model, but did not exert a significant 
effect on HEV replication (Figure 3A and 3B). IFN-λ is currently under clinical investigation for 
treating chronic HCV patients and has been shown to possess good anti-HCV antiviral activity 
but with fewer adverse events as compared to IFN-α 12. In HCV replicon, IFN-λ1, IFN-λ2 and 
IFN-λ3 showed significant inhibition on viral replication. Unexpectedly, high dose of IFN-λ1, 
IFN-λ2 and IFN-λ3 even significantly enhanced viral replication in the HEV replicon after 24 
hrs treatment, although the effects were mild (Figure 3C-E). Thus, the anti-HEV activity of 
type I, II and III IFNs appears mechanistically distinct from that against HCV (Supplementary 
Figure 2). 
 
HEV replication is sensitive to basal IFN signaling  
Although humoral factors do not confer protection action against HEV replication, the only 
partial exception being IFN-α (Figure 2 and 3), humans appear to have powerful defence 
mechanisms combating HEV 18, raising questions as to the nature of these mechanisms. The 
partial activity of IFN-α against HEV replication led us hypotheses that signaling elements, in 
particular JAK-STAT cascades, involved in IFN-α signal transduction might contribute to anti-
HEV defence. Constitutive JAK-STAT signaling is an essential part of the innate immunity for 
host defence against viruses 16. To investigate how the endogenous JAK-STAT signaling 
affects HEV replication, JAK inhibitor I that is known to predominantly inhibit JAK1 (but may 
also inhibit JAK2 and JAK3) was first tested. As expected, it can effectively inhibit its 
downstream target, the phosphorylation of STAT1, induced by treatment of IFN-α or IFN-λ 
(Supplementary Figure 3A). Consistently, it significantly inhibited the stimulation of the IFN 
response reporter, IFN-stimulated response elements (ISRE)-luciferase transcription reporter 
(Supplementary Figure 3B). Accordingly, IFN-α triggered induction of ISGs, as represented by 
four important members RSAD2, ISG15, OAS1 and PKR, were blocked by this inhibitor 
(Supplementary Figure 3C). 
Importantly, treatment of JAK inhibitor I dramatically elevated HEV replication in 
both subgenomic replicon (Figure 4A) and the infectious model (Figure 4B). Treatment with 
10 µM for 72 hrs, increased HEV replication-related luciferase activity by 3.02 ± 0.50-fold 
(mean ± SEM, n = 3 independent experiments with each 3 replicates, P < 0.01) in the replicon 
(Figure 4A). Similarly, treatment with 10 µM for 48 hrs, it increased viral RNA by 4.78 ± 1.13-
fold (mean ± SEM, n = 3, P < 0.05) in the infectious model (Figure 4B). In contrast, JAK  
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Figure 3. IFN-β, γ and λs had no significant antiviral activity against HEV infection. In the Huh7 cell-
based subgenomic HCV and HEV replicon, viral replication-related luciferase activity determined after 
dose-dependently treatments with IFN-β (A), IFN-γ (B), IFN-λ1 (C), IFN-λ2 (D) and IFN-λ3 (E) (Mean ± 
SEM, n = 3 independent experiments with each 3-4 replicates). Treatment time was indicated as 24, 
48 or 72 hrs. * P < 0.05; ** P < 0.01. 
Interferon signaling in constraining HEV 
147 
inhibitor I had only minor effect on HCV replication (Figure 4C). To investigate whether JAK2 
(associated with type II IFN) and JAK3 (activated by cytokines with receptors containing the 
common gamma chain) are also involved, their corresponding inhibitors AG-490 and CP-
690550 were tested in both HEV and HCV replicon. As shown in Figure 4D and 4E, both 
inhibitors had no clear effects on both HEV and HCV replication. Of note, all three inhibitors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Pharmacological inhibition of JAK1 dramatically stimulated HEV replication (A) In the 
Huh7 cell-based subgenomic HEV replicon, treatment with Jak inhibitor I dose-dependently increased 
viral replication-related luciferase activity (Mean ± SEM, n = 3 independent experiments with each 3 
replicates). (B) In the full-length HEV infectious model, 10 µM Jak inhibitor I significantly increased 
cellular viral RNA at 48 hrs determined by qRT-PCR (Mean ± SEM, n = 3). (C) In the Huh7 cell-based 
subgenomic HCV replicon, treatment with Jak inhibitor I did not effectively affect viral replication-
related luciferase activity (Mean ± SEM, n = 3 independent experiments with each 3 replicates). (D) 
AG-490 is an inhibitor of JAK2 signaling and in the Huh7 cell-based subgenomic HEV and HCV 
replicon, treatment with AG-490 did not affect viral replication-related luciferase activity (Mean ± 
SEM, n = 3). (E) CP 690550 is an inhibitor of JAK3 signaling and in the Huh7 cell-based subgenomic 
HEV and HCV replicon, treatment with CP 690550 did not affect viral replication-related luciferase 
activity (Mean ± SEM, n = 3). Treatment time was indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 
0.01. 
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did have notable effects on cell growth determined by MTT assay (Supplementary Figure 
3D). Thus, the basal JAK-STAT pathway could effectively limit HEV infection, although 
exogenous IFN is ineffective, whereas it is vice versa for HCV. 
 
Key components of JAK-STAT cascades restrict HEV infection 
Upon binding of IFN-α to its receptor, JAK1 is stimulated, resulting in tyrosine 
phosphorylation of STAT1 and STAT2. This is followed by the formation and nuclear 
translocation of the STAT1-STAT2-IRF9, a transcription factor complex known as IFN-
stimulated gene factor 3 (ISGF3), which in turn combines to the ISREs in the genome DNA 
and subsequently drives transcription of ISGs to establish an antiviral status (Figure 5A) 28. 
Specific inhibition of the JAK/STAT signaling pathway has been reported to modulate HCV 
replication 29. 
To evaluate the direct effects of the key components of JAK-STAT pathway including 
JAK1, STAT1 and IFR9 on HEV infection, Huh7 cells were transduced with integrating 
lentiviral vectors expressing shRNA specifically targeting JAK1, STAT1, IRF9 or GFP as a 
control. For JAK1 knockdown cells, two of the tested three shRNA vectors targeting JAK1 
exert potent gene silencing capacity, resulted in a profound down-regulation of JAK1 mRNA 
level (Figure 5B). Correspondingly, JAK1 silencing led to significant increase of cellular HEV 
RNA level, which was measured by qRT-PCR after inoculation of HEV particles for 72 hrs. For 
instance, knockdown of shRNA clone 2 in JAK1 led to 2.47 ± 0.66-fold increase of HEV viral 
RNA (mean ± SEM, n = 4, P < 0.05) (Figure 5B). Furthermore, STAT1, which is phosphorylated 
by JAK1, was successfully silenced by shRNA targeting STAT1 in Huh7 cells with a potent 
reduction in protein level in shSTAT1 cells (Figure 5C). Consistently, STAT1 silencing could 
also significantly potentiated cellular HEV RNA level to 1.6 ± 0.13-fold (mean ± SEM, n = 3, P 
< 0.05) (Figure 5C). To further determine whether event downstream of JAK-STAT cascades 
influences HEV replication, IRF9 was silenced with a profound down-regulation of total IRF9 
protein level (Figure 5D). Similarly, silencing of IRF9 resulted in 3.70 ± 1.07-fold (mean ± 
SEM, n = 4, P < 0.05) elevation of cellular HEV RNA level. Therefore, key constituents of JAK-
STAT cascades including JAK1, STAT1 and IRF9 play an intrinsic role in restricting HEV 
infection. 
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Figure 5. Key components of JAK-STAT cascades restrict HEV infection (A) Key components in 
interferon JAK-STAT signaling. (B) Knockdown of JAK1 by lentiviral shRNA vectors. Compared with the 
control vector transduced cells, the shJAK1 clone 1 and 2 expert potent silencing capability shown at 
mRNA level (Mean ± SEM, n = 4). Correspondingly, knockdown of JAK1 of clone 2 resulted in 
significant increase of cellular HEV RNA level (Mean ± SEM, n = 4). (C) Knockdown of STAT1 by 
lentiviral shRNA vectors. Western blot assay presented a potent decrease of total STAT1 protein 
level, correspondingly, silencing of STAT1 led to significant increase of cellular HEV RNA level (Mean ± 
SEM, n = 4). (D) Knockdown of IRF9 by lentiviral shRNA vectors. Western blot assay presented a 
potent decrease of total IRF9 protein level, similarly, silencing of IRF9 led to significant increase of 
cellular HEV RNA level (Mean ± SEM, n = 4). Treatment time was indicated as 24, 48 or 72 hrs. * P < 
0.05; ** P < 0.01. 
 
Discussion 
Cytokines and chemokines are important components of the immune response for 
countering invading viruses 30. With this group of mediators, especially IFNs play a cardinal 
role, exerting a wide range of pleiotropic effects 25. Accordingly, IFN-α has become the 
mainstay for the treatment of chronic HCV and HBV infection, despite the considerable 
systemic side effects. Whereas IFN-λ shows a potent anti-viral activity as well in phase III 
clinical trial for treating HCV patients with much less reverse side effects, owing to the 
tissue-restricted expression of type III IFN receptor 31. Hitherto, there is no approved 
medication for hepatitis E. Lessons have learned from standard therapy of chronic hepatitis 
C that IFN-α, ribavirin, or a combination as off-label drugs have been used to treat individual 
HEV cases or small case series 3. As shown in this study (Figure 2D), four chronic hepatitis E 
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patients all eventually cleared the virus after monotherapy of pegylated IFN-α. However, the 
viral kinetics in responding to IFN-α is very different between chronic hepatitis C and E. In 
chronic HCV, patients who respond to the therapy often experience a rapid and sharp 
reduction of viral load within the first few days upon initiation of IFN-α therapy 26, 27, 32. In 
contrast, only one out of four chronic HEV patients had a rapid decline of viral load; whereas 
others had rather minor changes in the first two weeks of treatment. This is in line with our 
experimental results that HEV has a moderate and delayed responsiveness to IFN-α, 
compared with HCV in cell culture models. The HEV subgenomic model only mimics viral 
replication; whereas the HEV infectious cell culture system models the complete life-cycle of 
HEV infection. IFN-α probably interferes HEV infection at various steps. Thus, the infectious 
clone appears more sensitive to IFN-α compared to the subgenomic replicon (Figure 2A-C). 
Other types of IFNs, including IFN-λ, did not shown any notable antiviral activity against HEV 
(Figure 3).  
Previous studies have provided evidence of counteracting IFN response by HEV 33. In 
our study, we also observed that HEV inoculation could indeed inhibit IFN-α induced 
phosphorylation of STAT1 and attenuate the induction of ISGs in Huh7 cells (Supplementary 
Figure 4C and 4D). Nevertheless, this inhibitory effect was rather minor, which may only 
partially contribute to the resistance of HEV to interferon treatment. Thus, the insensitivity 
and resistance of HEV to IFN treatments may be because of the intrinsic characteristics and 
pathogenesis of HEV itself. Therefore, the scenario of developing IFN-based treatment 
against HEV shall be carefully re-considered. Interestingly, a recent large retrospective, 
multicentre study showed that ribavirin as monotherapy could be very effective for treating 
chronic HEV infection that viral clearance was observed in the majority of patients 34. In 
contrast, ribavirin monotherapy hardly has detectable effect on HCV viral load reduction 35, 
36. Only when combined with IFN-α, it doubles the response rate, compared with IFN-α alone 
37. 
Despite the inferiority of HEV in responding to exogenous IFN treatment, we in fact 
demonstrated a superior function of the basal interferon signalling, which mediates IFN-α, γ 
and λ signalling transduction, in protecting against HEV infection. Pharmacological inhibition 
of JAK1, the key upstream kinase controlling JAK-STAT cascades of the IFN pathway, has 
resulted in drastic facilitation of HEV but not HCV infection in cell culture models (Figure 4A-
C). Consistently, by gene silencing of JAK1, STAT1 and IRF9, key factors of JAK-STAT cascades, 
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HEV replication was efficiently potentiated (Figure 5B-D). These results highlighted the 
importance and mechanisms of basal IFN signaling in protecting HEV infection. 
This probably at least partially explains the distinct incidence of chronic development 
upon exposure to HEV or HCV. In general population, HEV is mostly acute and self-limiting, 
except in very young children, pregnant women and immunocompromised patients that 
could cause severe diseases 1. Chronic hepatitis E has so far only been reported in 
immunocompromised patients who are lacking of adequate immune defence power 20, 38. 
However, 55% to 85% individuals infected with HCV are not able to clear the virus, but 
develop chronic hepatitis C 39. Even an activated endogenous IFN response is ineffective in 
eradicating HCV, once chronic infection is established 40. The only option to cure chronic HCV 
is antiviral treatment, including IFN-based therapies. The fact that one-third of organ 
transplantation patients with chronic HEV could achieve virus clearance even without any 
treatment, but with dose reduction of immunosuppressants 38, suggests the indispensable 
role of endogenous innate immunity in HEV recovery. In addition, during the early stage of 
HEV infection, patients always remain subclinical and represent no apparent symptom at all. 
This rapidly turn to a self-limiting illness with spontaneously cleaning of HEV and need no 
specific treatment 41. The phenomenon of quick clearance of HEV infection by body itself 
without any treatment may be associated to the critical role of defence mechanism of basal 
IFN signaling in combating HEV infection. Therefore, the data in current study delineate that 
endogenous JAK-STAT signaling exerts much potency in protecting against HEV than HCV 
infection. The different sensitivities between HCV and HEV to endogenous IFN signaling may 
also determine the distinct clinical course and outcome between hepatitis C and hepatitis E 
patients. 
In conclusion, we revealed that HEV is in general insensitive to the regulation of 
cytokines and chemokines. IFN-α treatment exerts moderate but delayed antiviral activity 
against HEV infection in experimental models and in patients, which suggested the 
ineffectiveness of interferon-based monotherapy in treating chronic hepatitis E. 
Interestingly, blocking the basal IFN pathway resulted in drastic facilitation of HEV infection, 
suggesting that basal IFN pathway can effectively protect against HEV infection. Thus, this 
study has shed new light on the molecular insight of HEV-host interaction, in particular the 
role of therapeutically activated and the basal IFN signaling. This bears significant 
implications in management of HEV patients and future therapeutic development.
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Supplementary Figures and Tables 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Cytokines/chemokines did not affect cell proliferation at 72 hrs 
determined by MTT assay (OD490 value) (Mean ± SD, n = 4). 
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Supplementary Figure 2. (A) IFN-α, (B) IFN-β, (C) IFN-γ, (D) IFN-λ1, (E) IFN-λ2 and (F) IFN-λ3 
had significantly more potent antiviral effects against HCV than HEV in the subgenomic 
replication models. Treatment time was indicated as 24, 48 or 72 hrs. * P < 0.05; ** P < 0.01.  
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Supplementary Figure 3. (A) Western blot showed treatment of Jak inhibitor I for 48 hrs 
effectively inhibited downstream target of JAK1, the phosphorylation of STAT1, induced by 
treatment of IFN-α or IFN-λ for 30 min. β-actin served as an internal reference. (B) Jak 
inhibitor I significantly inhibited the stimulation of the IFN response reporter, the ISRE-
luciferase transcription reporter by IFN-α or IFN-λ for 30 min. (Mean ± SD, n = 4). (C) Jak 
inhibitor I blocked the induction ISGs of RSAD2, ISG15, OAS1 and PKR triggered by IFN-α. (D) 
Jak inhibitor I, AG-490 and CP 690550did not affect cell proliferation determined by MTT 
assay (OD490 value) (Mean ± SD, n = 3). Treatment time was indicated as 24, 48 or 72 hrs. * P 
< 0.05; ** P < 0.01. 
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Supplementary Figure 
4. (A) The basal 
expression of 16 ISGs 
was determined in naïve 
Huh7 cells by qRT-PCR. 
(B) The expression of 16 
ISGs were significantly 
stimulated by treatment 
of 1000 IU/ml IFN-α for 
24 hrs (Mean ± SD, n = 
4). (C) Western blot 
assay showed that the 
elevation of p-STAT1 
level was significantly 
attenuated upon 1000 
IU/ml IFN-α in HEV 
infected compared to 
naïve Huh7 cells for 48 
hrs. β-actin served as an 
internal reference. 
(Mean ± SD, n = 3). (D) 
Inoculation of HEV 
moderately inhibited 
the stimulation of most 
of 16 tested IGSs upon 
treatment with 1000 
IU/ml IFN-α for 24 hrs 
(Mean ± SD, n = 4-6). * P 
< 0.05; ** P < 0.01. 
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Supplementary Table 1. shRNA sequences. 
shJAK1-1 CCGGGAGACTTCCATGTTACTGATTCTCGAGAATCAGTAACATGGAAGTCTCTTTTT 
shJAK1-2 CCGGGACAGTCACAAGACTTGTGAACTCGAGTTCACAAGTCTTGTGACTGTCTTTTTG 
shJAK1-3 CCGGCGAGATCTTAAGGAACCTCTACTCGAGTAGAGGTTCCTTAAGATCTCGTTTTTG 
shSTAT1 CCGGGAACAGAAATACACCTACGAACTCGAGTTCGTAGGTGTATTTCTGTTCTTTTT 
shIRF9 CCGGCTCAGTAGTTGTCCGTGATAACTCGAGTTATCACGGACAACTACTGAGTTTTTG 
shIRF1 CCGGCGTGTGGATCTTGCCACATTTCTCGAGAAATGTGGCAAGATCCACACGTTTTT 
 
Supplementary Table 2. Human ISG primer sequences. Sequence 5' to 3' (including 
modification codes if applicable). 
 5’ FORWARD 3’ REVERSE 
GAPDH GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCCAA 
RP2 CCCATTAAACTCCAAGGCAA AAGCTGAGGATGCTCAAAGG 
IFITM1 GGCTTCATAGCATTCGCCTACTC AGATGTTCAGGCACTTGGCGGT 
ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
STAT2 CAGGTCACAGAGTTGCTACAGC CGGTGAACTTGCTGCCAGTCTT 
IFITM3 CTGGGCTTCATAGCATTCGCCT AGATGTTCAGGCACTTGGCGGT 
STAT1 ATGGCAGTCTGGCGGCTGAATT CCAAACCAGGCTGGCACAATTG 
IFI27 CGTCCTCCATAGCAGCCAAGAT ACCCAATGGAGCCCAGGATGAA 
PKR GAAGTGGACCTCTACGCTTTGG TGATGCCATCCCGTAGGTCTGT 
JAK1 GAGACAGGTCTCCCACAAACAC GTGGTAAGGACATCGCTTTTCCG 
IFIH1 GCTGAAGTAGGAGTCAAAGCCC CCACTGTGGTAGCGATAAGCAG 
IFIT2 GGAGCAGATTCTGAGGCTTTGC GGATGAGGCTTCCAGACTCCAA 
OAS1 AGGAAAGGTGCTTCCGAGGTAG GGACTGAGGAAGACAACCAGGT 
IFIT3 CCTGGAATGCTTACGGCAAGCT GAGCATCTGAGAGTCTGCCCAA 
IFI44L TGCACTGAGGCAGATGCTGCG TCATTGCGGCACACCAGTACAG 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
DDX58 CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
DDX60 GGTGTTTTCACCAGGGAGTATCG CCAGTTTTGGCGATGAGGAGCA 
IRF9 CCACCGAAGTTCCAGGTAACAC AGTCTGCTCCAGCAAGTATCGG 
MX2 AAAAGCAGCCCTGTGAGGCATG GTGATCTCCAGGCTGATGAGCT 
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Abstract 
Interferon regulatory factor 1 (IRF1) is one of the most important interferon-stimulated 
genes (ISGs) in cellular antiviral immunity. Although hepatitis E virus (HEV) is a leading cause 
of acute hepatitis worldwide, how ISGs counteract with HEV infection is largely obscure. This 
study aims to investigate the action of IRF1 on HEV replication. Multiple cell lines were used 
to harbor two HEV models. In different HEV cell culture systems, IRF1 effectively inhibited 
HEV replication. Surprisingly, IRF1 did not trigger interferon production and Chip-seq data 
analysis revealed that IRF1 was able to bind to the promoter region of signal transducers and 
activators of transcription 1 (STAT1). Functional assay confirmed that IRF1 could drive the 
transcription of STAT1, resulting in elevation of total and phosphorylated STAT1 proteins. 
This further activated the transcription of a panel of downstream antiviral ISGs. By 
pharmacological inhibitors and RNAi-mediated gene-silencing approaches, we revealed that 
antiviral function of IRF1 was dependent on the JAK-STAT cascade. Furthermore, induction 
of ISGs and anti-HEV effect of IRF1 overlapped with IFNα but were potentiated by ribavirin. 
We demonstrated that IRF1 effectively inhibited HEV replication through the activation of 
JAK-STAT pathway and the subsequent transcription of antiviral ISGs, but independent of 
interferon production. 
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Introduction 
Hepatitis E virus (HEV) infection is one of the most common causes of acute hepatitis, 
particularly in developing countries 1. Although it is often a self-limiting disease, fulminant 
hepatitis and high mortality were reported in pregnant women 2. In western countries, cases 
of chronic hepatitis E were frequently reported in immunocompromised patients with the 
potential cause of graft loss and even mortality 3, 4. However, the underlying mechanisms of 
how the host combats HEV infection remain largely elusive.  
Upon viral infection, the host rapidly reacts by producing a panel of inflammatory 
cytokines and chemokines to orchestrate the immunological reaction to the pathogenic 
invasion 5. Within this group of anti-viral mediators, interferons (IFNs) are vital cytokines for 
innate defense against viral infection 6. Because of their potent antiviral activity, pegylated 
interferon-α (PEG-IFNα) has been used for decades to treat chronic hepatitis B virus (HBV) 
and C virus (HCV) infection 7, 8. Since no registered medication is available for HEV infection, 
PEG-IFNα, ribavirin, or a combination of both has been used as off-label treatments for some 
cases of HEV infection, although the efficacy is still inconclusive 9. Mechanistically, type I 
interferon molecules bind to cell surface receptors and subsequently initiate a signaling 
cascade. This binding triggers the phosphorylation of pre-associated Janus kinase 1 (JAK1). 
Subsequently, this leads to the recruitment and phosphorylation of signal transducers and 
activators of transcription 1 and 2 (STAT1 and 2), which further bind to the interferon 
regulatory factor 9 (IRF9) to form the IFN-stimulated gene factor 3 (ISGF3) complex. ISGF3 
translocate to the nucleus to activate transcription of IFN-stimulated genes (ISGs), which are 
in turn regulated by the IFN-stimulated response element (ISRE). The products of ISGs are 
thought to be the ultimate antiviral effectors 10. 
Although there are hundreds of ISGs, in fact, only a few actually have specific or 
broad antiviral activities 10. Interferon regulatory factor 1 (IRF1) is one of the most important 
ISGs that has been shown to effectively inhibit HCV, yellow fever virus, chikungunya virus 
and Venezuelan equine encephalitis virus infections among the 380 tested ISGs 11. A further 
follow-up study demonstrated that IRF1 could potently inhibit the replication of 14 different 
viruses, representing 7 families including different DNA and RNA viruses 10. However, the 
exact antiviral mechanism of IRF1 remains unclear. 
IRF1 restricts HEV replication 
165 
Given the importance of IRF1 in innate defense against viral infection but insufficient 
knowledge in respect to HEV, we investigated the role of IRF1 in HEV infection and the 
interactions with antiviral treatments by using cell culture models. We found that 
independent of interferon production, IRF1 could effectively restrict HEV replication through 
the activation of JAK-STAT cascade and the subsequent induction of a wide range of ISGs. 
We further demonstrated that the anti-HEV effect of IRF1 overlapped with IFNα but was 
augmented by ribavirin. 
 
Materials and Methods 
Reagents 
Human IFNα (Thermo Scientific, the Netherlands) was dissolved in PBS. Stocks of JAK 
inhibitor 1 (CAS 457081-03-7, Santa Cruz Biotech, CA) were dissolved in DMSO with a final 
concentration of 5 mg/mL. Stocks of CP-690550 (Tofacitinib) (Santa Cruz Biotech, CA) were 
dissolved in DMSO with a final concentration of 10 mg/mL. Stock of ribavirin was dissolved in 
PBS with a final concentration of 10 mg/mL. Matched concentrations of DMSO were used as 
vehicle control. Phospho-STAT1 (Tyr701) (58D6, Rabbit mAb, #9167), STAT1 (Rabbit mAb, 
#9172), IRF1 (D5E4, Rabbit mAb, #8478) antibodies were obtained from Cell Signaling 
Technology. IRF9 antibody was obtained from LSBio (Rabbit Polyclonal, #LS-C155416, Life 
Span BioSciences, Inc.). β-actin antibodies (Mouse monoclonal, #sc-47778) were obtained 
from Santa Cruz Biotech (Santa Cruz, CA). Anti-rabbit or anti-mouse IRDye-conjugated 
secondary antibodies (Li-COR Biosciences, Lincoln, USA) were also used. 
 
Cell culture 
Naïve or vector transduced human hepatoma cells (Huh7), HEK293T cells, human lung 
epithelial carcinoma cells (A549) and human fetal lung fibroblast cells (MRC-5) 12 were 
cultured in Dulbecco’s modified Eagle medium (DMEM) (Lonza Biowhittaker, Verviers, 
Belgium) complemented with 10% (v/v) fetal calf serum (FCS) (Hyclone, Lonan, Utah), 100 
IU/ml penicillin, 100 µg/ml streptomycin. HepaRG cell line was maintained in William’s 
medium (Life Technologies) supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml 
streptomycin, as well as 5 μg/mL insulin and 5 × 10-7 M hydrocortisone hemisuccinate (Sigma 
Aldrich, the Netherlands) 13. Huh7 cells containing a subgenomic HCV bicistronic replicon 
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(I389/NS3-3V/LucUbiNeo-ET, Huh7-ET-Luc) were maintained with 250 μg/ml G418 (Sigma, 
Zwijndrecht, the Netherlands) and viral replication was monitored by measuring firefly 
luciferase activity 14. For ISRE reporter model (Huh7-ISRE-Luc), Huh7 cells were transduced 
with lentiviral transcriptional reporter system which expressing the firefly luciferase gene 
driven by a promoter containing multiple ISRE promoter elements (SBI Systems Biosciences, 
Mountain View, CA) and luciferase activity represents ISRE promoter activation 15. 
 
HEV cell culture models 
In this study, multiple cell lines were employed for HEV replication, including a human 
hepatoma cell line (Huh7) 16, 17, a human lung epithelial carcinoma cell line (A549) 18, a 
human fetal lung fibroblast cell line (MRC-5) as well as a hepatic cell line (HepaRG) which 
retains many characteristics of primary human hepatocytes. For the full-length HEV model, a 
plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank 
Accession Number: JQ679013) was used to generate HEV genomic RNA by using the Ambion 
mMESSAGE mMACHINE® in vitro RNA transcription Kit (Life Technologies Corporation, CA, 
USA) 17. Huh7 and HepaRG cells were electroporated with full-length HEV genome RNA to 
generate consecutive HEV infected cell models (Huh7-p6 and HepaRG-p6). For the 
subgenomic HEV model, a construct containing subgenomic HEV in which 5’ portion of HEV 
ORF2 was replaced with the in-frame Gaussia princeps luciferase reporter gene to yield p6-
Luc 17. Huh7 and A549 cells were electroporated with HEV subgenomic RNA to generate HEV 
subgenomic model (Huh7-p6-Luc and A549-p6-Luc) in which the accumulation of secreted 
luciferase serves as a reporter for HEV replication. For HEV genotype 1 replicon model, viral 
RNA was generated from a Sar55/S17/luc-encoding plasmid. Huh7 cells were electroporated 
with Sar55/S17/luc HEV RNA to generate genotype 1 replicon model as described 17, 19. 
 
Reinfection assays 
Supernatant from full-length Huh7-p6 HEV model was collected and purified by 
ultracentrifugation. The supernatant was first filtered through 0.45 mm filter followed by 
centrifugation at 10000 rpm for 30 min to remove cell debris and then 22000 rpm for 2 
hours to pellet HEV virus (SW 28 rotor, Beckman). The pellet was suspended and diluted to 1 
× 107 HEV viral RNA copies/ml. The diluted HEV virus stock was stored at -80 °C. For HEV 
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infection, Huh7, HepaRG, A549 and MRC5 cells were seeded into 12-well plates at a density 
of 7 × 104 cells per well and incubated for 24 h. Next, different cells were incubated with 
400µL HEV stock diluted to 1 × 107 viral RNA copies/ml per well at 37 °C for 6 h. Then, the 
inoculum was removed and cell layers were washed 3 times with 1 ml of PBS, and 1 ml of 
fresh medium was added to each well. For 6 well-plates, different cells were seeded at a 
density of 1.4 × 105 cells per well and incubated for 24 h. Next, different cells were incubated 
with 800µL HEV stock diluted to 1 × 107 viral RNA copies/ml per well at 37 °C for 6 h. Then, 
the inoculum was removed and cell layers were washed 3 times with 3 ml of PBS, and 2 ml of 
fresh medium was added to each well. 
To investigate the anti-viral effect of IRF1 in HEV refection models, Huh7 cells were 
transduced with IRF1 or infected by HEV as following time point: (A) HEV infection and IRF1 
transduction were start at the same time. After 6 h, the inoculum was removed, and 1 ml of 
medium with IRF1 lentivirus was added to each well. Intracellular HEV viral RNA was 
measured after 48 h. (B) Huh7 cells were first transduced with IRF1 for 48 h and then 
transduced cells were infected with HEV for 6 h. Next, the inoculum was removed, and 1 ml 
of fresh medium was added to each well. HEV viral RNA was quantified 48 h post HEV 
infection. (C) Huh7 cells were first infected with HEV for 6 h. 24 h post HEV infection, IRF1 
was transduced and HEV RNA was quantified 48 h after transduction.  
 
Gene knockdown and over-expression by lentiviral vectors 
For gene knockdown, pLKO.1 based lentiviral vectors (Sigma-Aldrich) targeting IRF1, STAT1, 
IRF9 and non-targeted control vector (shCTR) were obtained from the Biomics Center in 
Erasmus Medical Center. Lentiviral pseudoparticles were generated in HEK293T cells 
following the method described previously 20. To generate stable gene knockdown cell line, 
Huh7 cells were transduced with lentiviral particles for 3 days. Since the vectors also express 
a puromycin resistance gene, transduced cells were subsequently selected by adding 2.5 
μg/mL puromycin (Sigma-Aldrich) to the cell culture medium. After selection, cell lines 
shown optimal gene knockdown were chosen. pTRIP.CMV.IVSb.ISG.ires.TagRFP based IRF1 
over-expression vector was a kind gift from Prof. Charles M. Rice, the Rockefeller University 
11. Meanwhile, two vectors expressing reporter genes Photinus pyralis luciferase (Fluc) or 
GFP were used as control (also a kind gift from Prof. Charles M. Rice). Lentiviral 
pseudoparticles were generated as described and stored at -80 °C 11. Spinoculation method 
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was use as described for IRF1 transduction assay 11, target cell lines were seeded into 12-well 
plates at a density of 7 × 104 cells per well and transduced with transduced with lentiviral 
pseudoparticles at 37 °C for 24 h, 48 h or 72 h 11. The transduction time of each experiment 
was described in the figure legend of each figure. The control vector used in each 
experiment was also described in the figure legend of each figure.  
 
Quantification of Hepatitis E Virus Replication 
Two Huh7 based HEV models (Huh7-p6 and Huh7-p6-Luc) were well-established models 
which could stably harbor HEV replication for a long term. In this study, HEV viral RNA and 
HEV-related luciferase activity were measured around 2 months after HEV RNA 
electroporation when the HEV viral RNA level and luciferase activity were at stable level. For 
HepaRG-p6 and A549-p6-Luc model, lentivirus transduction and HEV RNA quantification was 
performed around 4 weeks and 2 weeks after HEV RNA electroporation, respectively. MRC5 
cells were infected by stock HEV virus medium as description in Reinfection assays for 24 h. 1 
week post HEV infection, IRF1 was transduced in MRC5 cells and HEV RNA was quantified 
48h after transduction. For HEV-related Gaussia luciferase analysis (HEV-p6-Luc), the activity 
of secreted luciferase in the cell culture medium was measured by BioLux® Gaussia 
Luciferase Flex Assay Kit (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions. Luciferase activity was quantified with a LumiStar Optima 
luminescence counter (BMG Lab Tech, Offenburg, Germany). For firefly luciferase and 
Photinus pyralis luciferase, luciferin potassium salt (100 mM; Sigma) was added to cells and 
incubated for 10 min at 37 °C and luciferase activity was measured. For the HEV-p6 model, 
intracellular RNA was isolated from cellular lysates. Cells were lysed with 350 μL RA1 buffer 
(Bioke, Leiden, Netherlands). RNA was isolated using the Machery-NucleoSpin RNA II kit 
(Bioke, Leiden, Netherlands) and quantified by a Nanodrop ND-1000 Spectrophotometer 
(Thermo, DE, USA). cDNA was prepared from total RNA using a cDNA Synthesis Kit (Takara 
Bio Inc.) with random hexamer primers. Intracellular HEV level and host gene expression 
were quantified by SYBR-Green-based (Applied Biosystems® SYBR® Green PCR Master Mix, 
Life technologies, CA, USA) real-time PCR with the StepOnePlus™ System (Applied 
BioSystems). PCR steps consisted of a 10 min holding stage (95°C) followed by 40 cycles of 15 
s at 95°C, 30 s at 58°C and 30 s at 72°C. GAPDH and RP2 (Human retinitis pigmentosa 2) were 
used as housekeep genes and all gene expression levels (relative) were normalized to 
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GAPDH and RP2 using the 2-ΔΔCT method. The HEV primer sequences were 5’-
ATCGGCCAGAAGTTGGTTTTTAC-3’ (sense) and 5’-CCGTGGCTATAACTGTGGTCT-3’ (antisense), 
and the primer sequences of housekeeping gene GAPDH were 5’-
TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ (antisense) 
and the primers of housekeeping gene RP2 were 5’-CCCATTAAACTCCAAGGCAA-3’ (sense) 
and 5’-AAGCTGAGGATGCTCAAAGG-3’ (antisense).  
 
Interferon production bioassay 
Cells were seeded into 6-well plates at a density of 10×104 cells per well and transduced with 
IRF1 or control lentiviral particles at 37 °C. After 72 h, lentiviral particles were removed and 
cells were washed 3 times with PBS and cultured for another 72 h. The cultured supernatant 
was subsequently collected and filtered through a 0.45 μm-pore size membrane and added 
to two luciferase reporter cell lines (Huh7-HCV-Luc and Huh7-ISRE-Luc) which are sensitive 
to interferons. 
 
Immunoblotting 
Whole cell extracts were obtained and were heated at 95 °C for 5 min. Proteins were 
subjected to a 10-15 % sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and 
separated at 120 V for 100 min. Proteins were electrophoretically transferred onto a 
polyvinylidenedifluoride (PVDF) membrane (pore size: 0.45µM, Invitrogen) for 1.5 hour (h) 
with an electric current of 250 mA. Subsequently, the membrane was blocked with blocking 
buffer (LI-COR Biosciences, Lincoln, USA) in 1×PBS containing 0.1% Tween-20. Membranes 
were incubated with primary antibodies overnight at 4 °C. Rabbit anti-IRF1, p-STAT1, STAT1, 
IRF9 (1:1000) antibodies or mouse anti-β-actin (1:2000) were diluted in 5% (mass/vol) BSA in 
1×PBS containing 0.1% Tween-20. The membrane was washed 3 times followed by 
incubation for 1 h with anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (Li-
COR Biosciences, Lincoln, USA) (1:5000) at room temperature. β-actin was served as 
standardization of sample loading. The membrane was scanned by Odyssey Infrared Imaging 
System (Li-COR Biosciences, Lincoln, USA). Results were visualized with Odyssey 3.0 
software. Band intensity of each immunoblot data was also quantified by Odyssey Software.  
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MTT assay 
Cells were seeded in 96-well plates and 10 mM 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) (Sigma, Zwijndrecht, Netherlands) was added. Plate was 
incubated at 37 °C with 5% CO2 for 3 h, then the medium was removed and 100 μL of DMSO 
was added to each well. Incubate the microplate at 37°C for 50min. The absorbance of each 
well was read on the microplate absorbance reader (Bio-Rad, CA, USA) at wavelength of 490 
nm. 
 
Confocal microscopy analysis  
1 × 104 cells Huh7 cells were seeded on glass slides in a 6 well-plate. Cells were transduced 
with IRF1 over-expression, Fluc or GFP control lentiviral viruses for 48 h. For IRF1 protein 
immunofluorescence staining, IRF1 antibody (1: 200, D5E4, Rabbit mAb, #8478) was used as 
primary antibody. Anti-rabbit-Alexa Fluor® 488-Conjugate antibody (1: 1000, Cell Signaling 
Technology) was used as secondary antibody. Cells were visualized in an inverted LSM 510 
confocal microscope (Zeiss LSM510, Jena, Germany) using a 40× oil immersion objective with 
1.7× zoom in. All images were analyzed with a Zeiss LSM Image Browser (version 4.2). 
 
ChIP-seq data analysis 
ChIP-seq datasets for IRF1 in K562 cells were retrieved from the ENCODE database. ChIP-seq 
datasets were processed and mapped to hg19 reference genome as described 21. ChIP-seq 
datasets with multiple replicates were merged. MACS 1.4.2 was used for peak calling and for 
the generation of binding profiles 22. The sequencing profiles of IRF1 were created in the IGV 
browser 23. 
 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a p-value less than 0.05. 
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Results 
IRF1 effectively inhibits HEV replication 
Although IRF1 exerts cell-autonomous anti-viral activity toward a broad range of viruses 10, 
11, its capacity to combat HEV infection remains unexplored. To determine the role of IRF1 in 
HEV infection, we first tested the effect of forced IRF1 expression in two Huh7 cell line-based 
HEV models. Successful over-expression of IRF1 was visualized by the red fluorescent protein 
(TagRFP) expression under the confocal electroscope, since the bicistronic lentiviral vector 
co-expresses IRF1 and a TagRFP reporter (Supplementary Figure 1A). Consistently, IRF1 
mRNA expression (Figure 1A) and protein level (Figure 1B and 1C) was increased in over-
expressed cells compared to high dose IFNα (1000 IU/mL) induction. Of note, 
immunofluorescence staining of IRF1 showed that it predominantly located in the nucleus 
(Figure 1C). To exclude the non-specific effect of lentivirus transduction, two control vectors 
that used in previous study which expressing reporter genes Photinus pyralis luciferase (Fluc) 
or Green fluorescent protein (GFP) were also employed 11. Transduction efficiency was 
confirmed by different methods, including visualization of TagRFP expression (data not 
shown), measurement of Photinus pyralis luciferase activity (Supplementary Figure 1B) and 
quantitation of TagRFP mRNA expression level (Supplementary Figure 1B) in transduced 
cells. As expected, Fluc and GFP control did not affect HEV replication in two Huh7-based 
models (Supplementary Figure 1C and 1D). 
Next, we showed that over-expression of IRF1 could profoundly inhibit HCV 
replication in a Huh7-based HCV luciferase replicon (Huh7-ET-Luc) model (Supplementary 
Figure 1E) without affecting cell viability (Supplementary Figure 1F), which was consistent 
with the previous study 11. Interestingly, after 48 h or 72 h of IRF1 transduction, HEV were 
significantly inhibited in both HEV Huh7-p6-Luc replicon and full-length infectious models 
(Figure 1D). Notably, the antiviral activity of IRF1 in both models was equivalent to high dose 
IFNα (1000 IU/mL) treatment (Figure 1D). Moreover, IRF1 could also effectively inhibit 
genotype 1 HEV-related luciferase activity in the Huh7 based genotype 1 HEV replicon model 
(Sar55/S17/luc) (Figure 1E) .To further validate the antiviral ability of IRF1, three other 
different human cell lines were used. A human hepatic progenitor cells derived cell line 
named HepaRG which exhibits many characteristics of primary human hepatocytes 13, a lung 
epithelial carcinoma cell line A549 that widely-used for HEV propagation 18 and a human  
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Figure 1. IRF1 effectively 
inhibits HEV replication. 
(A) qRT-PCR analysis of IRF1 
mRNA expression in Huh7 
cells transduced with IRF1, 
Fluc (control) vectors or 
treated with IFNα (1000 
IU/mL) for 48 h (n = 7). Data 
was normalized to two 
housekeeping genes (GAPDH 
and RP2). Immunoblotting (B) 
and immunofluorescence (C) 
analysis of Huh7 cells 
transduced with IRF1, Fluc 
(CTR) vector or treated with 
IFNα (1000 IU/mL) for 48 h. 
Band intensity of each 
immunoblot data was 
quantified by Odyssey 
Software. All data was 
normalized to Actin 
expression and control was 
set as 1. Green indicates IRF1 
protein and blue indicates 
DAPI (Scale bar: 10 µm). (D) 
HEV viral replication-related 
Gaussia luciferase activity in 
Huh7-p6-Luc model 
transduced with IRF1, Fluc 
vector or treated with IFNα 
(1000 IU/mL) for 24 h, 48 h or 
72 h (n = 4 independent 
experiments with each of 3-4 
replicates) and qRT-PCR 
analysis of HEV viral RNA in 
Huh7-p6 full-length HEV 
model transduced with IRF1, 
Fluc vector or treated with 
IFNα (1000 IU/mL) for 48 h (n 
= 7). RLU: relative luciferase 
unit. (E) Genotype 1 HEV 
(Sar55/S17/luc) viral 
replication-related Gaussia 
luciferase activity in Huh7-Sar55/S17/luc model transduced with IRF1 or Fluc vector for 48h (n = 4 
independent experiments with each of 3-4 replicates). (F) HEV viral replication-related Gaussia 
luciferase activity in A549-p6-Luc model (n = 4 independent experiments with each of 3-4 replicates) 
or qRT-PCR analysis of HEV viral RNA in HepaRG-p6-HEV and MRC-5-p6 HEV model transduced with 
IRF1 or Fluc vector for 48 h (HepaRG: n = 4; MRC-5: n = 5). (G) Immunoblotting analysis of Huh7 cells 
transduced with lentiviral shRNA vectors targeting IRF1 or non-targeted control (shCTR). (H) qRT-PCR 
analysis of IRF1 and HEV viral RNA level relative to shCTR (n = 3-5). Data was normalized to Fluc 
control (CTR, set as 1) (D, E and F). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 
0.001; NS, not significant). 
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fetal lung fibroblast cell line (MRC-5) 12 was used to further confirm the anti-HEV ability of 
IRF1. The over-expression of IRF1 in these cell lines was confirmed by measuring IRF1 mRNA 
and protein expression (Supplementary Figure 1G and 1H). Consistently, over-expression of 
IRF1 significantly inhibited intracellular HEV RNA level as well as HEV-related luciferase 
activity (Figure 1F) in these cell lines. To validate the antiviral ability of IRF1 in the reinfection 
HEV model, Huh7 cells were infected by HEV or transduced with IRF1 at different time point 
(described in Reinfection assays of Materials and Methods). The result showed over-
expression of IRF1 significantly inhibited HEV infection when IRF1 was transduced with 
(same time, Supplementary Figure 1I) or before (pre, Supplementary Figure 1J) or after 
(post, Supplementary Figure 1K) HEV infection. Taken together, these results demonstrated 
that IRF1 over-expression could effectively inhibit HEV replication and infection in different 
cell culture models. Furthermore, we also investigated whether HEV infection could trigger 
IRF1 expression in different cell lines. Different cell lines including Huh7, HepaRG, A549 and 
MRC5 were infected by HEV as described. Surprisingly, we found IRF1 expression can be 
induced at early stage of HEV infection (2h post infection) in HepaRG and A549 cells 
(Supplementary Figure 2A and 2B). In Huh7 and MRC5 cells, IRF1 was just slightly induced 6 
h or 2 h post infection (Supplementary Figure 2A and 2B).  
Subsequently, we determined whether basal IRF1 is necessary for anti-HEV 
immunity. This was pursued through a loss-of-function approach involving knockdown IRF1 
by lentiviral-based short hairpin RNA (shRNA) constructs. A non-targeted vector was used as 
a control (shCTR). Gene silencing of IRF1 was confirmed by immunoblotting and qRT-PCR 
(Figure 1G and 1H). Consistently, knockdown of IRF1 significantly promoted HEV replication 
(Figure 1H). Thus, both gain- and loss-of-function assays demonstrated that IRF1 plays an 
important role in restricting HEV replication. 
 
IRF1 over-expression does not trigger interferon production 
Because of the comparable anti-HEV effect of IRF1 and IFNα, we investigated whether the 
effect of IRF1 is merely via triggering of interferon production in our cell culture systems, 
since IRF1 has been reported to induce IFNβ expression in particular cell types 24. We first 
investigated the effect of IRF1 on gene expression level of different interferons, including 
IFNα, IFNβ and IFNλ in different cell lines. We found that the basal mRNA expression levels 
of several interferon genes including IFNα, IFNβ and IFNλ were very low in Huh7 and HepaRG  
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Figure 2. IRF1 over-expression does not trigger interferon production. qRT-PCR analysis of 
interferon gene expression in Huh7 (A), HepaRG (A), A549 (B) and MRC5 (B) cells transduced with 
IRF1 or Fluc vector for 48 h (n = 3). For A549 cells, 5’pppRNA (0.1 µg/mL) was transfected as a 
positive control (IRF1, n = 3; 5’pppRNA, n = 1). Data was normalized to Fluc control (CTR, set as 1). (C) 
Schematic illustration of the production of conditioned medium (supernatant). ISRE firefly luciferase 
activity in Huh7-ISRE-Luc model (D) and HCV luciferase activity in Huh7-ET-Luc model (E) treated with 
conditioned medium from Huh7 cells or IFNα for 48 h (n = 3 independent experiments with each of 
3-4 replicates). (F) ISRE firefly luciferase activity in Huh7-ISRE-Luc treated with conditioned medium 
from HepaRG, A549 cells or MRC-5 cells for 48 h (n = 3 independent experiments with each of 2-3 
replicates). Data was normalized to GFP control (D, E and F) (CTR, set as 1). Date presented as mean ± 
SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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cells (Supplementary Figure 2C) and were not significantly affected even by IRF1 over-
expression (Figure 2A). These results are consistent with the previous study that no 
interferon genes were affected in IRF1 over-expressed Huh7 cells 11. In addition, the 
expression of all these three interferon genes was also not affected by IRF1 over-expression 
in A549 cells and MRC-5 cells (Figure 2B). As positive control, IFNβ gene and IFNλ gene were 
effectively induced by the RIG-I activator (5’pppRNA) 25 in A549 cells (Figure 2B). To further 
confirm the lack of interferon production in IRF1 over-expressed cells, we collected the 
conditioned medium from these transduced cells (supernatant) and performed an interferon 
functional assay as well as a highly sensitive HCV-based bioassay (Figure 2C) 26. To this end, 
we employed a lentiviral transcriptional reporter system to mimic interferon response by 
expressing the firefly luciferase driven by a promoter containing multiple ISRE elements (15). 
As shown in Figure 2D, the supernatant from IRF1 over-expressed Huh7 cells was unable to 
stimulate interferon response in the ISRE reporter assay. Meanwhile, supernatants from 
HepaRG, A549 and MRC-5 cells were also not able to stimulate interferon response (Figure 
2F) in the ISRE reporter assay. Although HCV replicon is very sensitive to interferons, the 
supernatant collected from IRF1 transduced cells did not affect HCV replication (Figure 2E). 
These data indicated that IRF1 over-expression did not trigger interferon production in 
Huh7, HepaRG, A549 and MRC-5 cells.  
 
IRF1 activates STAT1 gene transcription leading to enhanced protein 
expression and phosphorylation 
Interestingly, IRF1 was first described as a transcription factor 24 and has more than 200 
binding sites in the human genome 27. By retrieving genome wide IRF1 ChIP-seq data from 
the ENCODE ChIP-seq Experiment Matrix database, we surprisingly found that IRF1 could 
directly bind to the promoter region of STAT1 gene (Figure 3A), a key component of the 
interferon signaling.  
To validate whether IRF1 induces transcription of STAT1 in our system, we first tested 
mRNA expression of STAT1 in IRF1 over-expressed Huh7 cells. Indeed, we observed that 
over-expression of IRF1 potently induced mRNA expression of STAT1 (Figure 3B) but not JAK 
or STAT2 (Figure 3C). In addition, IRF1 could also potently induce STAT1 mRNA expression in 
HepaRG, A549 and MRC-5 cells (Figure 3D). Subsequently, this led to enhanced expression of 
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STAT1 protein and activation of STAT1 phosphorylation at the Tyr701 site, which is an 
indispensable marker of STAT1 activation (Figure 3E). In addition, IRF1 also led to enhanced 
expression of STAT1 protein and activation of STAT1 phosphorylation in HepaRG, A549 and 
MRC5 cells (Figure 3F). Taken together, we demonstrated that IRF1 could effectively activate 
STAT1 gene transcription, resulting in enhanced protein expression and phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. IRF1 activates STAT1 gene transcription leading to enhanced protein expression and 
phosphorylation. (A) STAT1 genes with IRF1 binding to their promoter regions. The normalized 
binding signals were used as the input data. Binding peak detection was performed with PeakSeq 
v1.01 for identifying and ranking peak regions in ChIP-Seq data analysis. The Y axis value represents 
the binding signaling value; the black bar in the left corner represents the scale (5k bp). qRT-PCR 
analysis of STAT1 expression (B, n = 8) and STAT2 and JAK1 expression (C, n = 3) in Huh7 cells 
transduced with IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h. (D) qRT-PCR analysis of 
STAT1 expression in HepaRG, A549 and MRC-5 cells transduced with IRF1 vector or treated with IFNα 
(1000 IU/mL) for 48 h (n = 5-6). Immunoblotting analysis of Huh7 cells (E), HepaRG cell (F), A549 cells 
(F) and MRC5 cells (F) over-expressing IRF1 or treated with IFNα (1000 IU/mL) for 48 h. pSTAT1 
(Tyr701), STAT1 phosphorylated at Tyr701 site. Data was normalized to Fluc control (B, C and D) (CTR, 
set as 1). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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Figure 4. IRF1 activates the expression of ISGs. (A) ISRE promoter-related firefly luciferase activity in 
Huh7-ISRE-Luc model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h. (n = 4 
independent experiments with each of 3-4 replicates). qRT-PCR analysis of gene expression in Huh7 
cells (B), HepaRG cells (C), A549 (D) cells and MRC5 (E) cells transduced with IRF1, Fluc vector or 
treated with IFNα (1000 IU/mL) for 48 h (n = 3-5). Data was normalized to GFP (A, CTR, set as 1) or 
Fluc control (B, C, D and E) (set as 1, not shown). Date presented as mean ± SEM (*, P < 0.05; **, P < 
0.01; ***, P < 0.001; NS, not significant). 
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IRF1 activates the transcription of antiviral ISGs  
In general, binging of interferons to their receptors activates JAK1, resulting in tyrosine 
phosphorylation of STAT1 and STAT2. This is followed by the formation and nuclear 
translocation of the STAT1-STAT2-IRF9 complex, a transcription factor complex known as 
ISGF3, which in turn binds to the ISRE motifs in the genome DNA and subsequently drives 
the global transcription of ISGs to establish an antiviral status 28. Since IRF1 activates STAT1, 
we further investigated whether it can also trigger functional effects of STAT1 activation 
including ISG transcription. Indeed, IRF1 could significantly increase ISRE-regulated luciferase 
activity (Figure 4A) comparable to high dose of IFNα treatment on the Huh7-ISRE-Luc model. 
Furthermore, IRF1 was able to stimulate the expression of 17 tested ISGs at various levels 
(Figure 4B and Supplementary Figure 2D), whereas the control GFP or Fluc vectors did not 
affect their expression (Supplementary Figure 2E). The stimulation of ISGs by IRF1 was 
further confirmed in HepaRG, A549 and MRC-5 cells (Figure 4C, 4D and 4E). These results 
triggered us to further investigate whether these actions of IRF1 are totally via the JAK-STAT 
pathway. 
 
Induction of ISGs and anti-HEV of IRF1 relies on STAT1 phosphorylation 
JAK1 is the key upstream kinase that dictates STAT1 phosphorylation and the activation of 
interferon signaling. Activation of STAT1 phosphorylation by IFNα or IRF1 over-expression 
could be almost completely blocked by a pharmacological JAK inhibitor, JAK inhibitor 1 
(Figure 5A). Similarly, JAK inhibitor 1 could significantly diminish IRF1 and IFNα induced ISRE 
promoter activation (Figure 5B) and ISG transcription (Figure 5C and 5D) without affecting 
vector-delivered IRF1 over-expression (Figure 5E) and cell viability (Figure 5F). In line with 
the abrogation of ISG induction, the anti-HCV and anti-HEV ability of IRF1 was also 
diminished by JAK inhibitor 1 in HCV replicon model, HEV subgenomic and full-length models 
(Figure 5G, 5H and 5I). To further validate our observations, another JAK inhibitor, CP-
690550 (Tofacitinib) was used and similar results were obtained (Supplementary Figure 3A 
to 3H). 
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Figure 5. Inhibition of JAK1 diminishes the induction of ISG and the anti-HEV effect of IRF1. (A) 
Immunoblotting analysis of Huh7 cells transduced with IRF1 vector or treated with JAK inhibitor 1 (10 
µM) for 48 h or IFNα (1000 IU/mL) for 30 min or 48 h. (B) ISRE firefly luciferase activity in Huh7-ISRE-
Luc model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10 µM) 
for 48 h (n = 4 independent experiments with each of 3-4 replicates). qRT-PCR analysis of ISG 
expression (C, n = 6; D, n = 3), IRF1 (E) (n = 4) and MTT assay analysis of cell viability (F) (n = 3 
independent experiments with each of 3-4 replicates) in Huh7 cell HEV model transduced with IRF1 
vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10µM) for 48 h. HCV viral replication-
related firefly luciferase activity in Huh7-ET-Luc model (G, n = 3 independent experiments with each 
of 2-3 replicates) and HEV-related luciferase activity (H, n = 4 independent experiments with each of 
3-4 replicates) as well as HEV viral RNA (I, n = 7) in Huh7-based cell HEV model transduced with IRF1 
vector or treated with IFNα (1000 IU/mL) or JAK inhibitor 1 (10µM) for 48 h. Data was normalized to 
untreated GFP (B and G) or Fluc (C, D, E, F, H and I) control (CTR) (set as 1). Date presented as mean ± 
SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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Figure 6. The antiviral function of IRF1 requires key components of the ISGF3 complex. 
(A) Immunoblotting and qRT-PCR analysis (n = 4) of Huh7 cells transduced with lentiviral shRNA 
vectors that targeting STAT1 or non-targeted control vector (shCTR). (B) qRT-PCR analysis of HEV viral 
RNA in Huh7-p6 model with STAT1 knockdown relative to shCTR (n = 4). Data was normalized to 
shCTR control (A and B). (C) ISRE firefly luciferase activity in STAT1 knockdown Huh7-ISRE-Luc cells 
transduced with IRF1 vector (stock with 100 times dilution) or treated with IFNα (1 IU/mL) (n = 3 
independent experiments with each of 4 replicates). (D) qRT-PCR analysis of HEV viral RNA in STAT1 
knockdown Huh7-p6 model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h 
(n = 6). Data on (C) and (D) was normalized to untreated shCTR or STAT1sh1 cells, respectively (both 
set as 1). (E) qRT-PCR analysis of gene expression in STAT1 knockdown or shCTR cells transduced with 
IRF1 or Fluc vector for 48 h (n = 4). Data was normalized to shCTR cells that transduced Fluc vector 
(set as 1, not shown). (F) Immunoblotting analysis of Huh7 cells transduced with lentiviral shRNA 
vectors that targeting IRF9 or non-targeted control vector (shCTR). (G) qRT-PCR analysis of HEV viral 
RNA in Huh7-p6 model with IRF9 knockdown relative to shCTR (n = 4). (H) ISRE firefly luciferase 
activity in IRF9 knockdown Huh7-ISRE-Luc model transduced with IRF1 vector (stock with 100 times 
dilution) or treated with IFNα (1 IU/mL ) (n = 3 independent experiments with each of 3 replicates). 
Data was normalized to untreated shCTR or IRF9sh1 cells, respectively (both set as 1). (I) qRT-PCR 
analysis of HEV viral RNA and gene expression in IRF9 knockdown Huh7-p6 model transduced with 
IRF1 vector or treated with IFNα (1000 IU/mL) for 48 h (n = 5). Data on (H, I and J) was normalized to 
untreated shCTR or IRF9sh1 cells, respectively (both set as 1). Date presented as mean ± SEM (*, P < 
0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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The anti-HEV ability of IRF1 also requires key components of the ISGF3 
complex 
To further investigate the antiviral ability of IRF1 related to JAK-STAT pathway, we studied 
the effects of ISGF3 complex, which is a downstream element of JAK-STAT cascade. ISGF3 
complex consists of STAT1, STAT2 and IRF9 and mediates ISG transcription. Gene knockdown 
of STAT1 (Figure 6A) significantly promoted HEV replication (Figure 6B), suggesting a basal 
defense function of this pathway. Importantly, when STAT1 was silenced, IRF1 or IFNα 
induced ISRE promoter activation was significantly attenuated (Figure 6C). Consistently, ISG 
induction as well as anti-HEV effects of IRF1 were significantly attenuated in STAT1 silenced 
Huh7 cells (Figure 6D and 6E). Next, we silenced IRF9, another component of the ISGF3 
complex (Figure 6F). Similarly, HEV replication was also significantly promoted when IRF9 
was silenced (Figure 6G), also suggesting a basal anti-HEV function. Consistently, the 
depletion of IRF9 attenuated IRF1 induced ISRE promoter activation and ISG expression 
(Figure 6H and 6J). As expected, the antiviral ability of IRF1 or IFNα was also attenuated 
(Figure 6I). Collectively, these results suggest that ISGF3 complex is required for the 
induction of ISGs and the anti-HEV effect of IRF1. 
 
The induction of ISGs and the anti-HEV effect of IRF1 overlaps with IFNα but is 
potentiated by ribavirin  
We observed that the patterns of ISG induction by IFNα and IRF1 were highly correlated, 
suggesting a potential overlap of these two anti-HEV mechanisms (Figure 7A). Interestingly, 
gene knockdown of IRF1 did not impair IFNα mediated anti-HEV effect (Figure 7B) and ISG 
induction (Figure 7C and 7D). Furthermore, combination of IFNα and IRF1 over-expression 
did not yield additional induction of STAT1 and IRF1 expression (Figure 7E and 7F), nor the 
additional anti-HEV activity (Figure 7G and 7H). These results suggested that IFNα and IRF1 
converged in the JAK-STAT pathway to exert anti-HEV effects.  
A previous study showed that ribavirin could potentiate antiviral interferon response 
by augmenting ISG induction 29. Thus, we tested the combination effect of ribavirin and IRF1 
over-expression on ISGs induction. Consistent with this study, we observed that ribavirin 
alone could already up-regulate several ISGs. Interestingly, in contrast to IFNα, ribavirin 
further promoted IRF1-induced ISG expression including IRF1 in Huh7 cells (Figure 8A).  
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Figure 7. The induction of ISGs and the anti-HEV action of IRF1 overlaps with IFNα. (A) 
Correlation analysis of ISG expression in Huh7 cells transduced with IRF1 vector or treated 
with IFNα (1000 IU/mL) for 48 h. Data was normalized to Fluc control (set as 1). Data was 
analyzed by the two-tailed Pearson correlation method. (B) qRT-PCR analysis of HEV viral 
RNA in IRF1 knockdown cells treated with IFNα (10, 100 or 1000 IU/mL) for 48 h (shCTR: n = 
4; IRF1sh1 and IRF1sh2: n = 3). Data was normalized to untreated shCTR, IRF1sh1 or IRF1sh2 
cells, respectively (all set as 1). qRT-PCR analysis of IRF1 (C), STAT1 (C), ISG15 (D), MX1 (D) 
and IFI6 (D) expression in IRF1 knockdown Huh7 cells treated with IFNα (10, 100 or 1000 
IU/mL) for 48 h (n = 3). IRF1 expression was normalized to untreated shCTR (set as 1). STAT1, 
ISG15, MX1 and IFI6 expression was normalized to untreated shCTR, IRF1sh1 or IRF1sh2 
cells, respectively (all set as 1). qRT-PCR analysis of IRF1 (E, n = 5), STAT1 (F, n = 5) and HEV 
viral RNA (H, n = 6) expression in Huh7-p6 model and HEV-related luciferase activity (n = 3 
independent experiments with each of 2-4 replicates) in Huh7-p6-Luc model transduced 
with IRF1 vector or treated with different doses of IFNα (10, 100 and 1000 IU/mL) for 48 h. 
Data on (E, F, G and H) was normalized to Fluc control without IFNα treatment (set as 1). 
Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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Furthermore, ribavirin could also enhance the ISG induction and anti-HEV ability of IRF1 in 
HepaRG, A549 and MRC5 cell (Supplementary Figure 4A, 4B and 4C). More importantly, the 
combination of ribavirin and IRF1 further augmented their anti-HCV and anti-HEV effects 
(Figure 8B, 8C and 8D). Overall, these results indicated that the induction of ISGs and the 
anti-HEV effect of IRF1 overlapped with IFNα but was potentiated by ribavirin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Ribavirin potentiates IRF1-mediated ISG induction and anti-HEV activity. (A) qRT-PCR 
analysis of IRF1, STAT1, DDX58, RSAD2, ISG15, IRF9 and IFI6 expression in Huh7 cells transduced with 
IRF1 vector or treated with ribavirin (1, 10 or 100 μM) for 48 h (n = 5). (B) HCV-related luciferase 
activity in Huh7-ET-Luc model and transduced with IRF1 vector (stock with 50 times dilution) or 
treated with ribavirin (1, 10 or 100 μM) for 48 h (n = 3 independent experiments with each of 4 
replicates). (C) HEV-related luciferase activity in Huh7-p6-Luc model and transduced with IRF1 vector 
or treated with ribavirin (1, 10 or 100 μM) for 48 h (n = 3 independent experiments with each of 4 
replicates) and qRT-PCR analysis of HEV viral RNA in Huh7-p6 model transduced with IRF1 vector or 
treated with ribavirin for 48 h (n = 5). Data was normalized to GFP (B) or Fluc (A, C and D) control 
without ribavirin treatment (set as 1). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P 
< 0.001; NS, not significant). 
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Discussion 
Innate immunity is the frontier against viral pathogens 30. The activation of innate immune 
response relies on the recognition of pathogens by specific pattern recognition receptors 
(e.g. Toll-like receptors, RIG-I-like receptors, NOD-like receptors) 31, leading to the 
production of cytokines and chemokines such as interferons. Interferon triggers 
transcription of hundreds of ISGs through the JAK-STAT pathway. The products of these ISGs 
ultimately exert antiviral functions 30. Several recent studies have focused on the 
characterization of individual ISGs, with respect to their antiviral efficacy and potential 
mechanism-of-action 32-34. Surprisingly, two large-scale screening studies found out that 
actually only a small subset of ISGs have antiviral abilities and some even have proviral 
effects on certain viruses 10, 11. Among more than 380 tested ISGs, IRF1 was one of the 
strongest antiviral ISGs against a broad spectrum of viruses 10, 11. In this study, we reported 
that IRF1 is basally expressed in liver cells and confers resistance to HEV infection. Ectopic 
over-expression of IRF1 effectively inhibits HEV replication as shown in multiple cellular 
systems.  
Although IRF1 was reported could induce the expression of some ISGs similar to type 
I interferons 10, 11, the exact antiviral mechanism of IRF1 remains largely elusive. It has been 
reported that IRF1 could act as a transcription factor that activates either IFNβ gene 
expression in virus-infected fibroblasts 24 or IFNα gene expression in un-infected cells 35. 
Therefore, we initially hypothesized that the anti-HEV effect of IRF1 might via the induction 
of interferon production in the cell model. However, we convincingly demonstrated that HEV 
cell models including human hepatoma cell line (Huh7), primary human hepatocytes-like cell 
line (HepaRG), human lung epithelial carcinoma cell line (A549) and human fetal lung 
fibroblast cell line (MRC-5) are not capable of producing interferons upon IRF1 over-
expression by both gene expression and functional assays. Our observation in this respect is 
consistent with a previous study showing that Huh7 cell line responds to interferon but does 
not produce interferon 36. Furthermore, microarray analysis has shown that no interferon 
genes were up-regulated in IRF1 over-expressed Huh7 cells 11.  
IFNα was widely used to treat chronic HBV and HCV infection 28. In some cases, IFNα 
was also used to treat chronic HEV infection 9. In our previous study, we demonstrated that 
IFNα had moderate and delayed anti-HEV effects in cell culture models and IFNβ/λ/γ did not 
IRF1 restricts HEV replication 
185 
show a notable anti-viral effect on HEV replication 37. Similarly, Todt, D. et al. also reported a 
weak to moderate inhibition of HEV replication by different types of IFN 38. Interestingly, in 
this study we demonstrated that IRF1 could effectively inhibit HEV replication without 
triggering interferon production in host cells. This finding may provide new ideas for 
developing anti-HEV strategies. Surprisingly, both studies demonstrated that HEV could 
down-regulate ISG expression induced by different IFN types 37, 38. These observations 
suggest HEV have developed some strategies to subvert host antiviral defenses. 
Consistently, we also observed that IRF1 was induced at the early stage in most cell lines 
(Supplementraly Figure 2A and 2B). This result indicates after the infection was established, 
HEV have the ability to suppress the immune response elicited by itself.  
Given the fact that IRF1 is also a transcription factor and has more than 200 binding 
sites in the human genome 27, we have explored this scenario to understand its anti-HEV 
mechanism-of-action. Indeed, the IRF1 ChIP-seq data retrieved form database revealed that 
IRF1 could directly bind to the promoter region of STAT1 gene. Consistently, our functional 
assay demonstrated that IRF1 could drive the transcription of STAT1, resulting in protein 
expression and phosphorylation at Tyr701 site, which is an indispensable marker of STAT1 
activation. Correspondingly, the IRF1 induced STAT1 phosphorylation leading to the 
transcription of a series of individual ISGs. We further showed that ISG induction and anti-
HEV ability of IRF1 heavily rely on STAT1 phosphorylation. Furthermore, the integrity of the 
ISFG3 complex is also required. Although previous study has reported the induction of some 
ISGs in STAT1 deficient fibroblasts by IRF1 11, this may indicate that there are multiple 
mechanisms mediating the function of IRF1, including STAT1 dependent or independent 
mechanisms, probably depending on the cell type and particular circumstances. In this study, 
we reported a new antiviral mechanism of IRF1 by inducing the expression and 
phosphorylation STAT1 without triggering interferon production. This subsequently activates 
the JAK-STAT pathway to transcribe antiviral ISGs. It would be interesting to also address the 
relevance of this mechanism in IRF1-mediated effects on other viruses. 
Since IRF1 and IFNα converged in the JAK-STAT cascade to drive ISG transcription, we 
further evaluated the combinatory effects of IFNα and IRF1. As expected, combination of 
IFNα and IRF1 did not further promote ISG induction and anti-HEV activities. In contrast, 
IFNα and ribavirin have moderately synergistic anti-HEV effects in two HEV cell culture 
replication models 39. As a broad antiviral agent 40, ribavirin can potentiate interferon by 
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augmenting ISG induction in HCV culture model, which is mediated by a novel mechanism 
different from the classical interferon or intracellular RNA sensing pathways 29. In this study, 
we also tested the combinational effects of IRF1 and ribavirin. Interestingly, ribavirin further 
enhanced the IRF1 induced ISGs expression. More importantly, combination of IRF1 and 
ribavirin could reinforce ISG induction and their anti-HEV effects, although the exact 
mechanism remains to be further investigated.  
In conclusion, as Fiugre 9 shown, we characterized IRF1 as an important host factor 
that effectively inhibited HEV replication. Mechanistically, without triggering interferon 
production in host cells, IRF1 activates gene transcription of STAT1, which subsequently 
enhances its protein expression and phosphorylation to stimulate antiviral ISG transcription. 
Furthermore, the induction of ISGs and the anti-HEV effect of IRF1 overlapped with IFNα but 
were potentiated by ribavirin. Thus, this study has shed new light on the molecular insight 
into an important anti-HEV ISG, which may help to understand the complicity of HEV-host 
interactions and to develop new antiviral strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. IRF1 restricts HEV replication by activating STAT1 to induce the expression of ISGs. IRF1 
could induce the expression of STAT1. The induction of STAT1 expression further activated the 
transcription of a panel of downstream antiviral ISGs. The production of these ISGs could inhibit HEV 
replication.  
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Supplementary Figures 
Supplementary Figure 1. Over-expression of control vectors does not affect HEV 
replication. (A) Fluorescent microscopic analysis of Huh7 cells transduced with TagRFP-IRF1 
lentiviral vector for 48 h. Red indicates TagRFP and blue indicates DAPI (Scale bar: 50 µm). 
(B) Photinus pyralis luciferase activity (n = 4-8) and qRT-PCR analysis of TagRFP mRNA 
expression (n = 3) in Huh7 cells transduced with Fluc, GFP vector or untreated (CTR) for 48 h. 
HEV viral replication-related Gaussia luciferase activity in Huh7-p6-Luc model (C) transduced 
with GFP, Fluc vector or untreated (CTR) for 24 h, 48 h and 72 h (n = 3 independent 
experiments with each of 2-3 replicates) and qRT-PCR analysis of HEV viral RNA in Huh7-p6 
full-length HEV model (D) transduced for 48 h (n = 3). RLU: relative luciferase unit. HCV-
related firefly luciferase activity in Huh7-ET-Luc model (E) (n = 4 independent experiments 
with each of 3-4 replicates) and MTT assay analysis of cell viability in Huh7 cells (F) (n = 3 
independent experiments with each of 3-4 replicates) transduced with IRF1, GFP vector or 
treated with IFNα (1000 IU/mL) for 48 h. qRT-PCR analysis (G, n = 6) or immunoblotting 
analysis (H) of HepaRG cells, A549 cells and MRC5 cells transduced with IRF1, Fluc vector or 
treated with IFNα (1000 IU/mL) for 48 h. (I, J, K) qRT-PCR analysis of HEV and IRF1 expression 
in Huh7 cells transduced with IRF1 or infected by HEV at indicted time point. Date presented 
as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant). 
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Supplementary Figure 2. HEV infection induces IRF1 expression in some cell lines. qRT-PCR 
analysis (A, n = 5) and immunoblotting analysis (B) of Huh7, HepaRG, A549 and MRC5 cells 
infected by HEV for 6h (For 2 h post infection, cells were incubated with HEV for 2 hours and 
then cells were lysed). At different time point post HEV infection (2 h, 6 h, 24 h or 48 h post 
infection), HEV RNA and IRF1 expression level was quantified. HEV RNA level was normalized 
to 2 h post infection. IRF1 mRNA level and protein level was normalized to un-infected cells 
at each time point. (C) Plot of qRT-PCR analysis of interferon gene expression in Huh7 and 
HepaRG cells transduced with IRF1 or Fluc (CTR) vector for 48 h. Rn: Fluorescence signal 
from the reporter dye normalized to that from the negative control. (D) qRT-PCR analysis of 
gene expression in Huh7 cells transduced with IRF1 vector or treated with IFNα (1000 IU/mL) 
for 48 h. (E) qRT-PCR analysis of gene expression in Huh7 cells transduced with GFP, Fluc 
vector or untreated for 48 h (n = 3). Data was normalized to untreated control (CTR, set as 1, 
not shown). Date presented as mean ± SEM (*, P < 0.05; NS, not significant). 
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Supplementary Figure 3. JAK inhibitor, CP-690550 diminishes the induction of ISG and the 
anti-HEV effect of IRF1. (A) Immunoblotting analysis of Huh7 cells transduced with IRF1 
vector or treated with CP-690550 (1000 ng/mL) for 48 h or IFNα (1000 IU/mL) for 30 min or 
48 h. (B) ISRE firefly luciferase activity in Huh7-ISRE-Luc model transduced with IRF1 vector 
or treated with IFNα (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (n = 4 independent 
experiments with each of 3-4 replicates). qRT-PCR analysis of ISG expression (C, n = 4; D, n = 
3), IRF1 (E, n = 5) and MTT assay analysis of cell viability (F, n = 3 independent experiments 
with each of 3-4 replicates) in Huh7 cell HEV model transduced with IRF1 vector or treated 
with IFNα (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h.HEV-related luciferase activity 
(G, n = 4 independent experiments with each of 4 replicates) and HEV viral RNA (H, n = 6) in 
Huh7-based cell HEV model transduced with IRF1 vector or treated with IFNα (1000 IU/mL) 
or CP-690550 (1000 ng/mL) for 48 h. Data was normalized to untreated GFP (B) or Fluc (C, D, 
E, F and H) control (CTR, set as 1). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; 
***, P < 0.001; NS, not significant). 
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Supplementary Figure 4. Ribavirin potentiates IRF1-mediated ISG induction and anti-HEV 
activity in different cell lines. qRT-PCR analysis of IRF1, STAT1, DDX58, IFIH1, ISG15, IRF9, 
IFI27, MX1 expression and HEV viral RNA level in HepaRG-p6 model (A), A549-p6 model (B) 
and HEV infected MRC5 cells (C) transduced with IRF1 vector or treated with ribavirin (1, 10 
or 100 μM) for 48 h (n = 4-6). Date presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P 
< 0.001; NS, not significant). 
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Abstract  
Hepatitis E virus (HEV) infection, one of the foremost causes of acute hepatitis, is becoming a 
health problem of increasing magnitude. As other viruses, HEV exploits elements from host 
cell biochemistry, but we understand little as to which components of the human 
hepatocellular machinery are perverted for HEV multiplication. It is, however, known that 
the eukaryotic translation initiation factors 4F (eIF4F) complex, the key regulator of the 
mRNA-ribosome recruitment phase of translation initiation, serves as an important 
component for the translation and replication of many viruses. Here we aim to investigate 
the role of three subunits of the eIF4F complex: eukaryotic translation initiation factor 4A 
(eIF4A), eukaryotic translation initiation factor 4G (eIF4G) and eukaryotic translation 
initiation factor 4E (eIF4E) in HEV replication. We found that efficient replication of HEV 
requires eIF4A, eIF4G and eIF4E. Consistently, the negative regulatory factors of this 
complex: programmed cell death 4 (PDCD4) and eIF4E-binding protein 1 (4E-BP1) exert anti-
HEV activities, which further illustrates the requirement for eIF4A and eIF4E in supporting 
HEV replication. Notably, phosphorylation of eIF4E induced by MNK1/2 activation is not 
involved in HEV replication. Although ribavirin and interferon-α (IFN-α), the most often-used 
off-label drugs for treating hepatitis E, interact with this complex, their antiviral activities are 
independent of eIF4E. In contrast, eIF4E silencing provokes enhanced anti-HEV activity of 
these compounds. Thus, HEV replication requires eIF4F complex and targeting essential 
elements of this complex provides important clues for the development of novel antiviral 
therapy against HEV. 
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Introduction 
Hepatitis E virus (HEV), a single-strand-positive RNA virus classified within the genus 
Hepevirus in the family Hepeviridae, represents the most common cause of acute viral 
hepatitis 1. Like all viruses, HEV is completely dependent on the translational machinery of 
host cells to synthesize the viral proteins essential for its productive infection 2. The host 
protein synthesis machinery commandeered by viruses has major impact on viral protein 
synthesis and genome replication 3, but little is known regarding how HEV uses host 
translational machinery for its life-cycle. 
As a heterotrimeric protein complex, eukaryotic translation initiation factor 4F (eIF4F) 
mediates recruitment of ribosomes to mRNA and is the rate-limiting step for cap-dependent 
translation in viruses and cells under most circumstances 4. Functions of the constituent 
proteins of eIF4F include delivery of an RNA helicase eukaryotic initiation translation factor 
4A (eIF4A) to the 5’ region, bridging mRNA and ribosome by eukaryotic initiation translation 
factor 4G (eIF4G) scaffolding protein and recognition of the mRNA 5’ cap structure by 
eukaryotic initiation translation factor 4E (eIF4E) cap-binding protein 4. Not surprisingly, all 
these translation initiation factors are required for various types of viruses during their 
translation and replication 2, 5-7. In addition, eIF4E phosphorylation is induced by the eIF4G-
associated kinase MNK1 to facilitate eIF4F assembly 8. This process of translational control 
has been reported to be critical for the efficient viral infection 2, 9, 10. Furthermore, other 
cellular regulatory proteins of eIF4F complex such as eukaryotic translation initiation factor 
4B (eIF4B) 11, programmed cell death 4 (PDCD4) 12 and eIF4E-binding protein 1 (4E-BP1) have 
been reported vital for viral protein synthesis 13-15. HEV, however, has not been investigated 
in this context and it is currently unknown whether the virus requires eIF4F complex for 
efficient replication. 
Interestingly, the eIF4F complex can interact with antiviral regimens, such as ribavirin 
or interferon-α (IFN-α), which are the classical standard therapy of chronic hepatitis C but 
also as off-label drugs for treating individual HEV cases or small case series 16, 17. Ribavirin 
can directly bind to eIF4E and compete for 5’ cap mRNA binding 18, 19, whereas some 
regulatory factors of eIF4F complex are involved in interferon mediated antiviral immune 
response 20, 21. In absence, however, of information as to requirement of HEV for elements of 
the host translational machinery it is impossible to make statements whether ribavirin exerts 
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its anti-HEV action through inhibition of the eIF4F complex or whether alternative 
mechanisms are involved. 
The lack of knowledge as to the requirements made by HEV on the hepatocellular 
host cell machinery with respect to translation of viral gene products represents a major gap 
in our understanding of the biology of this virus and hampers design of rational treatment. 
Therefore, this study has investigated the role of the eIF4F complex and its regulatory factors 
in HEV replication, as well as their potential involvements in the anti-HEV actions of ribavirin 
and IFN-α. 
 
Materials and methods 
Reagents 
Compound GCP57380 as Mnk1 inhibitor ( > 98% purity) was purchased from Abcam 
Biochemicals (UK). Ribavirin was purchased from Sigma-Aldrich (St Louis, MO). Human IFN-α 
(Thermo Scientific, the Neterlands) was dissolved in PBS. Doxycycline hyclate ( ≥ 98% TLC) 
was purchased from Sigma-Aldrich (St Louis, MO). Stocks of Jak inhibitor I (Santa Cruz 
Biotech, Santa Cruz, CA) was dissolved in DMSO (Sigma-Aldrich, St Louis, MO) with a final 
concentration of 5 mg/mL. Antibodies including total-eIF4E, phosphor-eIF4E, total-4E-BP1 
(Cell Signalling Technology, Netherlands) and β-actin (Santa Cruz Biotech, Santa Cruz, CA); 
anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies (Stressgen, Glandford Ave, 
Victoria, BC, Canada) were also used. 
 
Cell culture and cell models 
Naïve or vector transduced HuH7 cells was established from a hepatocellular carcinoma, 
immortalized mouse embryonic fibroblasts (MEFs) derived from wild-type and 4E-BP1 knock-
out (4E-BP1-/-) mice (kind gifts from E.N. Fish’s lab), eIF4E-S209A MEFs containing an eIF4E 
mutation in which eIF4E cannot be phosphorylated (kind gift from Dr Sonenberg's lab, McGill 
University) were cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen-Gibco, 
Breda, Netherlands) complemented with 10% v/v fetal calf serum (Hyclone, Lonan, Utah), 
100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen-Gibco). 
Authentication of cell line was performed at the Department of Pathology, Erasmus MC and 
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regular testing for mycoplasma contamination was performed at the Laboratory of 
Gastroenterology and Hepatology, Erasmus MC. 
HEV genomic RNA was generated from a plasmid construct containing the full-length 
HEV genome (Kernow-C1 p6 clone, GenBank Accession Number JQ679013) or a construct 
containing subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene (p6-
Luc), using the Ambion MESSAGE MACHINE in vitro RNA transcription Kit (Life Technologies 
Corporation) 22, 23. The human hepatoma 7 (HuH7) cells were collected and centrifuged for 5 
min, 1500 rpm, 4°C. Supernatant was removed and washed with 4 mL Opti-MEM by 
centrifuging for 5 min, 1500 rpm, 4°C. The cell pellet was re-suspended in 100 μl Opti-MEM 
and mixed with p6 full-length HEV RNA or p6-Luc subgenomic RNA. Electroporation was 
performed with the Bio-Rad’s electroporation systems using the protocol of a designed 
program (240 V, pulse length 0.5, number 1 and cuvette 4 mm) 22. All cells were grown at 37 
°C, 5% CO2, and 100% humidity. 
 
Gene knockdown and overexpression by lentiviral vector 
Lentiviral vectors of shRNA (Sigma-Aldrich) targeting eIF4A, eIF4G, eIF4B, PDCD4, eIF4E, 4E-
BP1 and controls were obtained from the Erasmus Center for Biomics and produced in HEK 
293T cells as previously described 24. Three types of control vectors have been tested on HEV 
replication (CTR1: Control that will not activate the RNAi pathway because the vector does 
not contain an shRNA insert, CTR2: Control that will activate RISC and the RNAi pathway, but 
does not target any human or mouse genes. The short hairpin sequence contains 5 bp 
mismatches and scrambled sequences to any known human or mouse gene, CTR3: Control 
contains shRNA sequence that targets GFP reporter that is not expressed in our cell lines. 
Since no off-target effect was observed (Supplementary Figure 1), the most advanced shRNA 
control vector targeting GFP (GFP is not expressed in our cell lines) was used in this study as 
control (shCTR). After a pilot study, the shRNA vectors exerting optimal gene knockdown 
were selected. These shRNA sequences were described in Supplementary Table 1. To 
generate gene knockdown cells, HuH7 cells were transduced with lentiviral vectors. Since 
the knockdown vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 3 μg/mL puromycin to the cell culture medium. 
Overexpression of 4E-BP1 lentivector (Addgene) was a kind gift from Dr Sonenberg's lab, 
McGill University. To generate overexpression cells, HuH7 cells were transduced with 
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lentiviral vectors and doxycycline was used to add in the 4E-BP1 overexpression cell lines as 
the stimulation factor. 
 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA was quantified with a SYBR 
Green-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) according to the 
manufacturer’s instructions. GAPDH or β-actin was considered as reference gene to 
normalize gene expression. The HEV primer sequences were 5’-
ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-CCGTGGCTATAATTGTGGTCT-3’ (antisense). 
Other human and mouse primer sequences were included in Supplementary Table 2. 
 
Western blot assay 
Proteins in cell lysates were heated 5 min at 95 °C followed by loading onto a 10-15% sodium 
dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and separated by electrophoresis. After 90 
min running at 100 V, proteins were electrophoretically transferred onto a 
polyvinylidenedifluoride (PVDF) membrane (Invitrogen) for 1.5 hrs with an electric current of 
250 mA. Subsequently, the membrane was blocked with blocking buffer. It was followed by 
incubation with rabbit t-eIF4E, p-eIF4E, t-4E-BP1 (1:1000) antibodies overnight at 4 °C. The 
membrane was washed 3 times followed by incubation for 1 hrs with anti-rabbit or anti-
mouse IRDye-conjugated secondary antibodies (LI-COR Biosciences, Lincoln, USA) (1:5000) at 
room temperature. Blots were assayed for β-actin content as standardization of sample 
loading, scanned, and quantified by Odyssey infrared imaging (Li-COR Biosciences, Lincoln, 
NE, USA). Results were visualized and quantitated with Odyssey 3.0 software. 
 
Measurement of luciferase activity 
For Gaussia luciferase, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly 
luciferase, luciferin potassium salt (100 mM, Sigma) was added to cells and incubated for 30 
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min at 37 °C. Both gaussia and firefly Luciferase activity was quantified with a LumiStar 
Optima luminescence counter (BMG LabTech, Offenburg, Germany). 
 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were performed 
with Mann-Whitney test. Differences were considered significant at a p value less than 0.05 
*or 0.01 **. 
 
Results 
Requirements of eIF4A and eIF4G for efficient HEV replication 
Most of cellular and viral mRNAs rely on cap-dependent mRNA translation. The canonical 
mechanism of initiation commences with recognition of 5’ end m7GpppN cap structure by 
the eIF4F complex formed by the DEAD-box helicase eIF4A, the scaffolding protein eIF4G and 
the cap recognition factor eIF4E 25. Among these initiation factors, eIF4A is a subunit in 
charge of unwinding of secondary structure within the leader sequence of mRNA, while large 
scaffolding subunit eIF4G is associated with many other translation initiation factors 7. 
Because of the important roles of both eIF4A and eIF4G subunits reported in translation and 
replication of many viruses, we investigated their roles in HEV replication. 
Firstly, we evaluated the role of the DEAD-box RNA helicase eIF4A by using RNAi-
based gene loss-of-function approach. Two out of four (sheIF4A-1 and sheIF4A-2) shRNAs 
targeting eIF4A showed significant reduction of its mRNA level in HuH7 cells, compared with 
a control shRNA targeting GFP (shCTR) (Figure 1A). Consistently, their protein levels were 
also downregulated without affecting the expression of eIF4G and eIF4E, which suggested a 
successful knockdown of eIF4A (Figure 1B). No cytotoxicity has been observed in these cells 
as measured by MTT assay (Supplementary Figure 2A). Silencing of eIF4A resulted in 
significant decrease of cellular HEV RNA level by 63.1% ± 8.6% and 57.6% ± 13.8% (mean ± 
SEM, n = 4, P < 0.05) after three days inoculation of HEV particles, respectively (Figure 1C). 
Next, knockdown of scaffold protein eIF4G by four shRNAs were also performed in HuH7 
cells. Two clones (sheIF4G-1 and sheIF4G-4) showed efficient down-regulation of eIF4G at 
both mRNA level and protein level, but did not influence the protein level of eIF4A or eIF4E 
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(Figure 1D and 1E). No cytotoxicity was observed in these knockdown cells (Supplementary 
Figure 2B). Correspondingly, HEV RNA levels was significantly reduced by 36.1% ± 10.6% and 
33.8% ± 11.0% (mean ± SEM, n = 4, P < 0.05) in both eIF4G knockdown cells, respectively, 
compared to shCTR cells (Figure 1F). These results demonstrate that both eIF4A and eIF4G 
are required for efficient HEV replication.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Requirements of eIF4A and eIF4G for HEV replication. Knockdown of eIF4A and eIF4G by 
lentiviral shRNA vectors were performed in Huh7 cells. Compared with the control vector transduced 
cells, the sheIF4A clone 1 and 2 (A and B) or the sheIF4G clone 1 and 4 (D and E) showed potent gene 
silencing at mRNA level and protein level. Correspondingly, knockdown of eIF4A (C) and eIF4G (F) 
resulted in significant increase of cellular HEV RNA level (Mean ± SEM, n = 4). * P < 0.05. 
 
PDCD4, the negative regulatory factor of eIF4A, restricts HEV replication 
Given the fact that the function of eIF4A is regulated by multiple cellular factors, we first 
investigated the effect of its activator eIF4B that can increase the helicase activity of eIF4A. 
Knockdown of eIF4B by two out of four shRNA clones (sheIF4B-2 and sheIF4B-3) resulted in 
significant down-regulation of eIF4B expression (Figure 2A), but has no significant influence 
on cellular HEV RNA level (Figure 2B).  
We next examined a negative regulatory factor of eIF4A, PDCD4, which prevents the 
binding of eIF4A to eIF4G and thereby inhibits the initiation of translation 26, To assess the 
effect of PDCD4 on HEV replication, lentiviral shRNA vectors were used to stably knockdown 
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its expression in HuH7 cells. Potent down-regulation of PDCD4 mRNA and protein expression 
of two clones (shPDCD4-1 and shPDCD4-3) (Figure 2C and 2D) resulted in a significant 
increase of HEV RNA after inoculation of HEV particles for three days (Figure 2E). No 
cytotoxicity was observed in knockdown cells (Supplementary Figure 2C). These results are 
consistent with the finding that eIF4A supports HEV replication and inhibiting the function of 
eIF4A by PDCD4 in turn suppresses HEV replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The regulatory factors of eIF4A, PDCD4 but not eIF4B, restricted HEV replication. (A) Clone 
2 and 3 Knockdown of eIF4B by lentiviral shRNA vectors exerted significant downregulation of eIF4B 
at mRNA level. (B) Silencing of eIF4B did not influence HEV replication during 72 hrs inoculation of 
viral particles. mRNA level (C) and protein level (D) of PDCD4 were significantly reduced in clone 1 
and 3. (E) HEV RNA level were dramatically increased when silencing PDCD4 in clone 1 and 3. (Mean 
± SEM, n = 4). * P < 0.05. 
 
eIF4E is also required for efficient HEV replication 
eIF4E, the least abundant component of the eIF4F complex, is a rate-limiting factor for 
translation 27, To investigate the role of eIF4E in HEV replication, its expression was silenced 
by RNAi. Two out of five shRNAs targeting eIF4E exerted potent knockdown at both protein 
(Figure 3A) and mRNA levels (Figure 3B). No off-target effect was observed on protein 
expression of eIF4G or eIF4A (Figure 3A), or on genes such as CyA, CyB, 4E-BP1 and mTOR, 
which are known to affect HEV replication as previously shown 28, 29 (Supplementary Figure 
3). MTT assay showed no cytotoxicity of eIF4E silencing in cells (Supplementary Figure 2D). 
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Accordingly, inoculation of HEV led to reduction by 44% ± 12% and 41% ± 25% (mean ± SEM, 
n = 5, P < 0.05) in viral RNA level in these two knockdown cells compared to shCTR cells 
(Figure 3C). We observed similar effect in MEFs (Figure 3D and 3E), further confirming that 
eIF4E plays an important role in HEV replication.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. eIF4E supports HEV 
replication. Knockdown of human 
eIF4E by five lentiviral shRNA vectors 
were performed in HuH7 cells. Clone 1 
and 2 exhibited a potent down-
regulation of eIF4E at protein (A) and 
mRNA (B) levels. β-actin served as an 
internal reference. (C) 
Correspondingly, these two clones of 
eIF4E knockdown inhibited HEV 
replication. (D) Knockdown of mouse 
eIF4E by lentiviral shRNA vector was 
applied in MEFs showed a significant 
decrease at eIF4E mRNA level. (E) HEV 
RNA level was significantly reduced 
with eIF4E silencing in MEFs. (Mean ± 
SEM, n = 4). * P < 0.05. 
 
Phosphorylation is not required for eIF4E to support HEV replication 
Ser209 phosphorylation has been shown to be required for the oncogenic potential of eIF4E 
30. To examine whether this is also important in the context of HEV infection, HuH7 cells 
harboring the HEV subgenomic replicon or the full-length genome were treated with 10-100 
µM CGP57380, a well-characterized inhibitor of MNK. MNK is the only known physiologic 
kinase that phosphorylates eIF4E (Ser209 site) 31. This compound potently inhibited eIF4E-
S209 phosphorylation without effect on total eIF4E protein level (Figure 4A). However, 
CGP57380 had no effect on HEV replication in both luciferase replicon model (Figure 4B) and 
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infectious model (Figure 4C). To further confirm the function of phosphorylation of eIF4E, 
MEFs cultured from mice with S209A mutation were used. This mutation targeting the 
conserved phosphorylation site for MNK1/2 kinase with serine-to-alanine completely 
abolished phosphorylation of eIF4E at Ser209 without effect on total eIF4E (Figure 4D). 
Consistently, no significant effect was observed on HEV replication between mutated and 
wild type MEFs (Figure 4E). These data suggest that phosphorylation of eIF4E is dispensable 
for HEV replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. eIF4E phosphorylation did not significantly affect HEV replication. (A) Treatment with MNK1/2 
inhibitor CGP57380 of 100 μM dramatically decreased the phosphorylation of eIF4E, but not total 
eIF4E protein shown by Western blot assay. β-actin served as an internal reference. 10-100 μM 
CGP57380 did not significantly affected viral replication-related luciferase activity during the three 
days (B) and viral RNA level in HuH7-p6 infectious model for 48 hrs (C). (D) MEFs of S209A mutation 
abolished phosphorylation of eIF4E at Ser209 shown by Western blot assay. β-actin served as an 
internal reference. (E) Inhibition of phosphorylation in S209A MEFs did not significantly influence 
HEV replication. (Mean ± SEM, n = 4). 
 
HEV replication is inhibited by the eIF4E suppressor, 4E-BP1 
eIF4E can be released by 4E-BP1 hyperphosphorylation with elimination of translational 
repression 21. For a more detailed characterization of the role of eIF4E suppressor 4E-BP1 in 
HEV infection, we employed both loss- and gain-of-function approaches in HuH7 cells. Using 
lentiviral RNAi technique, 4E-BP1 was dramatically down-regulated at both protein and 
mRNA levels (Figure 5A). Accordingly, 48 hrs inoculation of HEV resulted in 2.6 ± 1.2 fold 
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(mean ± SEM, n = 4, P < 0.05) increase of viral RNA in 4E-BP1 knockdown HuH7 cells, 
compared with the mock knockdown cells (Figure 5A). In contrast, using an inducible over-
expression lentiviral vector, 4E-BP1 expression was drastically up-regulated at both protein 
and mRNA levels with treatment of dose dependent doxycycline, which resulted in 
significant reduction of HEV RNA by 59% ± 17% (mean ± SEM, n = 4, P < 0.05) (Figure 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The eIF4E suppressor, 4E-BP1, limited HEV replication. (A) Efficient silencing of 4E-BP1 at 
protein level was detected by Western blot assay. β-actin served as an internal reference. Similarly, 
4E-BP1 was significantly down-regulated at mRNA level (Mean ± SEM, n = 7). Correspondingly, 
inoculation of HEV resulted in significant increase of viral RNA in 4E-BP1 knockdown Huh7 cells, 
compared with the mock knockdown cells (Mean ± SEM, n = 4). (B) 4E-BP1 was drastically up-
regulated at protein level when the over-expression cell lines were treated with different 
concentrations of doxycycline for 24 hrs. β-actin served as an internal reference. Similarly, mRNA 
levels of 4E-BP1 was dramatically increased after treatment of 4 μg/ml doxycycline for 24 hrs. (Mean 
± SEM, n = 5). Correspondingly, 4E-BP1 over-expression cell line with treatment of 4 μg/ml 
doxycycline for 24 hrs resulted in significant reduction of HEV RNA level (Mean ± SEM, n = 4). (C). 
MEFs derived from 4E-BP1 knockout (4E-BP1-/-) mice presented an efficient silencing of 4E-BP1 at 
protein level compared to WT MEFs, leading to significant increase of HEV RNA level (Mean ± SEM, n 
= 4). * P < 0.05. 
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To further validate 4E-BP1 function in HEV infection, MEFs cultured from 4E-BP1 
knockout mice were studied. Western blot assay showed a complete knockout of 4E-BP1 at 
protein level (Figure 5C). Accordingly, 48 hrs inoculation of HEV led to 3.9 ± 0.8 fold (mean ± 
SEM, n = 4, P < 0.05) increase of cellular HEV RNA level in 4E-BP1 knockout MEFs (4E-BP1-/-) 
compared to wild type MEFs (4E-BP1+/+) (Figure 5C). Hence, these data supported a role of 
4E-BP1 in constraining HEV replication. 
 
The anti-HEV activities of ribavirin and IFN-α are independent of eIF4E  
Ribavirin is a well-known inhibitor of eIF4E 18. To evaluate whether the anti-HEV activity of 
ribavirin is mediated by the inhibition of eIF4E, both shCTR and sheIF4E-1 cells with HEV 
inoculation were used for the treatments of 6.25, 12.5, 25, 50, 100 μM ribavirin for 48 hrs. 
Comparable IC50 in shCTR and sheIF4E cells were found with the range between 12.5-25 μM 
(Figure 6A).  
 
Figure 6. The anti-HEV activities of ribavirin and IFN-α is independent of eIF4E. (A) IC50 of RBV was 
with the range between 12.5 - 25 μM: 15.67 μM in shCTR cells and 17.24 μM in sheIF4E cells and (B) 
IFN-α was with the range between10 - 50 IU/ml: 14.55 IU/ml in shCTR cells and 47.75 IU/ml in 
sheIF4E cells). (C) 25 μM ribavirin and 1000 IU/ml IFN-α were treated in shCTR and sheIF4E cells. HEV 
RNA level was detected by qRT-PCR after 72 hrs inoculation of viral particle. (Mean ± SEM, n = 4 - 8). 
* P < 0.05. ** P < 0.01. 
 
The antiviral activity of IFN-α has also been associated to the regulation of translation 
initiation factors in particular circumstances 20, 21. To further assess whether eIF4E could 
mediate the anti-HEV activity of IFN-α, treatments of 1, 10, 100, 1000, 10000 IU/ml IFN-α on 
HEV in both shCTR and sheIF4E-1 cells for 48 hrs has been performed. Comparable IC50 of 
IFN-α were observed with the range between 10-50 IU/ml in shCTR and sheIF4E cells (Figure 
6B). Furthermore, as expected, HEV replication were significantly inhibited with treatment of 
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25 μM ribavirin and 1000 IU/mL IFN-α for 48 hrs. However, the anti-HEV effects of ribavirin 
and IFN-α were further enhanced by eIF4E knockdown(Figure 6C). In addition, no clear 
cytotoxicity was observed in both shCTR and sheIF4E cells (Supplementary Figure 4A and 
4B). These results indicated that the antiviral effects of ribavirin and IFN-α are independent 
of eIF4E, although silencing of eIF4E could already inhibit HEV replication. 
 
Discussion 
Most of the viruses can only encode restricted numbers of proteins and therefore they 
heavily rely on the host cellular machinery and their ingredients to accomplish the virus life-
cycles 3. Recent studies show that translation initiation mechanisms especially eIF4F complex 
is employed by many viruses as a primary target for cap-dependent translational control to 
confer advantages to generate progeny 32. Three proteins: RNA helicase eIF4A, scaffolding 
protein eIF4G and cap binding protein eIF4E, which are components of the eIF4F complex, 
are related to the efficient translation and replication of various viruses 2, 5-7. It is, however, 
unknown to what extent HEV requires elements from the translation initiation complex. Our 
study was aimed to provide more insight in this area of HEV biology, also with the explicit 
goal to provide directions for the development of rational treatment of HEV-related disease. 
Our study demonstrated a requirement of the eIF4F complex for efficient HEV replication 
(Figure 1 and 3). 
Among all three subunits of the eIF4F complex, eIF4E is the main regulatory nexus 
involved in the complex formation and has impact on many types of viral infections 3, 
including on HEV as we showed in this study. One of the mechanisms by which eIF4E takes 
control of complex formation and translation initiation process is via phosphorylation on 
serine 209 carried out by MNK1/2 3. Stimulation of eIF4E phosphorylation is correlated with 
facilitated translation and replication of some viruses 2, 9, 30. In contrast, we found that S209 
phosphorylation is not required for eIF4E to support HEV replication (Figure 4). Another 
regulatory mechanism of eIF4E is exerted via 4E-BP1, a small-molecular-weight repressor of 
5’ capped mRNA translation, which has also been implicated in host defense against viral 
infection 15. In apparent agreement, we show that 4E-BP1 can inhibit HEV replication (Figure 
5). 4E-BP1 is a phosphoprotein that binds to eIF4E depending on its phosphorylation status. 
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4E-BP1 hyperphosphorylation results in releasing eIF4E to form the functional eIF4F 
complex. Conversely, 4E-BP1 hypophosphorylation allows binding of this protein to eIF4E 
and counteracts the formation of eIF4F complex 3. Therefore, without this hijacking of eIF4E 
in a 4E-BP1-deficient context, eIF4E can still exert its pro-HEV activity (as we have shown in 
Supplementary Figure 5). Similarly, the eIF4A suppressor PDCD4 can also restrict HEV 
replication (Figure 2). PDCD4 sequesters eIF4A from the eIF4E-eIF4G complex, resulting in 
repressed translation of mRNAs 12 and thus modulates replication of various viruses 13, 14. 
Apparently this notion also holds true in the biology of HEV infection. 
 
Figure 7. Schematic illustration of the involvement of the eIF4F complex in HEV replication. Three 
subunits of eIF4F complex: eIF4A, eIF4G and eIF4E play important roles in efficient HEV replication. 
Furthermore, HEV replication is limited by the cap dependent translational suppressors, PDCD4 and 
4E-BP1, but is not influenced by eIF4E phosphorylation induced by MNK1/2 kinase activation. 
 
Despite the absence of proven medications for treating HEV, ribavirin, IFN-α, or the 
combination have been use as off-label antiviral drugs to treat individual HEV cases or small 
case series 16. The antiviral effect of interferons and their signaling pathways have been 
attributed to effects in the 4E-BP1 cascade 15, 20. However, loss- or gain-function of 4E-BP1 
had no significant effects on the expression of IFN-α and -β (Supplementary Figure 6A) and 
no effect on phosphorylation of STAT1, the key element of interferon signalling transduction 
(Supplementary Figure 6B). Furthermore the effect of 4E-BP1 on HEV is independent of JAK-
STAT cascades (Supplementary Figure 6C). Conversely, the anti-HEV effect of IFN-α is also 
independent of 4E-BP1 (Supplementary Figure 6D). Although ribavirin directly binds to eIF4E 
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and competes for 5’ cap mRNA binding 18, 19, the anti-HEV activity of ribavirin is also 
independent of eIF4E in our experimental system (Figure 6). Instead, loss of eIF4E exerts 
additive anti-HEV effect of IFN-α or ribavirin and suggests that treatments aimed at targeting 
the translation initiation complex in conjunction with IFN-α or ribavirin have significant 
promise. 
In conclusion, we revealed that cap dependent translation machinery plays a critical 
role in help with efficient HEV replication. The translational suppressors PDCD4 and 4E-BP1 
are important antiviral factors in restraining HEV infection (Figure 7). Thus, these results 
have shed new light on virus-host interactions and provided new avenue for potential 
antiviral drug development against HEV infection. 
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Supplementary Figures and Tables 
 
Supplementary Figure 1. eIF4E knockdown did not significant affect off-target genes 
expression in Huh7 cells. CyA, CyB, 4E-BP1 and mTOR mRNA levels were not influenced in 
sheIF4E-1 (A) and sheIF4E-2 cells (B). (Mean ± SEM, n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. eIF4E is required for efficient HEV replication in 4E-BP1-/- knockout 
MEFs. Clone sheIF4E-2 of mouse eIF4E knockdown showed a potent eIF4E silencing at 
protein (A) and mRNA levels (B). β-actin served as an internal reference in Western blot 
assay. (C) HEV RNA level was significantly reduced in sheIF4E-2 MEFs deficient of 4E-BP1. 
(Mean ± SEM, n = 4). * P < 0.05. 
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Supplementary Figure 3. (A) IFN-α and -β production were not influenced by 4E-BP1 
expression in Huh7 cells and MEFs. (B) IFN-α induced phosphorylation of STAT1, which 
represents key elements in antiviral JAK-STAT1 cascades, showed no difference in 4E-BP1 
over-expression HuH7 cells and 4E-BP1 knockout MEFs by Western blot assay. β-actin served 
as an internal reference. 4E-BP1 did not mediate the pro-HEV effects of Jak inhibitor I (C) and 
anti-HEV effects of IFN-α (D) for 48 hrs. (Mean ± SD, n = 4). 
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Supplementary Table 1. shRNA target sequences. 
sheIF4A-1 
(human) 
CCGGGCCGTGTGTTTGATATGCTTACTCGAGTAAGCATATCAAACACACGGCTTTTTG 
sheIF4A-2 
(human) 
CCGGGCCGTAAAGGTGTGGCTATTACTCGAGTAATAGCCACACCTTTACGGCTTTTTG 
sheIF4A-3 
(human) 
CCGGCCTTGTATCAAGGGTTATGATCTCGAGATCATAACCCTTGATACAAGGTTTTTG 
sheIF4A-4 
(human) 
CCGGCGAAATGTTAAGCCGTGGATTCTCGAGAATCCACGGCTTAACATTTCGTTTTTG 
sheIF4G-1 
(human) 
CCGGCCCTACAGAATTTGGGACCTACTCGAGTAGGTCCCAAATTCTGTAGGGTTTTTG 
sheIF4G-2 
(human) 
CCGGGCCCTTGTAGTGACCTTAGAACTCGAGTTCTAAGGTCACTACAAGGGCTTTTTG 
sheIF4G-3 
(human) 
CCGGGCAGATAGTATCCAACACGTTCTCGAGAACGTGTTGGATACTATCTGCTTTTTG 
sheIF4G-4 
(human) 
CCGGCCCAAGTAATGATGATCCCTTCTCGAGAAGGGATCATCATTACTTGGGTTTTTG 
sheIF4B-1 
(human) 
CCGGGCGGAGAAACACCTTGATCTTCTCGAGAAGATCAAGGTGTTTCTCCGCTTTTTG 
sheIF4B-2 
(human) 
CCGGGCCGTGATAGAAATCGGGATTCTCGAGAATCCCGATTTCTATCACGGCTTTTTG 
sheIF4B-3 
(human) 
CCGGCGGGATGATTATAGGCGTGATCTCGAGATCACGCCTATAATCATCCCGTTTTTG 
sheIF4B-4 
(human) 
CCGGCTACCCTATGATGTTACAGAACTCGAGTTCTGTAACATCATAGGGTAGTTTTTG 
shPDCD4-1 
(human) 
CCGGGCGGTTTGTAGAAGAATGTTTCTCGAGAAACATTCTTCTACAAACCGCTTTTTG 
shPDCD4-2 
(human) 
CCGGCTGACCTTTGTGGGACAGTAACTCGAGTTACTGTCCCACAAAGGTCAGTTTTTG 
shPDCD4-3 
(human) 
CCGGCTACCATTACTGTAGACCAAACTCGAGTTTGGTCTACAGTAATGGTAGTTTTTG 
sheIF4E-1 
(human) 
CCGGCCACTCTGTAATAGTTCAGTACTCGAGTACTGAACTATTACAGAGTGGTTTTTG 
sheIF4E-2 
(human) 
CCGGCCAAAGATAGTGATTGGTTATCTCGAGATAACCAATCACTATCTTTGGTTTTTG 
sheIF4E-3 
(human) 
CCGGCCGACTACAGAAGAGGAGAAACTCGAGTTTCTCCTCTTCTGTAGTCGGTTTTTG 
sheIF4E-4 
(human) 
CCGGCGGCTGATCTCCAAGTTTGATCTCGAGATCAAACTTGGAGATCAGCCGTTTTTG 
sheIF4E-5 
(human) 
CCGGCTGTTGTTAATGTTAGAGCTACTCGAGTAGCTCTAACATTAACAACAGTTTTTG 
sheIF4E 
(mouse) 
CCGGCCGAAGATAGTGATTGGTTATCTCGAGATAACCAATCACTATCTTCGGTTTTTG 
sh4E-BP1 
(human) 
CCGGGCCAGGCCTTATGAAAGTGATCTCGAGATCACTTTCATAAGGCCTGGCTTTTTG 
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Supplementary Table 2. Human and mouse ISG primer sequences. Sequence 5' to 3' 
(including modification codes if applicable). 
Human 
GAPDH-F TGTCCCCACCCCCAATGTATC 
GAPDH-R CTCCGATGCCTGCTTCACTACCTT 
eIF4A-F AAGCCGTGGATTCAAGGACCAG 
eIF4A-R CACCTCAAGCACATCAGAAGGC 
eIF4G-F GCCATTTCAGAGCCCAACTTCTC 
eIF4G-R CGGAAGTTCACAGTCACTGTTGG 
eIF4B-F GGCAAAGCCTGTTGACACAGCT 
eIF4B-R TTCACTTCGCCAGCTTGGGTGT 
PDCD4-F ACTGTGCCAACCAGTCCAAAGG 
PDCD4-R CCTCCACATCATACACCTGTCC 
eIF4E-F ATGCCTGGCTGTGACTACTCAC 
eIF4E-R GAGGTCACTTCGTCTCTGCTGT 
4E-BP1-F CACCAGCCCTTCCAGTGATGAG 
4E-BP1-R CCTTGGTAGTGCTCCACACGAT 
Mouse 
GAPDH-F CATCACTGCCACCCAGAAGACTG 
GAPDH-R ATGCCAGTGAGCTTCCCGTTCAG 
eIF4E-F ATGCCTGGCTGTGACTACTCAC 
eIF4E-R GTGTCTCTAGCCAGAAGCGATC 
4E-BP1-F GGAGAGCTGCACAGCATTCAGG 
4E-BP1-R GGAGGTATGTGCTGGTGTTCAC 
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Abstract 
The ubiquitin proteasome system plays important role in virus infection. A previous study 
showed that the proteasome inhibitor MG132 could potentially affect hepatitis E virus (HEV) 
replication. In this study, we found that MG132 could inhibit HEV and hepatitis C virus (HCV) 
replication-related luciferase activity in subgenomic models. Furthermore, treatment with 
MG132 in a HEV infectious model resulted in a dramatic reduction in the intracellular level of 
HEV RNA. Surprisingly, MG132 concurrently inhibited the expression of a luciferase gene 
used as a control as well as a wide range of host genes. Consistently, the total cellular RNA 
and protein content was concurrently reduced by MG132 treatment, suggesting a 
nonspecific antiviral effect. 
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Introduction  
The ubiquitin proteasome system (UPS), which serves as a major pathway for protein 
degradation and modification in eukaryotic cells, can be utilized by many types of viruses 1-3. 
Previous studies have demonstrated that UPS can regulate viral RNA-dependent RNA 
polymerase (RdRp), which mediates viral RNA synthesis 1, 4-6. In addition, UPS can also 
regulate ubiquitylation and degradation of some viral structural proteins 7-9, and thus 
representing as a potential antiviral target. 
Hepatitis E virus (HEV) is a single-strand positive-sense RNA virus that belongs to 
Hepeviridae family. It is a small non-enveloped virus with a 7·2 kb RNA genome, which is 
capped at the 5´ termini and polyadenylated at the 3´ termini 10. Outbreaks of hepatitis E 
occur periodically throughout the developing world. It typically causes an acute and self-
limiting infection, but fulminant hepatitis and high mortality (reaching 25%) are described in 
cases of pregnant women. In the western world, HEV mainly affects immunocompromised 
patients with high risk of developing chronic hepatitis 11. However, no proved medication is 
available to treat hepatitis E. A recent study reported potent antiviral effects of a well-known 
proteasome inhibitor MG132 against HEV 12. In a Renilla-luciferase-coupled HEV replication 
model, the author showed that treatment of MG132 resulted in dramatic reduction of HEV-
related luciferase activity 12. These important findings have inspired us to further evaluate 
the effects of MG132 in two HEV cell culture models. 
 
Matirials and methods 
In this study, two human hepatoma cell line (Huh7)-based HEV cell culture models are 
employed: a subgenomic HEV replicon containing gaussia luciferase reporter (p6-Luc) in 
which the accumulation of secreted luciferase serves as a reporter for HEV replication, and a 
full-length infectious model (p6) in which Huh7 was electroporated with full-length HEV 
genome RNA (Kernow-C1 p6 clone, GenBank Accession NumberJQ679013) 13. Two firefly 
luciferase cell models, a cell line for normalization which stable express luciferase driven by a 
phosphoglyserate kinase (PGK) promoter (Huh7-PGK) and a hepatitis C virus (HCV, also a 
single-strand positive-sense RNA virus) subgenomic cell culture model (Huh7-ET) were also 
used 14. The gaussia luciferase and firefly luciferase activity was measured as described 
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previously 13 by using a Lumi Star Optima luminescence counter (BMG Lab Tech, Offenburg, 
Germany). MTT assay was performed as previously described 15. The absorbance of each 
well was read on the microplate absorbance readers (Bio-rad) at wavelength of 490 nm. 
RNA was isolated with the Machery-NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Thermo, DE, USA). cDNA was 
prepared from total RNA using a cDNA Synthesis Kit (Takara Bio Inc.). HEV, GAPDH, RP2 
(Human retinitis pigmentosa 2), CyA (Cyclosporin A), CyB (Cyclosporin B), CD81 (Cluster of 
Differentiation 81) and IMPDH2 (Inosine-5'-monophosphate dehydrogenase 2) were 
quantified by SYBR-Green-based real-time PCR. The HEV primer sequences were 5’-
ATTGGCCAGAAGTTGGTTTTCAC-3’ (sense) and 5’-CCGTGGCTATAATTGTGGTCT-3’ (antisense), 
and the primer sequences of housekeeping gene GAPDH were 5’-
TGTCCCCACCCCCAATGTATC-3’ (sense) and 5’-CTCCGATGCCTGCTTCACTACCTT-3’ (antisense) 
and the primers of housekeeping gene RP2 were 5’-CCCATTAAACTCCAAGGCAA-3’ (sense) 
and 5’-AAGCTGAGGATGCTCAAAGG-3’ (antisense). The primer sequences of CyA were 5’-
GGCAAATGCTGGACCCAACACA-3’ (antisense) and 5’-TGCTGGTCTTGCCATTCCTGGA-3’ (sense) 
and the primers CyB were 5’-AACGCAGGCAAAGACACCAACG-3’ (antisense) and 5’-
TCTGTCTTGGTGCTCTCCACCT-3’ (sense). The primer sequences of CD81 were 5’- 
CTGCTTTGACCACCTCAGTGCT-3’ (antisense) and 5’- TGGCAGCAATGCCGATGAGGTA-3’ (sense) 
and the primers IMPDH2 were 5’- AGTGGCTCCATCTGCATTACGC-3’ (antisense) and 5’- 
GGATTCCTCCATCAGCAATGACC-3’ (sense). 
For Western blot, cell lysates were heated 5 minutes at 95 ℃ followed by loading 
same volume of sample onto a 10% sodium dodecyl sulfate polyacrylamide gel and 
separating by electrophoresis. Mouse β-actin antibody (1:1000) was used as primary 
antibody. For SDS-PAGE, after 90 min running at 120 V, the gel was stained in Coomassie 
Brilliant Blue solution and distained.  
 
Results  
Consistent with a previous study 12, treatment with 1 µM and 10 µM MG132 did not 
significantly impair cell viability determined by MTT assay after 24 hrs (Figure 1A) and 48 hrs 
(Figure 1B). As expected, treatment with 1 µM MG132 potently inhibited HEV replication-
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related gaussia luciferase activity in the p6-Luc model (Figure 1) after 24 hrs and 48 hrs. 
Furthermore, we tested this proteasome inhibitor on the Huh7 based hepatitis C virus 
subgenomic model (Huh7-ET). Consistently, MG132 inhibited HCV coupled firefly luciferase 
activity (Figure 1). Surprisingly, when the Huh7-PGK cell line treated with MG132, the control 
firefly luciferase activity driven by the PGK promoter was also potently inhibited (Figure 1). 
These results raised the concern regarding the specificity of MG132 on viral replication. 
To investigate further, the HEV infectious model (p6) was treated with MG132 for 48 
hrs. The relative levels of HEV viral RNA and two host reference genes (GAPDH and RP2) 
were quantified by SYBR-based qRT-PCR. As shown in Figure 2A, treatment with 1 or 10 µM 
MG132 resulted in a significant decrease in intracellular HEV viral RNA by 32 ± 19% and 76 ± 
24% (mean ± SD, n = 6, p < 0.01), respectively. Strikingly, the expression levels of two  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The proteasome 
inhibitor MG132 exerted 
non-specific effects on 
luciferase activity. 
Treatment with MG132 
after 24 hrs (A) and 48 hrs 
(B) resulted in dramatic 
reduction of luciferase 
activity in subgenomic HEV 
replicon (p6-Luc) (mean ± 
SD, n = 12), HCV replicon 
(Huh7-ET) (mean ± SD, n = 
4) and Huh7 cells 
constantly expressing 
control luciferase gene 
under control of the PGK 
promoter (Huh7-PGK) 
(mean ± SD, n = 4). MG132 
treatment did not affect 
cell viability determined by 
MTT assay (OD 490 value) 
(mean ± SD, n = 4).  
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references genes, GAPDH and RP2 were concurrently decreased. In addition, the expression 
levels of four other host genes that we tested, including CyA, CyB, CD81 and IMPDH2, also 
decreased simultaneously (Figure 2B). These results confirm that the effect of MG132 is non-
specific.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 HEV viral RNA was significantly decreased by MG 132 treatment (A). The expression of two 
reference genes (GAPDH, RP2) and 4 host genes ( CyA, CyB, CD81 and IMPDH2 ) were concurrently 
inhibited by treatment of MG132. Relative gene expressions was quantified by qRT-PCR. Data is 
presented as 2-Ct and normalized to untreated control (mean ± SD, n = 6). 
 
 
Next, we measured the RNA concentration and total protein content of the cells after 
MG132 treatment and we found that MG132 treatment (1 µM and 10 µM) drastically 
reduced the total cellular RNA content (Figure 3A). Furthermore, cells that were treated 
with MG132 and lysed showed reduced cellular protein expression. As shown in Figure 3B, 
the protein level of internal reference β-actin was decreased after treatment with 1 µM 
and 10 µM MG132, and the total protein content was also reduced (Figure 3C). However, 
the effects of MG132 at the protein level were less profound than that at the RNA level. 
These results suggest that MG132 inhibits expression and translation of a broad range of 
genes rather than having a specific effect on viral infection. 
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Figure 3 Internal reference β-actin was inhibited by MG132 treatment after 48 hrs. Same volume of 
cell lysates was loaded and the protein level was determined by Western blot (A). Total intracellular 
RNA in cells was dramatically reduced by MG132 treatment after 48 hrs. RNA concentration was 
determined by the NanoDrop 2000 spectrophotometer (mean ± SD, n = 7) (B). Total intracellular 
protein was dramatically reduced by MG132 treatment after 48 hrs. Same volume of cell lysates was 
loaded and the gel was stained in Coomassie Brilliant Blue solution and distained (C). 
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Discussion 
There is a substantial evidence suggest that the cellular UPS is associated with viral infection. 
RdRp, the essential enzyme for viral replication, can be regulated by UPS in turnip yellow 
mosaic virus (TYMV) 1, sindbis virus 4, hepatitis A virus (HAV) 5 and HCV 6 infections. Virus-
encoded proteases cleave viral polyprotein proteolytically but can also mediate the 
processing of many host proteins 16. Mature 3C proteases of HAV and encephalomyocarditis 
virus (EMCV) have been attributed to rapid, ubiquitin-mediated protein degradation 17,18. As 
a combat strategy, some viral proteases have been shown to contain de-ubiquitinating 
enzyme activity. Papain-like cysteine proteases of coronavirus 19, HEV 20 and foot-and-mouth 
disease virus (FMDV) 21 have the ability to hydrolyze ubiquitinating substrates. Therefore, 
modulating UPS represents as a potential antiviral strategy. 
Treatment with proteasome inhibitor MG132 has been shown to decrease the titers 
of porcine circovirus type 2 (PCV2) at the early infection stage 22. Treatment with MG132 
was also shown to decrease the activity of Renilla luciferase expressed from an HEV replicon 
12. However, our study raised the concern regarding the specificity of MG132 on HEV 
replication. Although we confirmed the inhibitory effects on luciferase activity of both HEV 
and HCV replicon models, MG132 also inhibited a constitutively expressed luciferase in 
control cells. Furthermore, in the full-length HEV model, MG132 treatment reduced HEV 
RNA levels, it also simultaneously inhibited the expression of reference genes and other host 
genes. We further demonstrated that MG132 dramatically decrease the total intracellular 
RNA and protein, which explaines such a non-specific effect on viral infection.  
It is not surprising that inhibition of this system could exert variety of effects on cell 
physiology, since UPS plays essential roles in cellular proteins processes. Proteasome could 
promptly degrades ubiquitylated proteins 23, and some of these proteins are important 
mediators of cell-cycle progression and apoptosis 24. MG132 has been shown to induce the 
expression of death receptor 5 (DR5), a receptor for tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), resulting in enhanced sensitivity to TRAIL-induced apoptosis in 
cancer cells 25,26. Thus, inhibition of this major intracellular protein degradation pathway 
could un-specifically affect viral infection, but we do not fully exclude that UPS may also 
specifically modulate certain viruses 2. 
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In summary, this study demonstrated that inhibition of HEV infection by proteasome 
inhibitor MG132 was non-specific. Thus, we should be careful of interpreting data regarding 
the effects and mechanisms of proteasome inhibitor on viral infection. Although proteasome 
inhibitors are emerging as anticancer agents in preclinical phase 24,27, we would call for 
caution of developing proteasome-targeted antiviral therapies. 
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Part I: Hepatitis in immunocompromised patients 
HEV infection, the most frequent cause of acute hepatitis, has emerged as an important 
public health issue worldwide 1. Although the majority of infections are thought to remain 
asymptomatic and usually cause self-limiting disease, persistent infection with chronic 
hepatitis may be observed in immunocompromised patients in particular organ transplant 
recipients 2. Therefore, there is an urgent need to properly evaluate the clinical impact of 
HEV in these patients. In Chapter 2 of this thesis we have performed a comprehensive 
review on the prevalence, infection course, and management of HEV infection after solid 
organ transplantation. On the basis of a series of published cohort studies, the prevalence of 
anti-HEV IgG is approximately 11.6%, and genomic viral RNA is 2% in SOT patients. A total of 
65% of patients who were positive for HEV RNA developed chronic infection. Although a 
combination of serologic and molecular assays were used for many of the studies in the 
transplant settings, there is still a possibility of positivity for only antibody or only viral RNA 3, 
4. Thus, there is an urgent need for developing robust and standardized diagnostic assays, 
possibly combining both serology and molecular techniques and including properly produced 
control materials. Regarding the condition of Immunocompetence in general, significant 
lower lymphocyte subset counts, in particular CD4 T-cells, were found in HEV infected 
patients developing chronic hepatitis, compared with those who cleared the virus within six 
months 5. Hence, a healthy immune system can control and eliminate the infection, 
indicating dose reduction or even withdrawal (if possible) of immunosuppressants is the first 
intervention strategy to clear HEV infection in SOT patients.  
Different types of immunosuppressants could interact either positively or negatively 
with the host immune system 4. Clinical evidence indicated that different 
immunosuppressive regimens can differentially affect the course of HEV infection as well 2, 6. 
In fact, there is an evidence in HEV-transplant patients showing that tacrolimus but not CsA 
is more frequently associated with persistent infection 2, whereas the MMF, the pre-drug 
form of MPA can help clearing the virus 6. However, current clinical studies have not been 
able to conclusively address the impact of different immunosuppressants, because of limited 
patient numbers and lack of mechanistic insight as to how differences in immunosuppressive 
medication might be linked with an altered clinical course of HEV infection. Thus, there is 
substantial room for fundamental and translational research to further investigate these 
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interesting questions by using state-of-the-art HEV cell culture. In Chapter 3 and Chapter 4 
we applied recent development of a genotype 3-based cell culture system 7, 8 to investigate 
the effects of different immunosuppressants, including steroids (Pred and Dex), calcineurin 
inhibitors (FK506 and CsA), MPA, and rapalogs (rapamycin and everolimus) on HEV 
replication.  
In Chapter 3 we observed no clear effect of either Pred or its close analogue Dex on 
HEV replication in both subgenomic and infectious models in culture system. Although 
limited studies have reported the impact of steroids in HEV patients, one case report has 
documented a good clinical and biochemical response to steroid therapy in a patient of 
acute hepatitis E with autoimmune hepatitis, who maintained health with a low dose of 
steroids 9. Next, CsA, a calcineurin inhibitor, directly promoted HEV replication, through 
inhibiting the activity of cyclophilins (CypA and CypB). Whereas another calcineurin inhibitor, 
FK506, only at high dose of treatment provokes a proviral effects. In fact, compared to CsA, 
dose reduction of FK506 appeared to be more associated with clearance of HEV in cases of 
renal transplantation with acute infection 10. In a large retrospective study (although only 85 
patients included), the use of FK506 was the main predictive factor for chronic hepatitis E in 
organ recipients 2. Our in vitro results have indicated that both FK506 and CsA can promote 
HEV infection. However, these data do not necessarily contradict to the clinical observation, 
because the number of patients currently investigated in the clinic is rather too small to 
draw solid conclusion. In contrast, MPA potently suppressed HEV infection by depletion of 
cellular nucleotide pools. In addition, a clear beneficial effect was observed when MPA 
combined with another antiviral regimen ribavirin. 
In Chapter 4 we dig deeper into the effects and mechanism-of-action of another type 
of important immunosuppressants rapalogs, including rapamycin and everolimus, on HEV 
infection. Both immunosuppressants are gaining increasing popularity in the transplantation 
context, mainly because of the low nephrotoxicity 11. Their molecular mode of action is well 
characterized and involves inhibition of the mammalian target of rapamycin (mTOR) 
pathway. mTOR is a central element within the phosphatidylinositol-3 kinase (PI3K)-protein 
kinase B (PKB)-mTOR signaling 11 and integrates nutritional information and receptor 
tyrosine kinase signaling to control cellular growth via a variety of cellular effectors, 
including activation of p70 S6 kinase and subsequent protein synthesis as well as inhibition 
of autophagy. In both subgenomic and full-length HEV models, HEV infection was 
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substantially elevated following treatment with rapamycin or everolimus. Consistently, 
stable silencing of mTOR by lentiviral RNAi resulted in a significant increase in intracellular 
HEV RNA, suggesting an antiviral function of mTOR in HEV infection. By targeting a series of 
other up- and down-stream elements of mTOR signaling, we further revealed an effective 
basal defense mechanism mediated by the PI3K-PKB-mTOR pathway against HEV, which 
involves phosphorylated eIF4E-binding protein 1 (4E-BP1), however independent of 
autophagy formation. This novel action of mTOR in directly counteracting viral replication in 
liver cell themselves rather as acting through the adapted immune system, represents a 
highly novel non-canonical action of this kinase and constitutes a novel adaptive immune 
system-independent antiviral mechanism.  
 
Part II: Extra-hepatic manifestations 
Although HEV, defined as a hepatotropic virus, is supposed to exclusively infect the liver and 
only causes hepatitis, a broad range of extrahepatic manifestations have been recently 
reported in association with its infection 12. Most of these are case reports or small case 
series published during the last 5 years, reflecting increased awareness of the extra-hepatic 
manifestations associated with this infection in general 12.  
HEV infection has been reported to be related to renal manifestations 10 and HEV has 
been demonstrated to be present in the urine of acute and chronically infected individuals 
and experimentally acute infected monkeys 13. Since we are interested in chronic HEV, in 
Chapter 5 we have establish a monkey model for persistent infection and detected HEV RNA 
in the urine of two monkeys at 272 and 650 days post infection, respectively. One macaque 
persistently infected with HEV died unexpectedly and we observed HEV RNA positivity in 
both liver and renal tissues. Furthermore, there was no clear histological change with liver 
tissue, but indeed there were clear pathological changes in renal tissue. This may indicate 
that HEV could replicate in kidney and subsequently cause tissue injury, which may facilitate 
the release of virus into urine. As reported, HEV-Ag EIA S/CO values were clearly higher in 
urine than serum, while the HEV RNA concentrations were lower in urine than serum in most 
patients and infected monkeys 13. This may suggest that HEV in urine is not solely in the form 
of virions; HEV-Ag without HEV RNA, as free antigen or empty capsids may be quite 
abundant.  
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Among these extra-hepatic manifestations, neurological disorders have been 
described as a relatively common, but under-recognized, extrahepatic manifestation related 
to HEV infection 12, 14, 15. An increasing number of central or peripheral nervous system 
diseases have been documented in patients associated with acute or chronic HEV infection 
12, 14, including Guillain-Barre syndrome (GBS) and neuralgic amyotrophy (NA) 14, 16, 17. 
However, the etiology of HEV-associated neurological injury is unknown. In the existing 
paradigm, HEV is considered to be primarily a hepatotropic virus. Hitherto, the most widely 
held neuropathogenic hypothesis posits that HEV causes neurological injury by immune 
mechanisms related to molecular mimicry, as has been well described for GBS associated 
with a variety of infectious triggers 14, 18. The alternative hypothesis, however, that HEV 
causes direct injury via neurotropism has not been sufficiently evaluated. In Chapter 6 we 
demonstrated that various human neural cell lines and embryonic stem cell-derived neural 
lineage cells were susceptible to HEV infection. Induced pluripotent stem (iPS) cell-derived 
human neurons and primary mouse neurons were more permissive to HEV infection 
compared to human liver cells. In mice and monkeys peripherally inoculated with HEV 
particles, viral RNA and protein were detected in brain tissues. Finally, patients with HEV-
associated neurological disorders shed virus into cerebrospinal fluid (CSF), indicating direct 
infection of their nervous system. These results challenge the dogma of HEV as a pure 
hepatotropic virus and suggest that HEV infection should be considered in the differential 
diagnosis of idiopathic neurological disorders. 
 
Part III: Anti-viral therapy 
Since no registered medication is available for HEV infection, pegylated IFN-α, 
ribavirin, or a combination of both has been used as off-label treatments for some cases of 
HEV infection 19. Because of the potent antiviral activity, pegylated interferon-α (PEG-IFNα) 
has been used for decades to treat chronic hepatitis B virus (HBV) and C virus (HCV) infection 
19, 20. However, the efficacy and molecular mechanisms of how IFN signaling interacts with 
HEV remain undefined. In Chapter 7 we revealed that HEV is in general insensitive to the 
regulation of cytokines and chemokines. IFN-α treatment exerts moderate but delayed 
antiviral activity against HEV infection in experimental models and in patients, which 
suggested the ineffectiveness of interferon-based monotherapy in treating chronic hepatitis 
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E. Interestingly, blocking the basal IFN pathway resulted in drastic augmentation of HEV 
infection, suggesting that basal IFN pathway can effectively protect against HEV infection. 
These results revealed distinct mode-of-actions of basal and treatment activated IFN 
signaling in controlling HEV infection. 
Mechanistically, interferon molecules bind to cell surface receptors and subsequently 
initiate a signaling cascade to activate transcription of IFN-stimulated genes (ISGs), which are 
in turn regulated by the IFN-stimulated response element (ISRE). The products of ISGs are 
thought to be the ultimate antiviral effectors 21. Interferon regulatory factor 1 (IRF1) is one 
of the most important ISGs which potently inhibits the replication of 14 different viruses, 
representing 7 families including different DNA and RNA viruses 21. However, the exact 
efficacy and molecular mechanism of IRF1 on HEV remains unclear. In Chapter 8 we 
investigated the role of IRF1 in HEV infection and the interactions with antiviral treatments 
by using cell culture models. We found that independent of interferon production, IRF1 
could effectively restrict HEV replication through the activation of JAK-STAT cascade and the 
subsequent induction of a wide range of ISGs. We further demonstrated that the anti-HEV 
effect of IRF1 overlapped with IFNα but was augmented by ribavirin. 
Besides the importance of host innate defense against HEV infection, other essential 
host elements could also be a target for the development of novel antiviral therapy against 
HEV. Like all viruses, HEV is completely dependent on the translational machinery of host 
cells to synthesize the viral proteins essential for its productive infection 22. The way host 
protein synthesis machinery is commandeered by viruses has a major impact on viral protein 
synthesis and genome replication 23, but little is known regarding how HEV uses host 
translational machinery for its life-cycle. In Chapter 9 we revealed that cap dependent 
translation machinery eIF4F complex plays a critical role in help with efficient HEV 
replication. The translational suppressors PDCD4 and 4E-BP1 are important antiviral factors 
in restraining HEV infection. Interestingly, the eIF4F complex can interact with antiviral 
regimens, such as ribavirin or interferon-α (IFN-α), which are the classical standard therapy 
of chronic hepatitis C but also as off-label drugs for treating individual HEV cases or small 
case series 24, 25. Ribavirin can directly bind to eIF4E and compete for 5’ cap mRNA binding 26, 
27, whereas some regulatory factors of eIF4F complex are involved in interferon mediated 
antiviral immune response 28, 29. In our study we observed that the antiviral effects of 
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ribavirin and IFN-α are independent of eIF4E, although silencing of eIF4E could already 
inhibit HEV replication. 
Last but not least, viral functional structures which serve for various steps in the HEV 
life cycle can also be good drug targets 30. A recent study reported potent antiviral effects of 
a well-known proteasome inhibitor MG132 against HEV 31. In Chapter 10 we found that 
MG132 could inhibit HEV and hepatitis C virus (HCV) replication-related luciferase activity in 
subgenomic models. Furthermore, treatment with MG132 in a HEV infectious model 
resulted in a dramatic reduction in the intracellular level of HEV RNA. Surprisingly, MG132 
concurrently inhibited the expression of a luciferase gene used as a control as well as a wide 
range of host genes. Consistently, the total cellular RNA and protein content was 
concurrently reduced by MG132 treatment, suggesting a nonspecific antiviral effect. 
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Final remarks 
 Although experimental research alone will not be able to clarify these complicated 
but important clinical issues, our laboratory investigation of the effects of different 
immunosuppressants on HEV infection does provide a proof of concept for the 
notion that it is important to choose the right immunosuppressive medication to aid 
antiviral therapy for HEV infection in organ transplantation. Hopefully, it will also 
promote the initiation of randomized controlled clinical studies to address these 
issues in the near future. 
 Extra-hepatic manifestations represent an important aspect of HEV infection and 
signs and symptoms of these conditions should be considered in the clinical 
management of patients with acute or chronic HEV infection. Our further 
investigations in pathogenesis of HEV-associated neurological disorders challenged 
the notion the HEV is primarily a hepatotropic virus and suggested HEV infection as a 
possibility in idiopathic neurologic disease. Thus large-scale testing for HEV in 
idiopathic neurological disease if called for. 
 Our discovery of a novel antiviral mechanism has shed new light on the molecular 
details of HEV-host interaction, in particular the role of therapeutically-activated and 
the basal IFN signaling, an important anti-HEV ISG, as well as the host translation 
machinery, which may help to understand the complicity of HEV-host interactions 
and bears significant implications in management of HEV patients and future 
therapeutic development. 
In conjunction, I hope our studies have contributed to the battle of humanity 
with HEV infection.  
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Samenvatting voor de leek in de Nederlandse taal. 
Het hepatitis E virus (HEV) is één van de verwekkers van virale hepatitis. Het HEV komt het 
bloed binnen via het maag-darm kanaal en zou zich uitsluitend vermenigvuldigen in de lever. 
Het verloop van een acute HEV-infectie kent een aantal stadia: van subklinisch, naar acuut 
en uiteindelijk fulminant. Hepatitis E, dat in toenemende mate wordt gezien als een “public 
health concern”, heeft een mortaliteit van 0.2-1.0 %, maar kan bij zwangere vrouwen in het 
laatste trimester van hun zwangerschap oplopen tot een mortaliteit van 20-25%. Daarnaast 
is er zorg over het gevaar van het virus voor andere groepen, met name voor 
transplantatiepatiënten. Zulke patiënten krijgen immuunsysteem onderdrukkende medicatie 
voorgeschreven die potentieel de weerstand tegen HEV zouden kunnen verminderen. 
Inderdaad bleek uit een systematisch door mij uitgevoerd literatuuronderzoek (hoofdstuk 2) 
met betrekking tot de vatbaarheid van transplantatiepatiënten voor HEV infectie, dat zo’n 
twaalf procent van deze patiënten antistoffen voor HEV in haar bloed had. Bovendien was in 
zo’n twee procent der patiënten ook viraal RNA aanwezig. In deze laatste groep  ontwikkelde 
65% van de patiënten een chronische infectie. Ik concludeerde dat hepatitis E een groot 
probleem is bij orgaan transplantatie. 
Orgaan transplantatie gaat gepaard met het gebruik van immunosuppressiva. 
Immers, anders wordt het getransplanteerde orgaan afgestoten. Verschillende 
immunosuppressiva werken mechanistisch op andere wijze; het is dus goed voorstelbaar dat 
sommige immunosuppressiva een directe interactie met de levenscyclus van het HEV en het 
virus direct remmen, terwijl andere immunosuppressiva niet zo’n interactie zouden hebben. 
Uiteraard zou het gebruik van een immunosuppressief regime dat tegelijkertijd ook 
virusreplicatie remt de voorkeur moeten hebben voor patiënten  met een verhoogd risico op 
het ontwikkelen van hepatitis E. In hoofdstuk 3 en hoofdstuk 4 ga ik op zoek naar zulke 
immunosuppressiva. Ik vond dat verschillende immunosuppressiva inderdaad een andere 
interactie met de HEV levens cyclus hadden. Sommigen, in het bijzonder remmers van mTOR 
(een moleculair element dat informatie van de voedingsstaat van de cel integreert met de 
informatie gegeven door immunostimulatoire hormonen) leken HEV infectie te bevorderen 
(mTOR lijkt dan ook een element van de verdediging van de cel tegen HEV). Andere 
immunosuppressiva, zoals steroïden, hadden geen effect, maar mycofenolzuur (een potent 
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middel om orgaanafstoting te voorkomen) remde juist HEV infectie. Dit laatste middel lijkt 
dan ook aangewezen bij patiënten met een verhoogd risico op hepatitis E. 
Vervolgens ging ik mij op eigenschappen van het HEV richten die mogelijk de 
klinische verschijnselen kunnen verklaren. Met name was ik geïnteresseerd in de 
zogenaamde extra-hepatische manifestaties van dit virus. HEV infectie gaat vaak gepaard 
met neurologische verschijnselen. De reden voor deze verschijnselen is onduidelijk, maar er 
wordt gedacht dat de virusinfectie een auto-immuun fenomeen kan oproepen. In hoofdstuk 
5, echter, laat ik zien dat HEV niet lever specifiek is, maar zich ook kan vermenigvuldigen in 
zenuwcellen. HEV infectie van zenuwcellen vormt dan ook een rationele verklaring voor de 
neurologische klachten geassocieerd met hepatitis E. Bovendien zou HEV infectie in 
sommige gevallen ook een verklaring kunnen vormen voor onbegrepen neurologische 
ziektes. 
Het laatste gedeelte van mijn proefschrift handelt over antivirale therapie die 
gebruikt zou kunnen worden om hepatitis E te behandelen. Zo exploreer ik in hoofdstuk 7 
behandeling met interferon alfa. Interferon alfa wordt gebruikt bij allerlei virusziekten, maar 
in dit hoofdstuk stel ik vast dat dit hormoon ook een belangrijke rol kan spelen bij de 
behandeling van hepatitis E. Mechanistisch wordt dit verder onderzocht in hoofdstuk 8. Hier 
identificeer ik een set genen die worden geactiveerd door interferon alfa en die de effecten 
van interferon alfa op de levenscyclus van het HEV lijken te verklaren, met name door het 
aanjagen van zogenaamde JAK-STAT signalering. Bovendien laat ik in dit hoofdstuk zien dat 
de anti-HEV activiteit van interferon alfa verder versterkt wordt door co-applicatie van het 
medicijn ribavirine. De data uit deze twee hoofdstukken laten zien dat voor het behandelen 
van hepatitis de combinatie van interferon alfa en ribavirine een rationele keuze is. 
Een venster op verbeterde behandeling van hepatitis E in de toekomt wordt geopend 
in hoofdstuk 9. Hier onderzoek ik het belang van de zogenaamde cellulaire eiwit-
translerende machinerie voor de vermenigvuldiging van HEV. Ik laat zien dat het remmen 
van elementen uit deze machinerie een belangrijke antivirale werking heeft, met name het 
onderdrukken van eIF4E inhibeert virale replicatie in sterke mate. Omdat deze inhibitie 
onafhankelijk is van interferon alfa en ribavirine, zou het eIF4E een belangrijk nieuw doelwit 
kunnen worden voor nieuwe antivirale therapie. Helaas blijkt dit niet het geval voor de 
proteosoom inhibitor MG132. Anderen hadden eerder gerapporteerd dat deze inhibitor 
efficiënt was voor het bestrijden van HEV infectie. In hoofdstuk 10 echter, laat ik zien dat 
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deze effecten waarschijnlijk niet specifiek zijn en dat proteosoominhibitoren waarschijnlijk 
dus toekomst hebben in de behandeling van hepatitis E. 
In het laatste hoofdstuk (hoofdstuk 11) van dit proefschrift tenslotte, probeer ik alle 
informatie die ik heb vergaard gedurende mijn promotieonderzoek te integreren en te 
duiden aan de hand van de reeds bestaande biomedische literatuur. Ik concludeer dat de 
keuze van immunosuppressie voor transplantatiepatiënten gevolgen heeft, sommige 
immunosuppressiva maken de patiënt meer gevoelig voor een daaropvolgende HEV infectie, 
terwijl andere medicatie, in het bijzonder mycofenolzuur, juist patiënten kan beschermen 
tegen dit virus. Ook stel ik vast dat de extrahepatische manifestaties van hepatitis E 
waarschijnlijk samenhangenmet directe infectie van niet-leverorganen door het virus en 
tenslotte doe ik uitspraken over de mechanismen die door de antivirale medicatie interferon 
alfa worden aangezwengeld en het virus bestrijden. Samen hoop ik dat mijn studies een 
nieuwe bijdrage hebben kunnen leveren in de strijd der mensheid tegen hepatitis E. 
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Engineering at Hunan Institute of Technology. She graduated in 2009, and moved to 
Guangzhou, the capital of Guangdong Provice, south part of China, to start her Master 
reseach in Biochemistry and molecular biology at South China University of Technology. 
Under supervision of Prof. Ying Lin, she started to do the research in the application of 
glycosylphosphatidylinositol (GPI)-anchored glycoproteins in Pichia pastoris. Later on, she 
graduated in 2012. 
In 2012, she moved to the department of Gastroenterology and Hepatology, Erasmus 
Medical Center Rotterdam, the Netherlands, to carry out his PhD research on hepatitis E 
virus (HEV) infection. Under supervision of Prof. Maikel P. Peppelenbosch and Dr. Qiuwei 
(Abdullah) Pan, she focused on pathogenesis and therapy for hepaitits E. Specifically, she 
devoted to projects, including (I) effects and mechanisms of different immunosuppressants 
on HEV infection; (II) the extra-hepatic manifestations related to HEV infection; (III) the 
therapy for hepatitis patients and potential antiviral targets of the host. 
Currently, she would be a lecturer in Guangzhou, Southern Medical University and wants 
to continue her research. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
